US6294334B1 - Genetic test for equine severe combined immunodeficiency disease - Google Patents

Genetic test for equine severe combined immunodeficiency disease Download PDF

Info

Publication number
US6294334B1
US6294334B1 US09/407,562 US40756299A US6294334B1 US 6294334 B1 US6294334 B1 US 6294334B1 US 40756299 A US40756299 A US 40756299A US 6294334 B1 US6294334 B1 US 6294334B1
Authority
US
United States
Prior art keywords
leu
ser
glu
lys
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/407,562
Inventor
Katheryn D. Meek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Priority to US09/407,562 priority Critical patent/US6294334B1/en
Application granted granted Critical
Publication of US6294334B1 publication Critical patent/US6294334B1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: THE UNIVERSITY OF TEXAS SYSTEM
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Definitions

  • the present invention relates generally to the fields of molecular genetics and veterinary medicine. More specifically, the present invention relates to the mutation of a DNA-dependent protein kinase protein which results in equine severe combined immunodeficiency and a diagnostic test to identify carriers of the mutation.
  • V(D)J rearrangement is the molecular mechanism b y which distinct gene segments (V, D, and J) are joined to form the coding sequences of immunoglobulin (Ig) and T cell receptor (TCR) variable regions.
  • the rearrangement process is targeted by simple DNA sequence elements (recombination signal sequences, RSS) found immediately adjacent to all functional immune receptor gene segments and involves two double-stranded DNA cuts and subsequent re-ligations. This process results in the formation of two new DNA joints; coding joints which contain the coding information, and signal joints which contain the two recombination signal sequences.
  • V(D)J rearrangement is mediated by a lymphoid-specific endonuclease (the RAG 1 and RAG 2 proteins) and ubiquitously expressed components of the double strand break repair pathway.
  • the centrality of V(D)J recombination to the development of the vertebrate immune system is evident in situations where the process is defective.
  • V(D)J recombination results in a complete block of B and T cell lymphopoiesis and the disease severe combined immunodeficiency (SCID).
  • SCID disease severe combined immunodeficiency
  • the first example of defective V(D)J recombination was described in 1983 by Bosma and colleagues, relating to a spontaneous mutation in mice that results in severe combined immunodeficiency (C.B-17 mice).
  • C.B-17 mice severe combined immunodeficiency mice
  • the only step in V(D)J recombination that appears to be impaired is resolution of coding ends. Instead of being resolved into functional immune receptors, cleaved coding ends accumulate abnormally in developing severe combined immunodeficiency lymphocytes. However, cleaved signal ends are resolved at a similar rate as in wild type lymphocytes in mice.
  • DNA-dependent protein kinase catalytic subunit has been identified as the determinative factor in C.B-17 severe combined immunodeficiency mice.
  • the DNA-end binding Ku heterodimer interacts with DNA-dependent protein kinase catalytic subunit to generate a protein kinase (DNA-PK) that is dependent on linear DNA for activation (i.e., DNA-dependent protein kinase).
  • DNA-PK protein kinase
  • DNA-dependent protein kinase catalytic subunit is related to the phosphatidylinositol 3-kinase family whose members function in a variety of roles such as signal transduction by phosphorylation of phospholipids, control of cell cycle progression, and maintenance of telomere length.
  • the prior art is deficient in the lack of effective means of determining the presence of the genetic deteminant for equine severe combined immunodeficiency in an animal of interest.
  • the present invention fulfills this longstanding need and desire in the art.
  • SCID autosomal recessive disease severe combined immunodeficiency
  • the present invention presents the genotypic analysis of the defective DNA-dependent protein kinase catalytic subunit allele in Arabian horses and provides the sequence for the normal and mutant DNA-dependent protein kinase catalytic subunit gene and protein. These results formally establish the importance of the DNA-dependent protein kinase catalytic subunit in signal end resolution during V(D)J rearrangement.
  • DNA-dependent protein kinase catalytic subunit defects models are that low levels of DNA-dependent kinase (likely present in severe combined immunodeficiency mice) can support signal end resolution, but normal levels are required to support coding resolution.
  • composition of matter comprising an isolated DNA molecule encoding a DNA-dependent protein kinase catalytic subunit protein in Arabian horses having a sequence shown in SEQ ID No. 28.
  • composition of matter comprising an oligonucleotide having a sequence selected from the group of SEQ ID Nos. 24 and 25.
  • oligonucleotides precisely span the SCID-determinant region of the DNA-PK CS gene, and are diagnostic for the normal and SCID alleles, respectively.
  • a method of identifying an Arabian horse that is a carrier of equine severe combined immunodeficiency comprising the step of: determining whether said horse has a mutation in a SCID determinant region of a DNA-dependent protein kinase catalytic subunit gene.
  • a method of identifying an Arabian horse that is a carrier of equine severe combined immunodeficiency which further includes the step of screening a sample of DNA from said horse with an oligonucleotide having the sequence SEQ ID No. 25.
  • an additional step wherein a second sample of DNA from said horse is screened with an oligonucleotide having the sequence SEQ ID No. 24.
  • the determining step may include the step of amplifying said DNA-dependent protein kinase catalytic subunit gene.
  • a particular aspect of the present invention provides a method of determining whether an Arabian horse has a normal allele for a DNA-dependent protein kinase catalytic subunit gene, a SCID allele for a DNA-dependent protein kinase catalytic subunit gene, or both, comprising the steps of: obtaining samples from candidate horses; treating said samples obtained from candidate horses to expose nucleic acids; incubating said sample nucleic acids with a labeled oligonucleotide selected from the group of SEQ ID No. 24 and SEQ ID No.
  • An embodiment of this aspect of the present invention includes a DNA amplification step being performed on a SCID-determinant region in a DNA-dependent protein kinase catalytic subunit gene between said obtaining step and said treating step.
  • An additional aspect of the present invention includes a n isolated protein encoding a normal DNA-dependent protein kinase catalytic subunit protein having a sequence SEQ ID No. 29 and an isolated protein encoding a mutant DNA-dependent protein kinase catalytic subunit protein having a sequence SEQ ID No. 30.
  • the present invention also is drawn to an a plasmid containing a DNA encoding a DNA-dependent protein kinase catalytic subunit protein (SEQ ID No. 29) and regulatory elements necessary for expression of the DNA in the cell, said plasmid adapted for expression in a recombinant cell, and a plasmid containing the DNA of SEQ ID No. 28 and regulatory elements necessary for expression of said DNA in said cell, said plasmid adapted for expression in a recombinant cell.
  • a further aspect of the present invention provides a method of identifying an Arabian horse that is a carrier for equine severe combined immunodeficiency, comprising the step of: determining whether said horse has a gene that encodes a protein having a sequence SEQ ID No. 30, wherein a presence of said gene indicates a horse that is a carrier for equine severe combined immunodeficiency.
  • FIG. 1 is a diagramatic representation of the DNA-dependent protein kinase catalytic subunit transcript. Arrows and numbers denote positions of oligonucleotide primers used to amplify the equine transcripts. Each box represents an overlapping cDNA fragment derived from the 0176 and 1821 cell lines. Cloning the fragment from nucleotide 4950 to 9539 from the 1821 cell line was unsuccessful. Thus, the sequence of the 0176 transcript was determined for this region, and then four separate fragments were cloned and sequenced (denoted by dotted lines) from the 1821 cell line.
  • FIG. 2 presents the deduced amino acid sequence comparison of the equine DNA-dependent protein kinase catalytic subunit transcript (derived from the 0176 cell line) compared to the human counterpart. Comparison starts at amino acid 180 of the human sequence. Potential DNA-PK autophosphorylation sites and Leucine zipper motifs have been underlined. The conserved protein kinase motifs are shown in bold.
  • FIG. 3 shows the results of RT-PCR analysis of the DNA-dependent protein kinase catalytic subunit mutation.
  • RT-PCR was performed on cDNA derived from the 0176 (normal) and 1821 (SCID) cell lines using primer combination 396/392. Amplified products were electrophoresed on agarose gels and transferred to nylon membranes. One filter was hybridized with the N probe (left panel) and the other with the S probe (right panel).
  • FIG. 4A is a diagramatic depiction of the strategy used to determine the intron/exon organization of the region including the mutated DNA-dependent protein kinase catalytic subunit exon.
  • FIG. 4B shows genomic DNA from cell lines 0176 and 1821 amplified with oligonucleotides 392/405. Amplified fragments were cloned and sequenced with primer 392. Sequence analysis of the two clones reveals a five nucleotide deletion in the 1821 genomic fragment.
  • FIG. 4C shows the sequence comparison of the genomic fragments isolated from the 1821 and 0176 cell lines. These splice acceptor site is underlined. Positions of amplification primers are denoted with arrows.
  • FIG. 5 shows the genomic PCR analysis of DNA derived from SCID and phenotypically normal animals using primer combinations 392/405. Amplified products were electrophoresed on agarose gels and transferred to nylon membranes. One filter was hybridized with the N probe (top panel) and the other with the S probe (bottom panel). Phenotype and genotype (as determined b y this analysis) is indicated. S denotes SCID; N denotes normal; H denotes heterozygote.
  • FIG. 6 is a the diagrammatic representation of DNA-dependent protein kinase catalytic subunit isoforms generated by PI3K splice variation. Subregions of homology to other PI3K family members are as noted by Poltoratsky et al.
  • the murine SCID mutation results in an 80 amino acid truncation which leaves the PI3K domain intact.
  • the equine SCID mutation results in a 967 amino acid truncation which deletes the PI3K domain.
  • DSBR double strand break repair
  • DNA-PK DNA dependent protein kinase
  • DNA-PK CS catalytic subunit of DNA dependent protein kinase
  • V(D)J Variable (Diversity) Joining
  • RAG recombination activating gene.
  • amino acids described herein are preferred to be in the “L” isomeric form.
  • residues in the “D” isomeric form can be substituted for any L-amino acid residue as long as the desired functional property of immunoglobulin-binding is retained by the polypeptide.
  • NH 2 refers to the free amino group present at the amino terminus of a polypeptide.
  • COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide.
  • amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues.
  • the above Table is presented to correlate the three-letter and one-letter notations which may appear alternately herein.
  • a “replicon” is any genetic element (e.g., plasmid, chromosome, virus) that functions as an automous unit of DNA replication in vivo; i.e., capable of replication under its own control.
  • a “vector” is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.
  • a “DNA molecule” refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure herein according to the normal convention of giving only the sequence in the 5′ to 3′ direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).
  • An “origin of replication” refers to those DNA sequences that participate in DNA synthesis.
  • a DNA “coding sequence” is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5′ (amino) terminus and a translation stop codon at the 3′ (carboxyl) terminus.
  • a coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences.
  • a polyadenylation signal and transcription termination sequence will usually be located 3′ to the coding sequence.
  • Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.
  • a “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3′ direction) coding sequence.
  • the promoter sequence is bounded at its 3′ terminus by the transcription initiation site and extends upstream (5′ direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
  • a transcription initiation site (conveniently defined b y mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
  • Eukaryotic promoters will often, but not always, contain “TATA” boxes and “CAT” boxes.
  • Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the ⁇ 10 and ⁇ 35 consensus sequences.
  • An “expression control sequence” is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence.
  • a coding sequence is “under the control” of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.
  • a “signal sequence” can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.
  • oligonucleotide as used herein in referring to the probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.
  • the present invention is drawn to screening oligonucleotides having the sequence SEQ ID 24 or 25, or a portion of these oligonucleotides, which span the SCID-determinant portion of the DNA-dependent protein kinase catalytic subunit gene.
  • primer refers to a n oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH.
  • the primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use the method.
  • the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides.
  • primers used for amplification of the SCID-determinant region of DNA-dependent protein kinase catalytic subunit have the sequence of SEQ ID Nos. 22 and 23.
  • the primers herein are selected to be “substantially” complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5′ end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence or hybridize therewith and thereby form the template for the synthesis of the extension product.
  • restriction endonucleases and “restriction enzymes” refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.
  • a cell has been “transformed” by exogenous or heterologous DNA when such DNA has been introduced inside the cell.
  • the transforming DNA may or may not be integrated (covalently linked) into the genome of the cell.
  • the transforming DNA may be maintained on an episomal element such as a plasmid.
  • a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA.
  • a “clone” is a population of cells derived from a single cell or a common ancestor by mitosis.
  • a “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.
  • Two DNA sequences are “substantially homologous” when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., supra; DNA Cloning, Vols. I & II, supra; Nucleic Acid Hybridization, supra.
  • a “heterologous” region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature.
  • the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism.
  • coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.
  • the labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to untraviolet light, and others.
  • a number of fluorescent materials are known and can be utilized as labels. These include, for example, florescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow.
  • a particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.
  • Proteins can also be labeled with a radioactive element or with an enzyme.
  • the radioactive label can be detected by any of the currently available counting procedures.
  • the preferred isotope may be selected from 3 H, 14 C, 32 P, 35 S, 36 Cl, 51 Cr, 57 Co, 58 Co, 59 Fe, 90 Y, 125 I, 131 I, and 186 Re.
  • Enzyme labels are likewise useful, and can be detected by any of the presently utilized calorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques.
  • the enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase, ⁇ -glucuronidase, ⁇ -D-glucosidase, ⁇ -D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase.
  • U.S. Pat. Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.
  • normal allele refers to the gene that codes for the wildtype DNA-PK CS , and does not cause SCID. Specifically, the normal allele does not have the 5 base pair deletion present corresponding to nucleotide 9,454 of the 12,381 nucleotide coding sequence of the human transcript, and has the sequence AGGTAATTTATCATCTCA (SEQ. ID No. 24) at the SCID-determinant region.
  • SCID allele refers to the gene that codes for the mutant DNA-dependent protein kinase catalytic subunit protein, and causes equine SCID.
  • the SCID allele has the 5 base pair deletion present corresponding to nucleotide 9,454 of the 12,381 nucleotide coding sequence of the human transcript, and has the sequence AGGTAATTTATCAAATTC (SEQ. ID No. 25) at the SCID-determinant region of the DNA-dependent protein kinase catalytic subunit gene.
  • the 5 base pair deletion results in premature termination of the DNA-dependent protein kinase catalytic subunit protein at amino acid 3160 of the 4127 amino acid polypeptide.
  • SCID determinant region of the DNA-dependent protein kinase catalytic subunit gene refers to region of the DNA-dependent protein kinase catalytic subunit gene having the 5 base pair deletion in SCID-carrier animals which corresponds to nucleotide 9,454 of the 12,381 nucleotide coding sequence of the human transcript.
  • the SCID determinant region in normal individuals has the sequence AGGTAATTTATCATCTCA (SEQ. ID No. 24) in normal alleles and the sequence AGGTAATTTATCAAATTC (SEQ. ID No. 25) in SCID alleles.
  • the difference in the sequences between the normal and SCID alleles in the SCID-determinant region results in premature termination of the DNA-dependent protein kinase catalytic subunit protein at amino acid 3160 of the 4127 amino acid polypeptide in the SCID-causing DNA-dependent protein kinase catalytic subunit protein.
  • carrier refers to an animal heterozygous for a recessive genetic trait. Carriers are unaffected but have the potential to pass the trait on to their offspring.
  • the present invention describes the DNA-dependent protein kinase catalytic subunit gene in both normal and severe combined immunodeficiency horses.
  • SCID horses a 5 base pair deletion is present corresponding to nucleotide 9,454 of the 12,381 nucleotide coding sequence of the human transcript. This 5 base pair deletion results in premature termination of the DNA-dependent protein kinase catalytic subunit protein at amino acid 3160 of the 4127 amino acid polypeptide.
  • the equine DNA-dependent protein kinase catalytic subunit mutation most likely ablates DNA-dependent protein kinase activity completely.
  • equine DNA-dependent protein kinase catalytic subunit plays a role in both signal end resolution and coding end resolution.
  • Asymmetry of signal versus coding ligation in severe combined immunodeficiency mice (lacking in severe combined immunodeficiency foals) may be explained b y minimal DNA dependent protein kinase activity in severe combined immunodeficiency mice.
  • the following diagnostic strategy for differentiating SCID heterozygotes, homozygotes, and normal horses may be used by a person having ordinary skill in this art given the teachings of the present invention.
  • a simple diagnostic test for determining genotype of a given animal is straightforward to one skilled in the art of molecular biology. Since the present invention has identified precisely the same mutation in eight SCID animals and in two carriers, it is likely that this mutation is responsible for the majority of SCID cases in Arabian horses. This mutation is likely the result of a breeding bottleneck and a genetic founder effect.
  • a desirable diagnostic test would take advantage of the genomic sequence surrounding the mutation.
  • Such a test may use a strategy of amplifying the region of interest from DNA derived from the animal to be tested. Probes spanning the unmutated sequence or mutated sequence will, under the appropriate conditions, hybridize specifically. Thus, DNA from a normal animal which is not a carrier would hybridize with the probe based on the unmutated sequence, but would not hybridize with the probe based on the mutated sequence. DNA from a heterozygous, carrier animal will hybridize with both probes. DNA from a SCID animal will only hybridize with the probe based on the mutated sequence.
  • a method of identifying an Arabian horse that is a carrier of equine severe combined immunodeficiency comprising the step of: determining whether said horse has a mutation in a SCID determinant region of a DNA-dependent protein kinase catalytic subunit gene.
  • a method of determining whether an Arabian horse has a normal allele for a DNA-dependent protein kinase catalytic subunit gene, a SCID allele for a DNA-dependent protein kinase catalytic subunit gene, or both comprising the steps of: obtaining samples from candidate horses; treating said samples obtained from candidate horses to expose nucleic acids; incubating said sample nucleic acids with a labeled oligonucleotide selected from the group of SEQ ID No. 24 and SEQ ID No.
  • An embodiment of this aspect of the present invention includes a DNA amplification step being performed on a SCID-determinant region in a DNA-dependent protein kinase catalytic subunit gene between said obtaining step and said treating step.
  • a method of determining whether an Arabian horse has a normal allele for a DNA-dependent protein kinase catalytic subunit gene, a SCID allele for a DNA-dependent protein kinase catalytic subunit gene, or both comprising the steps of: obtaining samples from candidate horses; treating said samples obtained from candidate horses to expose nucleic acids; incubating said sample nucleic acids with a labeled oligonucleotide selected from the group of SEQ ID No. 26 and SEQ ID No.
  • oligonucleotides under conditions and for a time sufficient for said oligonucleotides to hybridize to a complementary sequence in said sample nucleic acid, if present; eliminating any unhybridized oligonucleotides; and detecting a presence or absence of said hybridized oligonucleotides; wherein a presence of hybridized oligonucleotide having a sequence SEQ ID No. 27 indicates a presence of a normal allele for a DNA-dependent protein kinase catalytic subunit gene, wherein a presence of hybridized oligonucleotide having a sequence SEQ ID No.
  • 26 indicates a presence of a SCID allele for a DNA-dependent protein kinase catalytic subunit gene, and wherein a presence of hybridized oligonucleotides having a sequence SEQ ID No. 26 and SEQ ID No. 27 indicates a presence of both a normal allele for a DNA-dependent protein kinase catalytic subunit gene and a presence of a SCID allele for a DNA-dependent protein kinase catalytic subunit gene.
  • primers can be designed easily which selectively amplify the mutated or the normal allele. Further, it is well within the expertise of the skilled artisan that primers can be designed such that products amplified from the mutated and normal alleles have unique sizes or unique restriction endonuclease sites to allow for rapid diagnosis. The main point being that no matter what molecular technique is used, all strategies involve detecting the portion of the DNA-dependent protein kinase catalytic subunit gene in which the 5-nucleotide deletion occurs in the mutated DNA-dependent protein kinase catalytic subunit gene. The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.
  • the 0176 fibroblast cell line was derived from a normal (non-Arabian) horse.
  • the 1821 fibroblast cell line was derived from a homozygous severe combined immunodeficiency foal. All cultures were carried out in DMEM medium (GIBCO Laboratories, Grand Island, N.Y.) supplemented with 10% FCS.
  • FIG. 1 Position of amplification primers is illustrated in FIG. 1 .
  • Sequences of oligonucleotides used were as follows:
  • GTCCCTAAAGATGAAGTG SEQ. ID No. 17
  • N AGGTAATTTATCATCTCA (SEQ. ID No. 24);
  • Total genomic DNA was analyzed from spleen, bone marrow, peripheral blood or fibroblast cell lines as indicated.
  • DNA was isolated using ABI DNA lysis buffer (Applied Biosystems, Foster City, Calif.).
  • Oligonucletide primers 405 and 392 (SEQ ID Nos. 22 and 23) were used to screen for the mutant severe combined immunodeficiency allele. Amplification conditions were 94° C. for 30 seconds, 55° C. for 90 seconds, and 68° C. for five minutes. Amplified DNA was loaded onto 1.5% duplicate agarose gels for Southern filter hybridization analysis. After electrophoresis, DNA was transferred in 0.4N NaOH onto nylon membranes (Zeta-probe, Biorad, Hercules, Calif.).
  • Southern filter hybridization was done in 6 ⁇ SSC, 0.5% SDS, and 5 ⁇ Denhardts at 42° C. 32 P-end labeled oligonucleotides specific for the normal and severe combined immunodeficiency alleles were used as hybridization probes. Filters were washed in 6X SSC and 0.5% SDS at 65° C.
  • RT-PCR strategy (depicted in FIG. 1) was used to clone and sequence the normal and severe combined immunodeficiency equine DNA-dependent protein kinase catalytic subunit transcripts. Amplification primers were based upon the published human DNA-dependent protein kinase catalytic subunit sequence.
  • cDNA was derived from two fibroblast cell lines, 0176 (derived from a normal, non-Arabian animal) and 1821 (derived from a severe combined immunodeficiency foal).
  • the deduced amino acid sequence of equine DNA-dependent protein kinase catalytic subunit is compared to the human counterpart in FIG. 2 .
  • the two proteins are 84% homologous.
  • the PI3K domain is well conserved between the human and equine sequences (87%), homology within this region was not dramatically higher than throughout the rest of the protein.
  • the region within the PI3K domain corresponding to the putative kinase active site was slightly more conserved. This corresponds to subdomain II as noted by Poltoratsky et al.
  • genomic DNA was derived from eight different severe combined immunodeficiency foals and five normal animals (four Arabian and one non-Arabian).
  • the diagnosis of severe combined immunodeficiency was established on the basis of lymphopenia ( ⁇ 1,000 lymphocytes/ ⁇ l peripheral blood), absence of IgM, and hypoplasia of lymphoid tissues as described previously.
  • the eight severe combined immunodeficiency foals were derived from eight different mares and sired by three different stallions. The adult heterozygotes were obtained from across the USA and were not related to one another.
  • FIG. 6 depicts the result of the equine DNA-dependent protein kinase catalytic subunit mutation and the murine severe combined immunodeficiency mutation described earlier this year b y Blunt et al. and Danska et al.
  • the difference in the two mutated forms of DNA-dependent protein kinase catalytic subunit is dramatic.
  • the conserved regions shared between DNA-dependent protein kinase catalytic subunit and other PI3 kinase family members are intact. This region is absent in the mutated equine protein.

Abstract

The present invention relates to the discovery of the mutation of a DNA-dependent protein kinase protein which results in equine severe combined immunodeficiency (SCID). Specifically, the present invention provides the sequence of the normal and SCID DNA-dependent protein kinase genes, proteins, and provides diagnostic tests for identifying carriers of the mutation utilizing oligonucleotides that differentiate between the normal and the SCID alleles.

Description

CROSS-REFERENCE TO RELATED APPLICATION
This is a continuation of application Ser. No. 08/970,269 filed Nov. 14, 1997, U.S. Pat. No. 5,976,803.
This application claims the benefit of provisional application No. 60/031,261, filed Nov. 15, 1996.
FEDERAL FUNDING LEGEND
This invention was created using funds under NIH grant No. AI32600. The U.S. government, has rights in this invention.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of molecular genetics and veterinary medicine. More specifically, the present invention relates to the mutation of a DNA-dependent protein kinase protein which results in equine severe combined immunodeficiency and a diagnostic test to identify carriers of the mutation.
2. Description of the Related Art
V(D)J rearrangement is the molecular mechanism b y which distinct gene segments (V, D, and J) are joined to form the coding sequences of immunoglobulin (Ig) and T cell receptor (TCR) variable regions. The rearrangement process is targeted by simple DNA sequence elements (recombination signal sequences, RSS) found immediately adjacent to all functional immune receptor gene segments and involves two double-stranded DNA cuts and subsequent re-ligations. This process results in the formation of two new DNA joints; coding joints which contain the coding information, and signal joints which contain the two recombination signal sequences. V(D)J rearrangement is mediated by a lymphoid-specific endonuclease (the RAG 1 and RAG 2 proteins) and ubiquitously expressed components of the double strand break repair pathway. The centrality of V(D)J recombination to the development of the vertebrate immune system is evident in situations where the process is defective.
Defective V(D)J recombination results in a complete block of B and T cell lymphopoiesis and the disease severe combined immunodeficiency (SCID). The first example of defective V(D)J recombination was described in 1983 by Bosma and colleagues, relating to a spontaneous mutation in mice that results in severe combined immunodeficiency (C.B-17 mice). In severe combined immunodeficiency mice, the only step in V(D)J recombination that appears to be impaired is resolution of coding ends. Instead of being resolved into functional immune receptors, cleaved coding ends accumulate abnormally in developing severe combined immunodeficiency lymphocytes. However, cleaved signal ends are resolved at a similar rate as in wild type lymphocytes in mice.
In 1990, it was demonstrated that the defect in severe combined immunodeficiency mice not only impairs V(D)J recombination, but also affects the more general process of double strand break repair (DSBR). This observation was the first to link V(D)J recombination and double strand break repair. In recent years it has been shown that at least four factors are required for both V(D)J recombination and double strand break repair: the Ku heterodimer, DNA-dependent protein kinasecatalytic subunit (PKCS), XRCC4, and XRCC6.
Recently, defective DNA-dependent protein kinasecatalytic subunit has been identified as the determinative factor in C.B-17 severe combined immunodeficiency mice. The DNA-end binding Ku heterodimer interacts with DNA-dependent protein kinasecatalytic subunit to generate a protein kinase (DNA-PK) that is dependent on linear DNA for activation (i.e., DNA-dependent protein kinase). DNA-dependent protein kinasecatalytic subunit is related to the phosphatidylinositol 3-kinase family whose members function in a variety of roles such as signal transduction by phosphorylation of phospholipids, control of cell cycle progression, and maintenance of telomere length.
Although DNA-dependent protein kinasecatalytic subunit has been implicated in a variety of different processes, its precise role is unclear. The factor defective in the double strand break repair mutant CHO cell line XRI. In sum, defects in either the lymphocyte specific components of the V(D)J recombinase (RAG 1 -/- mice, RAG 2-/- mice, RAG-deficient children) or any one of these double strand break repair factors (C.B-17 severe combined immunodeficiency mice, Arabian severe combined immunodeficiency foals, Ku80 -/- mice) results in B and T lymphocyte development being blocked and similar phenotypes are observed.
The occurrence of severe combined immunodeficiency in Arabian foals was initially reported in 1973 by McGuire and Poppie. Recently, it was demonstrated that severe combined immunodeficiency in Arabian foals is explained by a severe block in the generation of specific immune receptors because of defective V(D)J rearrangement. As is the case in murine severe combined immunodeficiency, equine severe combined immunodeficiency cells are hypersensitive to DNA damage because of severely diminished levels of DNA-dependent protein kinasecatalytic subunit. However, these two genetic defects have important mechanistic differences. Unlike severe combined immunodeficiency mice that are preferentially defective in coding resolution, severe combined immunodeficiency foals are defective in both coding and signal resolution.
The prior art is deficient in the lack of effective means of determining the presence of the genetic deteminant for equine severe combined immunodeficiency in an animal of interest. The present invention fulfills this longstanding need and desire in the art.
SUMMARY OF THE INVENTION
Previously, the mechanistic defect responsible for the autosomal recessive disease severe combined immunodeficiency (SCID) in Arabian foals was reported to involve a V(D)J recombination. As with the murine counterpart of SCID, cells from SCID foals have severely depressed levels of DNA dependent protein kinase activity because of a deficiency in the catalytic subunit of the enzyme (DNA-dependent protein kinasecatalytic subunit). However, unlike SCID mice which are specifically impaired in their ability to resolve immune receptor coding joints, SCID foals are incapable of resolving both coding and signal ends.
The present invention presents the genotypic analysis of the defective DNA-dependent protein kinasecatalytic subunit allele in Arabian horses and provides the sequence for the normal and mutant DNA-dependent protein kinasecatalytic subunit gene and protein. These results formally establish the importance of the DNA-dependent protein kinasecatalytic subunit in signal end resolution during V(D)J rearrangement.
In the equine severe combined immunodeficiency mutation, a frameshift deletion prematurely truncates the DNA-dependent protein kinasecatalytic subunit at amino acid 3160 of the normal 4127 amino acid polypeptide. This truncation apparently results in a kinase negative version of the protein. In contrast, the DNA-dependent protein kinasecatalytic subunit mutation responsible for severe combined immunodeficiency in C.B-17 mice may not completely ablate kinase activity. Thus, one explanation for the mechanistic differences in these two DNA-dependent protein kinasecatalytic subunit defects models is that low levels of DNA-dependent kinase (likely present in severe combined immunodeficiency mice) can support signal end resolution, but normal levels are required to support coding resolution.
In one embodiment of the present invention, there is provided a composition of matter comprising an isolated DNA molecule encoding a DNA-dependent protein kinasecatalytic subunit protein in Arabian horses having a sequence shown in SEQ ID No. 28.
In another embodiment of the present invention, there is provided a composition of matter comprising an oligonucleotide having a sequence selected from the group of SEQ ID Nos. 24 and 25. These oligonucleotides precisely span the SCID-determinant region of the DNA-PKCS gene, and are diagnostic for the normal and SCID alleles, respectively.
In yet another aspect of the present invention, there is provided an isolated DNA sequence having the sequence shown in SEQ ID No: 26 or SEQ ID No: 27.
In yet another aspect of the present invention, there is provided a method of identifying an Arabian horse that is a carrier of equine severe combined immunodeficiency, comprising the step of: determining whether said horse has a mutation in a SCID determinant region of a DNA-dependent protein kinasecatalytic subunit gene. In one embodiment of this aspect of the present invention, there is provided a method of identifying an Arabian horse that is a carrier of equine severe combined immunodeficiency which further includes the step of screening a sample of DNA from said horse with an oligonucleotide having the sequence SEQ ID No. 25. In yet another embodiment of this aspect of the invention, there is provided an additional step wherein a second sample of DNA from said horse is screened with an oligonucleotide having the sequence SEQ ID No. 24. In addition, the determining step may include the step of amplifying said DNA-dependent protein kinasecatalytic subunit gene.
A particular aspect of the present invention provides a method of determining whether an Arabian horse has a normal allele for a DNA-dependent protein kinasecatalytic subunit gene, a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene, or both, comprising the steps of: obtaining samples from candidate horses; treating said samples obtained from candidate horses to expose nucleic acids; incubating said sample nucleic acids with a labeled oligonucleotide selected from the group of SEQ ID No. 24 and SEQ ID No. 25, under conditions and for a time sufficient for said oligonucleotides to hybridize to a complementary sequence in said sample nucleic acid, if present; eliminating any unhybridized oligonucleotides; and detecting the presence or absence of said hybridized oligonucleotides, wherein a presence of hybridized oligonucleotide having a sequence SEQ ID No. 24 indicates the presence of a normal allele for a DNA-dependent protein kinasecatalytic subunit gene, wherein a presence of hybridized oligonucleotide having a sequence SEQ ID No. 25 indicates a presence of a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene, and wherein a presence of hybridized oligonucleotides having a sequence SEQ ID No. 24 and SEQ ID No. 25 indicates a presence of both a normal allele for a DNA-dependent protein kinasecatalytic subunit gene and a presence of a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene. An embodiment of this aspect of the present invention includes a DNA amplification step being performed on a SCID-determinant region in a DNA-dependent protein kinasecatalytic subunit gene between said obtaining step and said treating step.
An additional aspect of the present invention includes a n isolated protein encoding a normal DNA-dependent protein kinasecatalytic subunit protein having a sequence SEQ ID No. 29 and an isolated protein encoding a mutant DNA-dependent protein kinasecatalytic subunit protein having a sequence SEQ ID No. 30. The present invention also is drawn to an a plasmid containing a DNA encoding a DNA-dependent protein kinasecatalytic subunit protein (SEQ ID No. 29) and regulatory elements necessary for expression of the DNA in the cell, said plasmid adapted for expression in a recombinant cell, and a plasmid containing the DNA of SEQ ID No. 28 and regulatory elements necessary for expression of said DNA in said cell, said plasmid adapted for expression in a recombinant cell.
A further aspect of the present invention provides a method of identifying an Arabian horse that is a carrier for equine severe combined immunodeficiency, comprising the step of: determining whether said horse has a gene that encodes a protein having a sequence SEQ ID No. 30, wherein a presence of said gene indicates a horse that is a carrier for equine severe combined immunodeficiency.
Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention given for the purpose of disclosure.
BRIEF DESCRIPTION OF THE DRAWINGS
So that the matter in which the above-recited features, advantages and objects of the invention are attained and can b e understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.
FIG. 1 is a diagramatic representation of the DNA-dependent protein kinasecatalytic subunit transcript. Arrows and numbers denote positions of oligonucleotide primers used to amplify the equine transcripts. Each box represents an overlapping cDNA fragment derived from the 0176 and 1821 cell lines. Cloning the fragment from nucleotide 4950 to 9539 from the 1821 cell line was unsuccessful. Thus, the sequence of the 0176 transcript was determined for this region, and then four separate fragments were cloned and sequenced (denoted by dotted lines) from the 1821 cell line.
FIG. 2 presents the deduced amino acid sequence comparison of the equine DNA-dependent protein kinasecatalytic subunit transcript (derived from the 0176 cell line) compared to the human counterpart. Comparison starts at amino acid 180 of the human sequence. Potential DNA-PK autophosphorylation sites and Leucine zipper motifs have been underlined. The conserved protein kinase motifs are shown in bold.
FIG. 3 shows the results of RT-PCR analysis of the DNA-dependent protein kinasecatalytic subunit mutation. RT-PCR was performed on cDNA derived from the 0176 (normal) and 1821 (SCID) cell lines using primer combination 396/392. Amplified products were electrophoresed on agarose gels and transferred to nylon membranes. One filter was hybridized with the N probe (left panel) and the other with the S probe (right panel).
FIG. 4A is a diagramatic depiction of the strategy used to determine the intron/exon organization of the region including the mutated DNA-dependent protein kinasecatalytic subunit exon.
FIG. 4B shows genomic DNA from cell lines 0176 and 1821 amplified with oligonucleotides 392/405. Amplified fragments were cloned and sequenced with primer 392. Sequence analysis of the two clones reveals a five nucleotide deletion in the 1821 genomic fragment.
FIG. 4C shows the sequence comparison of the genomic fragments isolated from the 1821 and 0176 cell lines. These splice acceptor site is underlined. Positions of amplification primers are denoted with arrows.
FIG. 5 shows the genomic PCR analysis of DNA derived from SCID and phenotypically normal animals using primer combinations 392/405. Amplified products were electrophoresed on agarose gels and transferred to nylon membranes. One filter was hybridized with the N probe (top panel) and the other with the S probe (bottom panel). Phenotype and genotype (as determined b y this analysis) is indicated. S denotes SCID; N denotes normal; H denotes heterozygote.
FIG. 6 is a the diagrammatic representation of DNA-dependent protein kinasecatalytic subunit isoforms generated by PI3K splice variation. Subregions of homology to other PI3K family members are as noted by Poltoratsky et al. The murine SCID mutation results in an 80 amino acid truncation which leaves the PI3K domain intact. The equine SCID mutation results in a 967 amino acid truncation which deletes the PI3K domain.
DETAILED DESCRIPTION OF THE INVENTION
The following abbreviations may be used herein: Abbreviations: DSBR, double strand break repair; DNA-PK, DNA dependent protein kinase; DNA-PKCS, catalytic subunit of DNA dependent protein kinase; V(D)J, Variable (Diversity) Joining; RAG, recombination activating gene.
In accordance with the present invention there may b e employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Maniatis, Fritsch & Sambrook, “Molecular Cloning: A Laboratory Manual (1982); “DNA Cloning: A Practical Approach,” Volumes I and II (D. N. Glover ed. 1985); “Oligonucleotide Synthesis” (M. J. Gait ed. 1984); “Nucleic Acid Hybridization” (B. D. Hames & S. J. Higgins eds. (1985)); “Transcription and Translation” (B. D. Hames & S. J. Higgins eds. (1984)); “Animal Cell Culture” (R. I. Freshney, ed. (1986)); “Immobilized Cells And Enzymes” (IRL Press, (1986)); B. Perbal, “A Practical Guide To Molecular Cloning” (1984).
Therefore, if appearing herein, the following terms shall have the definitions set out below.
The amino acids described herein are preferred to be in the “L” isomeric form. However, residues in the “D” isomeric form can be substituted for any L-amino acid residue as long as the desired functional property of immunoglobulin-binding is retained by the polypeptide. NH2 refers to the free amino group present at the amino terminus of a polypeptide. COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide. In keeping with standard polypeptide nomeclature, J Biol. Chem., 243:3552-59 (1969), abbreviations for amino acid residues are shown in the following Table of Correspondence:
TABLE OF CORRESPONDENCE
SYMBOL
1-Letter 3-Letter AMINO ACID
Y Tyr tyrosine
G Gly glycine
F Phe Phenylalanine
M Met methionine
A Ala alanine
S Ser serine
I Ile isoleucine
L Leu leucine
T Thr threonine
V Val valine
P Pro proline
K Lys lysine
H His histidine
Q Gln glutamine
E Glu glutamic acid
W Trp tryptophan
R Arg arginine
D Asp aspartic acid
N Asn asparagine
C Cys cysteine
It should be noted that all amino-acid residue sequences are represented herein by formulae whose left and right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a peptide bond to a further sequence of one or more amino-acid residues. The above Table is presented to correlate the three-letter and one-letter notations which may appear alternately herein.
A “replicon” is any genetic element (e.g., plasmid, chromosome, virus) that functions as an automous unit of DNA replication in vivo; i.e., capable of replication under its own control.
A “vector” is a replicon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to bring about the replication of the attached segment.
A “DNA molecule” refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in either single stranded form, or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure herein according to the normal convention of giving only the sequence in the 5′ to 3′ direction along the nontranscribed strand of DNA (i.e., the strand having a sequence homologous to the mRNA).
An “origin of replication” refers to those DNA sequences that participate in DNA synthesis.
A DNA “coding sequence” is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5′ (amino) terminus and a translation stop codon at the 3′ (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. A polyadenylation signal and transcription termination sequence will usually be located 3′ to the coding sequence.
Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for the expression of a coding sequence in a host cell.
A “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3′ direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3′ terminus by the transcription initiation site and extends upstream (5′ direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined b y mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain “TATA” boxes and “CAT” boxes. Prokaryotic promoters contain Shine-Dalgarno sequences in addition to the −10 and −35 consensus sequences.
An “expression control sequence” is a DNA sequence that controls and regulates the transcription and translation of another DNA sequence. A coding sequence is “under the control” of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.
A “signal sequence” can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that communicates to the host cell to direct the polypeptide to the cell surface or secrete the polypeptide into the media, and this signal peptide is clipped off by the host cell before the protein leaves the cell. Signal sequences can be found associated with a variety of proteins native to prokaryotes and eukaryotes.
The term “oligonucleotide”, as used herein in referring to the probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide. The present invention is drawn to screening oligonucleotides having the sequence SEQ ID 24 or 25, or a portion of these oligonucleotides, which span the SCID-determinant portion of the DNA-dependent protein kinasecatalytic subunit gene.
The term “primer” as used herein refers to a n oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product, which is complementary to a nucleic acid strand, is induced, i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase and at a suitable temperature and pH. The primer may be either single-stranded or double-stranded and must be sufficiently long to prime the synthesis of the desired extension product in the presence of the inducing agent. The exact length of the primer will depend upon many factors, including temperature, source of primer and use the method. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide primer typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides. In the present invention, primers used for amplification of the SCID-determinant region of DNA-dependent protein kinasecatalytic subunit have the sequence of SEQ ID Nos. 22 and 23.
The primers herein are selected to be “substantially” complementary to different strands of a particular target DNA sequence. This means that the primers must be sufficiently complementary to hybridize with their respective strands. Therefore, the primer sequence need not reflect the exact sequence of the template. For example, a non-complementary nucleotide fragment may be attached to the 5′ end of the primer, with the remainder of the primer sequence being complementary to the strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided that the primer sequence has sufficient complementarity with the sequence or hybridize therewith and thereby form the template for the synthesis of the extension product.
As used herein, the terms “restriction endonucleases” and “restriction enzymes” refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence.
A cell has been “transformed” by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A “clone” is a population of cells derived from a single cell or a common ancestor by mitosis. A “cell line” is a clone of a primary cell that is capable of stable growth in vitro for many generations.
Two DNA sequences are “substantially homologous” when at least about 75% (preferably at least about 80%, and most preferably at least about 90 or 95%) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g., Maniatis et al., supra; DNA Cloning, Vols. I & II, supra; Nucleic Acid Hybridization, supra.
A “heterologous” region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature. Thus, when the heterologous region encodes a mammalian gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA in the genome of the source organism. In another example, coding sequence is a construct where the coding sequence itself is not found in nature (e.g., a cDNA where the genomic coding sequence contains introns, or synthetic sequences having codons different than the native gene). Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein.
The labels most commonly employed for these studies are radioactive elements, enzymes, chemicals which fluoresce when exposed to untraviolet light, and others. A number of fluorescent materials are known and can be utilized as labels. These include, for example, florescein, rhodamine, auramine, Texas Red, AMCA blue and Lucifer Yellow. A particular detecting material is anti-rabbit antibody prepared in goats and conjugated with fluorescein through an isothiocyanate.
Proteins can also be labeled with a radioactive element or with an enzyme. The radioactive label can be detected by any of the currently available counting procedures. The preferred isotope may be selected from 3H, 14C, 32P, 35S, 36Cl, 51Cr, 57Co, 58Co, 59Fe, 90Y, 125I, 131I, and 186Re.
Enzyme labels are likewise useful, and can be detected by any of the presently utilized calorimetric, spectrophotometric, fluorospectrophotometric, amperometric or gasometric techniques. The enzyme is conjugated to the selected particle by reaction with bridging molecules such as carbodiimides, diisocyanates, glutaraldehyde and the like. Many enzymes which can be used in these procedures are known and can be utilized. The preferred are peroxidase, β-glucuronidase, β-D-glucosidase, β-D-galactosidase, urease, glucose oxidase plus peroxidase and alkaline phosphatase. U.S. Pat. Nos. 3,654,090, 3,850,752, and 4,016,043 are referred to by way of example for their disclosure of alternate labeling material and methods.
As used herein, the term “normal allele” refers to the gene that codes for the wildtype DNA-PKCS, and does not cause SCID. Specifically, the normal allele does not have the 5 base pair deletion present corresponding to nucleotide 9,454 of the 12,381 nucleotide coding sequence of the human transcript, and has the sequence AGGTAATTTATCATCTCA (SEQ. ID No. 24) at the SCID-determinant region.
As used herein, the term “SCID allele” refers to the gene that codes for the mutant DNA-dependent protein kinasecatalytic subunit protein, and causes equine SCID. Specifically, the SCID allele has the 5 base pair deletion present corresponding to nucleotide 9,454 of the 12,381 nucleotide coding sequence of the human transcript, and has the sequence AGGTAATTTATCAAATTC (SEQ. ID No. 25) at the SCID-determinant region of the DNA-dependent protein kinasecatalytic subunit gene. The 5 base pair deletion results in premature termination of the DNA-dependent protein kinasecatalytic subunit protein at amino acid 3160 of the 4127 amino acid polypeptide.
As used herein, the term “SCID determinant region” of the DNA-dependent protein kinasecatalytic subunit gene refers to region of the DNA-dependent protein kinasecatalytic subunit gene having the 5 base pair deletion in SCID-carrier animals which corresponds to nucleotide 9,454 of the 12,381 nucleotide coding sequence of the human transcript. The SCID determinant region in normal individuals has the sequence AGGTAATTTATCATCTCA (SEQ. ID No. 24) in normal alleles and the sequence AGGTAATTTATCAAATTC (SEQ. ID No. 25) in SCID alleles. The difference in the sequences between the normal and SCID alleles in the SCID-determinant region results in premature termination of the DNA-dependent protein kinasecatalytic subunit protein at amino acid 3160 of the 4127 amino acid polypeptide in the SCID-causing DNA-dependent protein kinasecatalytic subunit protein.
As used herein, the term “carrier” refers to an animal heterozygous for a recessive genetic trait. Carriers are unaffected but have the potential to pass the trait on to their offspring.
The present invention describes the DNA-dependent protein kinasecatalytic subunit gene in both normal and severe combined immunodeficiency horses. In SCID horses, a 5 base pair deletion is present corresponding to nucleotide 9,454 of the 12,381 nucleotide coding sequence of the human transcript. This 5 base pair deletion results in premature termination of the DNA-dependent protein kinasecatalytic subunit protein at amino acid 3160 of the 4127 amino acid polypeptide. Unlike the murine DNA-dependent protein kinasecatalytic subunit mutation (which deletes the C terminal 80 amino acids of the protein), the equine DNA-dependent protein kinasecatalytic subunit mutation most likely ablates DNA-dependent protein kinase activity completely. Thus, equine DNA-dependent protein kinasecatalytic subunit plays a role in both signal end resolution and coding end resolution. Asymmetry of signal versus coding ligation in severe combined immunodeficiency mice (lacking in severe combined immunodeficiency foals) may be explained b y minimal DNA dependent protein kinase activity in severe combined immunodeficiency mice.
The following diagnostic strategy for differentiating SCID heterozygotes, homozygotes, and normal horses may be used by a person having ordinary skill in this art given the teachings of the present invention. Using the sequence information obtained of the DNA-PKCS transcripts from normal and SCID foals, a simple diagnostic test for determining genotype of a given animal is straightforward to one skilled in the art of molecular biology. Since the present invention has identified precisely the same mutation in eight SCID animals and in two carriers, it is likely that this mutation is responsible for the majority of SCID cases in Arabian horses. This mutation is likely the result of a breeding bottleneck and a genetic founder effect.
A desirable diagnostic test would take advantage of the genomic sequence surrounding the mutation. Such a test may use a strategy of amplifying the region of interest from DNA derived from the animal to be tested. Probes spanning the unmutated sequence or mutated sequence will, under the appropriate conditions, hybridize specifically. Thus, DNA from a normal animal which is not a carrier would hybridize with the probe based on the unmutated sequence, but would not hybridize with the probe based on the mutated sequence. DNA from a heterozygous, carrier animal will hybridize with both probes. DNA from a SCID animal will only hybridize with the probe based on the mutated sequence.
In one method of the present invention, there is provided a method of identifying an Arabian horse that is a carrier of equine severe combined immunodeficiency, comprising the step of: determining whether said horse has a mutation in a SCID determinant region of a DNA-dependent protein kinasecatalytic subunit gene. In a prefered embodiment of this method, there is provided a method of determining whether an Arabian horse has a normal allele for a DNA-dependent protein kinasecatalytic subunit gene, a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene, or both, comprising the steps of: obtaining samples from candidate horses; treating said samples obtained from candidate horses to expose nucleic acids; incubating said sample nucleic acids with a labeled oligonucleotide selected from the group of SEQ ID No. 24 and SEQ ID No. 25, under conditions and for a time sufficient for said oligonucleotides to hybridize to a complementary sequence in said sample nucleic acid, if present; eliminating any unhybridized oligonucleotides; and detecting the presence or absence of said hybridized oligonucleotides, wherein a presence of hybridized oligonucleotide having a sequence SEQ ID No. 24 indicates the presence of a normal allele for a DNA-dependent protein kinasecatalytic subunit gene, wherein a presence of hybridized oligonucleotide having a sequence SEQ ID No. 25 indicates a presence of a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene, and wherein a presence of hybridized oligonucleotides having a sequence SEQ ID No. 24 and SEQ ID No. 25 indicates a presence of both a normal allele for a DNA-dependent protein kinasecatalytic subunit gene and a presence of a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene. An embodiment of this aspect of the present invention includes a DNA amplification step being performed on a SCID-determinant region in a DNA-dependent protein kinasecatalytic subunit gene between said obtaining step and said treating step.
In another method of the present invention, there is provided a method of determining whether an Arabian horse has a normal allele for a DNA-dependent protein kinasecatalytic subunit gene, a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene, or both, comprising the steps of: obtaining samples from candidate horses; treating said samples obtained from candidate horses to expose nucleic acids; incubating said sample nucleic acids with a labeled oligonucleotide selected from the group of SEQ ID No. 26 and SEQ ID No. 27, or portions thereof, under conditions and for a time sufficient for said oligonucleotides to hybridize to a complementary sequence in said sample nucleic acid, if present; eliminating any unhybridized oligonucleotides; and detecting a presence or absence of said hybridized oligonucleotides; wherein a presence of hybridized oligonucleotide having a sequence SEQ ID No. 27 indicates a presence of a normal allele for a DNA-dependent protein kinasecatalytic subunit gene, wherein a presence of hybridized oligonucleotide having a sequence SEQ ID No. 26 indicates a presence of a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene, and wherein a presence of hybridized oligonucleotides having a sequence SEQ ID No. 26 and SEQ ID No. 27 indicates a presence of both a normal allele for a DNA-dependent protein kinasecatalytic subunit gene and a presence of a SCID allele for a DNA-dependent protein kinasecatalytic subunit gene.
In addition, several alternative amplification strategies are envisioned. Since equine SCID is the result of a 5 nucleotide deletion, primers can be designed easily which selectively amplify the mutated or the normal allele. Further, it is well within the expertise of the skilled artisan that primers can be designed such that products amplified from the mutated and normal alleles have unique sizes or unique restriction endonuclease sites to allow for rapid diagnosis. The main point being that no matter what molecular technique is used, all strategies involve detecting the portion of the DNA-dependent protein kinasecatalytic subunit gene in which the 5-nucleotide deletion occurs in the mutated DNA-dependent protein kinasecatalytic subunit gene. The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.
EXAMPLE 1
Cell Lines
The 0176 fibroblast cell line was derived from a normal (non-Arabian) horse. The 1821 fibroblast cell line was derived from a homozygous severe combined immunodeficiency foal. All cultures were carried out in DMEM medium (GIBCO Laboratories, Grand Island, N.Y.) supplemented with 10% FCS.
EXAMPLE 2
RT-PCR
RT-PCR was performed on RNA isolated from the 0176 and 1821 cell lines. RNA was isolated using RNAzol (Biotecx; Houston, Tex.). After ethanol precipitation, cDNA was prepared using Superscript (reverse transcriptase); PCR was performed using Elongase (Taq polymerase) according to the manufacturers recommendations (Gibco BRL, Gaithersburg, Md.). Transcripts amplified in this manner were subcloned and sequenced using standard techniques.
EXAMPLE 3
Oligonucleoties
Position of amplification primers is illustrated in FIG. 1. Sequences of oligonucleotides used were as follows:
262: GTATATGAGCTCCTAGG (SEQ. ID No.1);
265: GGGAGAATCTCTCTGCAA (SEQ. ID No.2);
TCAGGAGVRC ATCAGCTT (SEQ ID No.3)
266: GATCCAGCGGCTAACTTG (SEQ. ID No.4);
285: CATGTGCTAAGGCCAGAC (SEQ. ID No.5);
286: TCTACAGGGAATTCAGGG (SEQ. ID No.6);
293: CACCATGAATCACACTTC (SEQ. ID No.7);
296: CACCAAGGACTGAAACTT (SEQ. ID No. 8);
330: GCACTTTCATTCTGTCAC (SEQ. ID No.9);
317: ATTCATGACCTCGAAGAG (SEQ. ID No. 10);
318: TGGACAAACAGATATCCAG (SEQ. ID No. 11);
259: ATCGCCGGGTTTGATGAGCGGGTG (SEQ. ID No.12);
255: CAGACCTCACATCCAGGGCTCCCA (SEQ. ID No. 13);
348: GAGACGGATATTTAATG (SEQ. ID No. 14);
414: GGAGTGCAGAGCTATTCAT (SEQ. ID No.15);
415: GCAATCGATTTGCTAACAC (SEQ. ID No.16);
350: GTCCCTAAAGATGAAGTG (SEQ. ID No. 17);
382: GTCATGAATCCACATGAG (SEQ. ID No. 18);
357: TTCTTCCTGCTGCCAAAA (SEQ. ID No. 19);
358: CTTTGTTCCTATCTCACT (SEQ. ID No. 20);
383: AGACTTGCTGAGCCTCGA (SEQ. ID No. 21);
405: TTCCTGTTGCAAAAGGAG (SEQ. ID No. 22);
392: TTTGTGATGATGTCATCC (SEQ. ID No. 23);
N: AGGTAATTTATCATCTCA (SEQ. ID No. 24);
S: AGGTAATTTATCAAATTC (SEQ. ID No. 25).
EXAMPLE 4
Genomic PCR
Total genomic DNA was analyzed from spleen, bone marrow, peripheral blood or fibroblast cell lines as indicated. DNA was isolated using ABI DNA lysis buffer (Applied Biosystems, Foster City, Calif.). Oligonucletide primers 405 and 392 (SEQ ID Nos. 22 and 23) were used to screen for the mutant severe combined immunodeficiency allele. Amplification conditions were 94° C. for 30 seconds, 55° C. for 90 seconds, and 68° C. for five minutes. Amplified DNA was loaded onto 1.5% duplicate agarose gels for Southern filter hybridization analysis. After electrophoresis, DNA was transferred in 0.4N NaOH onto nylon membranes (Zeta-probe, Biorad, Hercules, Calif.). Southern filter hybridization was done in 6×SSC, 0.5% SDS, and 5×Denhardts at 42° C. 32P-end labeled oligonucleotides specific for the normal and severe combined immunodeficiency alleles were used as hybridization probes. Filters were washed in 6X SSC and 0.5% SDS at 65° C.
EXAMPLE 5
Results
An RT-PCR strategy (depicted in FIG. 1) was used to clone and sequence the normal and severe combined immunodeficiency equine DNA-dependent protein kinasecatalytic subunit transcripts. Amplification primers were based upon the published human DNA-dependent protein kinasecatalytic subunit sequence. cDNA was derived from two fibroblast cell lines, 0176 (derived from a normal, non-Arabian animal) and 1821 (derived from a severe combined immunodeficiency foal). Previously, it was demonstrated that 1) the 1821 cell line was hypersensitive to ionizing radiation, 2) had no detectable DNA-dependent protein kinase activity, 3) lacks DNA-dependent protein kinasecatalytic subunit protein, and 4) could not support RAG-induced recombination as assayed by signal joint formation.
Six overlapping cDNA fragments were isolated from the 0176 cell line; ten overlapping cDNA fragments were isolated from the 1821 cell line. Using this strategy, 11,811 nucleotides of the 12,381 DNA-dependent protein kinasecatalytic subunit transcript were sequenced. Isolation of the first 570 bp of the two equine transcripts was unsuccessful using this strategy. This may indicate less evolutionary conservation of this region between the human and equine DNA-dependent protein kinasecatalytic subunit genes.
The deduced amino acid sequence of equine DNA-dependent protein kinasecatalytic subunit is compared to the human counterpart in FIG. 2. Overall, the two proteins are 84% homologous. There are several small insertions within the equine transcript adding an additional 6 codons. Though the PI3K domain is well conserved between the human and equine sequences (87%), homology within this region was not dramatically higher than throughout the rest of the protein. The region within the PI3K domain corresponding to the putative kinase active site was slightly more conserved. This corresponds to subdomain II as noted by Poltoratsky et al. which includes the conserved protein kinase motifs; homology within this subdomain between human and equine DNA-dependent protein kinasecatalytic subunit is 92%. The leucine residues comprising a potential leucine zipper motif noted by Hartley et al. were completely conserved in the equine protein. Similarly, 17 of 18 potential DNA-dependent protein kinase autophosphorylation sites noted by Hartley et al. were also conserved.
In the RT-PCR fragment spanning nucleotide ˜8000 to ˜9650 from the 1821 severe combined immunodeficiency cell line, a nucleotide deletion was found. To rule out the possibility that this deletion was the result of a Taq polymerase error, this region was amplified again from both the 0176 and 1821 cell lines (FIG. 3). Two oligonucleotides spanning this region representing the normal (N probe) and severe combined immunodeficiency (S probe) sequences were synthesized. As can be seen, the product amplified from the normal cell line, 0176, hybridizes well with probe N but not at all with probe S. In contrast, the product amplified from the severe combined immunodeficiency cell line, 1821, hybridizes exclusively with the S probe.
Next, germline sequences encoding this region were isolated by amplifying spleen DNA derived from a severe combined immunodeficiency foal with oligonucleotides spanning the deletion. A 1.8 kB fragment including portions of two exons and a 1.5 kB intron was cloned (depicted in FIGS. 4A-C). The intron exon border of the exon containing the 5 bp deletion was determined. Genomic fragments spanning this region from the 0176 and 1821 cell lines were cloned; sequence analysis of the normal allele and severe combined immunodeficiency allele is shown in FIG. 4C, confirming this 5 bp deletion in DNA derived from the 1821 cell line.
Next, it was determined whether this 5 bp deletion accounts for severe combined immunodeficiency in many Arabian foals, or just a subset of affected animals. To that end, genomic DNA was derived from eight different severe combined immunodeficiency foals and five normal animals (four Arabian and one non-Arabian). For the severe combined immunodeficiency animals, the diagnosis of severe combined immunodeficiency was established on the basis of lymphopenia (<1,000 lymphocytes/μl peripheral blood), absence of IgM, and hypoplasia of lymphoid tissues as described previously. The eight severe combined immunodeficiency foals were derived from eight different mares and sired by three different stallions. The adult heterozygotes were obtained from across the USA and were not related to one another.
As can be seen in FIG. 5, in all severe combined immunodeficiency foals tested the probe specific for the 5 b p deletion hybridizes strongly; the probe specific for the normal allele does not hybridize at all. Furthermore, in all samples derived from normal animals, the hybridization probe derived from the normal allele hybridizes strongly. In two normal animals, both the N probe and the S probes hybridize well identifying these two animals a s heterozygotes. From these data, it can be concluded that this specific 5 bp mutation is responsible for a significant fraction of the cases of severe combined immunodeficiency in Arabian horses.
Severe combined immunodeficiency in Arabian foals was first described by McGuire and Poppie in 1973 and the mechanistic defect in these animals is V(D)J recombination and double strand break repair has now been demonstrated. The present invention establishes that the factor responsible for this genetic disease is a truncated form of the catalytic subunit of the DNA dependent protein kinase. Unlike the situation in the human disease ataxia telangiectasia, where mutations in the ATM gene (another PI3K family member) occur throughout the protein, in all severe combined immunodeficiency foals examined to date, the same mutation exists. Thus, since eight unrelated severe combined immunodeficiency foals have the identical DNA-dependent protein kinasecatalytic subunit mutation it is likely that this DNA-dependent protein kinasecatalytic subunit allele has common origins and because of a bottleneck in breeding results in a genetic “founder” effect.
Since there are several clear mechanistic differences between mice and horses, the finding that DNA-dependent protein kinasecatalytic subunit levels were severely diminished in both was initially paradoxical. The differences between severe combined immunodeficiency mice and severe combined immunodeficiency foals are actually twofold. First, in severe combined immunodeficiency foals, both signal and coding joint ligation is impaired; whereas signal ligation is relatively normal in severe combined immunodeficiency mice. In addition, by limiting dilution PCR analysis, it was determined that coding ligation is more severely impaired in severe combined immunodeficiency foals than in severe combined immunodeficiency mice. Whereas it is very easy to detect some coding ligation in severe combined immunodeficiency mice (“leaky” severe combined immunodeficiency phenotype), demonstration of any coding joint formation in severe combined immunodeficiency foals is exceedingly difficult. Thus, it was thought originally that the defective factors in these two animal models of severe combined immunodeficiency might be distinct. The definition of the specific DNA-dependent protein kinasecatalytic subunit mutation in equine severe combined immunodeficiency coupled with the description of the precise mutation responsible for murine severe combined immunodeficiency provide a good explanation for the mechanistic differences observed between severe combined immunodeficiency mice and severe combined immunodeficiency horses.
FIG. 6 depicts the result of the equine DNA-dependent protein kinasecatalytic subunit mutation and the murine severe combined immunodeficiency mutation described earlier this year b y Blunt et al. and Danska et al. The difference in the two mutated forms of DNA-dependent protein kinasecatalytic subunit is dramatic. In the murine mutation, the conserved regions shared between DNA-dependent protein kinasecatalytic subunit and other PI3 kinase family members are intact. This region is absent in the mutated equine protein. Thus, in cells from severe combined immunodeficiency foals, there can clearly be no DNA-dependent kinase activity; however, since the mutation in severe combined immunodeficiency mice preserves most of the PI3K homology domain, some kinase activity may be present.
The description of defective signal ligation in severe combined immunodeficiency foals is not the only evidence linking DNA-dependent protein kinasecatalytic subunit to signal ligation. The double strand break repair mutant cell line V3 also has diminished (though not absent) signal end resolution. As in murine severe combined immunodeficiency cells, in V3 cells some protein immunoreactive with anti-DNA-dependent protein kinasecatalytic subunit antibodies can be detected. Thus, an attractive hypothesis is that preferentially-defective coding versus signal resolution may result from diminished levels of DNA-dependent protein kinase kinase activity; whereas absence of DNA-dependent protein kinase activity impairs both signal and coding ligation. In support of that conclusion, Errami et al. recently demonstrated that cells which are completely defective in the regulatory subunit of DNA-dependent protein kinase, Ku (specifically in the 86 kD subunit of Ku), which were transfected with low levels of Ku80 are like mouse severe combined immunodeficiency cells, preferentially defective in coding joint ligation. Thus, this hypothesis can be extended in that preferentially defective coding versus signal resolution may result from diminished levels of any component of DNA-dependent protein kinase; whereas absence of any component of DNA-dependent protein kinase impairs both signal and coding ligation.
Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.
One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(iii) NUMBER OF SEQUENCES: 32
(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
GTATATGAGC TCCTAGG 17
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
GGGAGAATCT CTCTGCAA 18
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
TCAGGAGTTC ATCAGCTT 18
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
GATCCAGCGG CTAACTTG 18
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
CATGTGCTAA GGCCAGAC 18
(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
TCTACAGGGA ATTCAGGG 18
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
CACCATGAAT CACACTTC 18
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other
(iii) HYPOTHETICAL: No
(iv) ANTI-SENSE: No
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
CACCAAGGAC TGAAACTT 18
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
GCACTTTCAT TCTGTCAC 18
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
ATTCATGACC TCGAAGAG 18
(2) INFORMATION FOR SEQ ID NO:11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
TGGACAAACA GATATCCAG 19
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
ATCGCCGGGT TTGATGAGCG GGTG 24
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
CAGACCTCAC ATCCAGGGCT CCCA 24
(2) INFORMATION FOR SEQ ID NO:14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
GAGACGGATA TTTAATG 17
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
GGAGTGCAGA GCTATTCAT 19
(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 19 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
GCAATCGATT TGCTAACAC 19
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
GTCCCTAAAG ATGAAGTG 18
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
GTCATGAATC CACATGAG 18
(2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:
TTCTTCCTGC TGCCAAAA 18
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double-stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
CTTTGTTCCT ATCTCACT 18
(2) INFORMATION FOR SEQ ID NO:21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
AGACTTGCTG AGCCTCGA 18
(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
TTCCTGTTGC AAAAGGAG 18
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
TTTGTGATGA TGTCATCC 18
(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
AGGTAATTTA TCATCTCA 18
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
AGGTAATTTA TCAAATTC 18
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 243 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
AGTCATTGGG TCCATTTTAG CATCCGGATA TCTGTTTGTC CAGGTTTTTA GAAGTCTCTT 60
AAGGGGAATT TGATAAATTA CCTAAAAATA ATATTAGAGA ATGACTATAT CCACAGCTCA 120
ATGACAAGAC CAACTTATAA AGTGAGCTCC TATAGTAAAG AGAAACTTAA TTCAAATTTC 180
TTGTCCAAAT TAAAAAATTC TGTCTCCTTT TGCAACAGGA ACACAAAGCT ACCATATTAA 240
AAC 243
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 248 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
AGTCATTGGG TCCATTTTAG CATCCGGATA TCTGTTTGTC CAGGTTTTTA GAAGTCTCTT 60
AAGGGGAATT TGAGATGATA AATTACCTAA AAATAATATT AGAGAATGAC TATATCCACA 120
GCTCAATGAC AAGACCAACT TATAAAGTGA GCTCCTATAG TAAAGAGAAA CTTAATTCAA 180
ATTTCTTGTC CAAATTAAAA AATTCTGTCT CCTTTTGCAA CAGGAACACA AAGCTACCAT 240
ATTAAAAC 248
(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11883 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
GTATATGAGC TCCTAGGAGT ATTAGGTGAA GTTCATCCTA GTGAGATGAT AAGTAATTCA 60
GAACAACTGT TCCGGGCTTT TCTGGGTGAA CTTAAGTCCC AGATGACATC AACAGTAAGA 120
GAGCCCAAAC TACCTGTTCT GGCAGGGTGT CTGAAGGGAT TGTCATCACT TATGTGTAAC 180
TTCACTAAGT CCATGGAAGA AGATCCCCAG ACTTCAAGGG AGATTTTTGA TTTTGCGTTA 240
AAGGCAATTC GTCCTCAGAT TGATCTGAAG AGATATGCAG TGCCCTTAGC TGGTTTATGC 300
TTATTTACCC TGCATGCATC TCAATTTAGC ACCTGCCTTT TGGAGAACTA CGTTTCTTTG 360
TTTGAAGTGC TGTCAAAATG GTGTGGCCAT ACAAACATAG AATTGAAAAA AGCCGCACAT 420
TCAGCTCTGG AGTCTTTTCT GAAACAGGTT TCTTTTATGG TGGCAAAAGA TGCAGAAAGG 480
CATAAGAATA AGCTGCAGTA CTTTATGGAG CAATTCTATG GAATCATCAG GAACATGGAT 540
TCAAATAGCA AGGATTTATC AATTGCAATT CGTGGATATG GACTTTTTGC AGGCCCTTGC 600
AAGGTTATAA ACGCAAAAGA TGTTGACTTC ATGTACGTAG AGCTCATTCA GCGCTGCAAG 660
CAGCTGTTCC TCACCCAGAC AGATACTGTT GATGACCATA TTTACCAGAT GCCCAGTTTC 720
CTCCAATCTA TTGTAAGTGT CTTGCTTTAC CTTGATACAA TTCCTGAGGT GTATACTCCG 780
GTTCTGGAAC ATCTCATGGT GGTACAGATA GACAGCTTCC CACAGTATAG TCCAAAAATG 840
CAGCCGGTGT GTTGTAGAGC CATAGTGAAA CTTTTCCTAG CCTTAGCAGA AAAGGGACCA 900
GTTCTCTGGA ATTGCATTAG TACTGTGGTG CATCAAGGTT TAATTAGAAT ATGTTCTAAA 960
CCAGTCGTCT TTCAAAAGGG TGCTGGGTCT GAATCCGAAG ACTATCATAC ATCAGAGGAA 1020
GCTAGAACTG GCAAATGGAA AATGCCCACA TACAAAGACT ATTTGGATCT TTTTAGATAT 1080
CTCCTGAGCT GTGACCAGAT GATGGATTCT CTTTTAGCAG ATGAAGCATT TCTCTTTGTG 1140
AATTCCTCCC TTCATAGTCT GAATCGTTTG CTGTATGATG AATTTGTAAA ATCAGTTTTG 1200
AAGATTGTTG AGAAATTGGA TCTTACACTA GAAAAACAGA ATGTTGGGGA GCAAGAGGAT 1260
GAAACTGAAG CTACTGGTGT TTGGGTGATC CCGACTTCAG ATCCAGCGGC TAACTTGCAC 1320
CCTGCTAAAC CTAAAGATTT TTCAGCTTTC ATTAACCTGG TGGAATTTTG CAGAGAGATT 1380
CTTCCTGAGA AACATGTAGA ATTTTTTGAG CCATGGGTTT ACTCATTTGC GTATGAATTA 1440
ATTTTGCAGT CTACACGGTT ACCACTCATC AGTGTTTTTT ACAAATTGCT TTCTGTTGCT 1500
GTGAGAAATG CCAAGAAAAT GAAGTATTTT GAAGGAGTTG GTCCAAAGAG TCAGAAACAG 1560
TCTCCTGAGG ACCTAGAAAA GTATTCTTGC TTTGCTTTGT TTGCAAAATT TAGTAAAGAG 1620
GTATCAATTA AAATGAAGCA ATACAAAGAT GAACTTTTGG CCTCCTGTTT GACCTTTATT 1680
CTGTCCCTGC CACATGACAT CATTGAACTT GATGTTAGAG CCTACGTTCC TGCATTGCAG 1740
ATGGCTTTTA AACTGGGCCT GAGCTATACT CCATTGGCGG AAGTAGGCCT GAATGCTCTA 1800
GAAGAATGGT CAGGTTACAT CTGCAAACAT GTAATTCAGC CCTATTATAA GGACATTCTA 1860
CCCAGCCTTG ATGGATATCT GAAAACTTCA GTCTTATCAG ATGAGACCAA GAATAGCTGG 1920
CAAGTGTCAG CACTTTCTCG GGCTGCCCAG AAAGGATTTA ATAAAGTTGT GCTAAAGCAT 1980
CTGACAAAGA CAAAGAGCAT TTCATCAAAT GAAGCACTGT CCTTAGAAGA AGTGAGGATT 2040
AGAGTAGTAC GGATACTTGG CTCTCTAGGA GGACAAATAA ACAAGAATCT CGTAACAGCT 2100
GCATCATCAG ATGAAATGAT GAAGAAGTGT GTGGCATGGG ACAGAGAAAA AAGACTCCGT 2160
TTTGCAGTAC CATTTATGGA GATGAAGCCT GTCATTTATC TGGATCTATT CCTGCCTCGG 2220
GTCACCGAGT TAGCTCTTTC AGCTAGTGAC AGGCAGACTA CAGTTGCAGC CTGTGAACTT 2280
TTACATAGCA TGGTTATGTT TATGTTGGGA AAAGCCACTC AGATGCCTGA AGATGGTCAG 2340
GGTTCCCCAC CCATGTACCA GCTCTATAAG CGAACTTTTC CTGTTTTACT TCGACTTGCA 2400
TGTGATGTAG ATCAGGTGAC AAGGCAACTG TATGAGCCAC TAGTTATGCA ACTGATTCAC 2460
TGGTTCACTA ACAACAAGAA ATTTGAAAGT CAGGACACTG TCGCCTTACT AGAAACGATA 2520
TTGGATGGAA TTGTGGACCC TGTTGACAGT ACTTTGAGAG ATTTTTGTGG TCAGTGTATT 2580
CAAGAATTCC TTAAATGGTC CATTAAGCAG ACGACACCAC AGCAGCAGGA AAAAAGTCCA 2640
GTAAATACCA AATCGCTTTT CAAGCGACTG TATAGCTTTG CACTTCATCC GAATGCCTTC 2700
AAGAGGCTGG GAGCATCACT TGCTTTTAAT AATATCTACA GGGAATTCAG GGAAGAAGAG 2760
TCTCTGGTAG AACAGTTTGT GTTTGAAGCC TTGGTAACGT ATATGGAAAG TCTGGCCTTA 2820
GCACATACAG ATGAGAAATC CTTAGGTACA ATTCAACAAT GTTGTGATGC CATTGATCAT 2880
CTCAGTCTTA TCATTGAGAA GAAGCACGTT TCTTTAAACA AAGCAAAAAA ACGACGTTTG 2940
CCACGAGGCT TTCCACCTGC GACATCACTG TGTTTATTGG ATGTGGTCCA GTGGCTTTTA 3000
GCAAATTGTG GGAGACCCCA GACAGAATGT CGACACAAAT CCATAGAACT CTTTTATAAA 3060
TTTGTTACTT TATTGCCAGG CAACAAATCC CCTTTTTTAT GGCTGAAAGA TATTATCAAG 3120
AAAGAAGATA TTTCCTTTCT CATAAACACA TTTGAGGGCG GGGGAAGTGG TCGGCCGTCA 3180
GGCATCCTTG CTCAGCCAAC CCTCTTCCAT TTGCAAGGGC CGTTCAGTCT CAGAGCTGCC 3240
CTGCAGTGGA TGGACATGCT TCTGGCAGCA CTGGAGTGCT ACAACACATT CATTGAAGAG 3300
AAAACTCTGG AAGCACCCAA GGTCCTAGGT ACTGAAACCC AGTCTTCACT TTGGAAAGCG 3360
GTGGCTTTCT TTTTAGAAAG CATTGCTATG CATGATATTA TGGCAGCAGA AAAGTACTTT 3420
GGCACTGGGG CAACAGGTAA CAGACCCAGC CCACAAGAAG GAGAAAGATA TAATTATAGC 3480
AAATGTACAA TTGTGGTCCG CATTATGGAA TTTACCACAA CGCTCCTCAG CACCTCCCCA 3540
GAAGGCTGGA AGCTGCTTGA GAAGGATGTG TGTAACACAA ACCTTATGAA ACTCTTAGTG 3600
AAAACCCTGT GTGAGCCCTC AAGCATAGGT TTCAACATCG GAGATGTCGC AGTTATGAAC 3660
TATCTTCCCA GTGTTTGTAC CAACCTGATG AAAGCACTGA AGAAGTCCCC ATACAAAGAC 3720
ATCCTGGAGA TGCACCTCAA GGAAAAGATA ACAGCACAGA GCATTGAAGA GCTCTGTGCA 3780
GTTGACTTGT ATTGCCCTGA TGCTTGCGTG GACAGGGCCA GGCTGGCTTC TGTCGTGTCA 3840
GCTTGTAAAC AACTTCATAG AGCGGGGGTT TTGTGTGTTA TAATACCATC TCAGTCTGCA 3900
GATCAGCATC ATTCTATTGG CACAAAACTT CTTTCCTTGG TTTATAAAAG CATTGCACCT 3960
GGAGATGAAC AACAGTGCCT TCCTTCACTA GATCCCAATT GTAAGCGATT GGCCAGTGGA 4020
CTTCTGGAGT TGGCCTTTGC TTTTGGAGGA CTGTGTGAGC ACCTTGTGAG TCTTCTCCTG 4080
GACACGACAG TGTTGTCTAT GCCATCCAGA GGAGGGTCCC AGAAAAACAT CGTCAGCTTC 4140
TCTCATGGAG AGTATTTTTA TAGCTTGTTC TCAGAAACGA TCAACACTGA ATTGTTGAAA 4200
AATCTAGATC TTGCTGTATT GGAGCTCATG AAATCATCTG TGGATAATCC CAAAATGGTG 4260
AGCAATGTTT TGAATGGTAT GTTAGATCAG AGCTTCAGGG ATCGAACCAG TGAGAAACAC 4320
CAAGGACTGA AACTTGCAAC TATAATTCTG CAAAACTGGA AGAAGTGTGA TTCATGGTGG 4380
GCCAAAGATT CTGCTCCTGA AAGTAAAATG GCAGTGCTTA CCTTGTTGGC AAAAATTTTC 4440
CAGATTGATT CATCTGTTTG TTTTAATACA AATCACTGCA TGTTCCCTGA AGTCTTTACA 4500
ACATATGTTA GTCTACTTGC TGATTCAAAG TTGGACCTGC ATTTAAAGGG CCAAGCTATA 4560
ATTCTTCTTC CATTCTTCAC CAGTCTTACT GGAGGCAGCC TTGAGGACCT TAAGGTTGTT 4620
CTTGAAAACC TCATCGTTTC TAATTTTCCT ATGAAATCTG AAGAATTTCC CCCAGGAACT 4680
CTGCAGTACA ATAATTATGT GGACTGCATG AAGAAGTTTC TAGATGCATT GGAATTATCT 4740
AAAAGCCCTA TGTTGTTGCA GTTGATGACA GAAATTCTTT GTCGTGAACA GCAACATGTT 4800
ATGGAAGAAT TATTTCAGTC TACTTTCAAA AAGATTGCCA GAAAGAGTTC ATGTATCACA 4860
CAATTAGGCC TTCTGGAAAG TGTATATAGA ATGTTCAGGA GGGATGACCT GCTTTCAAAT 4920
ATCACTCGCC AAGCATTTGT AGACCGTTCT CTGCTCACTC TGTTGTGGCA CTGTAGCTTG 4980
AATGCTTTGA GGGAATTTTT TAGCAAAATT GTGGTGGAAG CCATTAATGT GTTGAAGTCC 5040
AGATTTATAA AGCTGAATGA ATCTGCCTTT GATACTCAAA TCACCAAGAA GATGGGCTAC 5100
TATAAGATGT TAGATGTGAT GTATTCTCGT CTTCCAAAAG ATGATGTTCA CTCTAAGGAA 5160
TCTAAAATTA ATCAAGTTTT CCATGGCTCA TGTATTACAG AAGGAAGTGA ACTTACAAAG 5220
ACACTTATTA AATTGTGCTA TGATGCCTTT ACAGAGAACA TGGCAGGCGA GAACCAGTTG 5280
CTGGAGAGGA GAAGACTTTA CCATTGTGCT GCATACAACT GTGCCATTTC TGTTGTCTGC 5340
TGTGTCTTCA ATGAATTAAA ATTTTACCAA GGTTTTCTGT TTACTGAAAA ACCAGAAAAG 5400
AACTTGCTTA TTTTTGAAAA TCTGATAGAC TTGAAGCGCT GCTACACGTT TCCTATAGAA 5460
GTTGAGGTTC CTATGGAGAG AAAGAAAAAG TACCTTGAAA TTAGAAAAGA AGCCAGGGAA 5520
GCAGCAGCAA GTGGGGATTC AGATGGTCCT CGTTATATAT CTTCCTTGTC ATATTTGGCA 5580
GACAGTAGCC TGAGTGAGGA AATGAGTCAA TTTGATTTCT CGACTGGAGT GCAGAGCTAT 5640
TCATATAGTT CCCAAGACCC TAAATCTACC ACTGCTCATT TTCGGAGACA GAAACATAAA 5700
GAGTCCATGA TCCAAGATGA TATCCTGGAG TTAGAGATGG ATGAACTCAA TCAACACGAA 5760
TGTATGGCAA CTATGACTGC TCTGATTAAG CACATGCAGA GAAATCAGAT CCTCCCTAAG 5820
GAAGAAGAGG GTTCAGTGCC AAGAAATCTT CCTCCTTGGA TGAAATTTCT TCATGACAAA 5880
CTAGGAAATC CATCAATATC ATTAAATATC CGTCTCTTCT TAGCCAAGCT TGTTATTAAT 5940
ACAGAAGAAG TCTTTCGTCC TTACGCGAGA TACTGGCTCA GCCCTTTGCT GCAGCTGGTT 6000
GTTTCTGGAA ACAACGGAGG AGAAGGAATT CACTATATGG TGGTTGAGAT AGTGGTTATT 6060
ATTCTTTCAT GGACAGGATT AGCTACTCCT ATAGGTGTCC CTAAAGATGA AGTGTTAGCA 6120
AATCGATTGC TTCATTTCCT AATGAAACAT GTTTTTCATC AAAAAAGAGC TGTGTTTAGA 6180
CACAACCTCG AAATTATAAA AACCCTTGTT GAATGCTGGA AGGATTGTTT ATCCATCCCT 6240
TACAGGTTAA TATTTGAAAA GTTTTCCAGT ACAGATCCTA ATTCTAAAGA CAATTCAGTA 6300
GGAATTCAAT TACTAGGCAT TGTAATGGCC AATAACTTGC CTCCTTATGA CCCAAAATGT 6360
GGCATAGAGA GCATAAAATA CTTTCAAGCT TTGGTCAATA ATATGTCCTT TGTAAGATAT 6420
AGAGAGGTAT ATGCAGCAGC GGCAGAAGTT CTAGGACTTG TTCTTCGATA TATTACTGAG 6480
AGAGAAAATA TACTGGAGGA GTCTGTGTGT GAACTGGTCA TAAAACAGTT GAAGCAACAT 6540
CAGAATACGA TGGAGGACAA ATTTATTGTG TGCTTGAACA AAGCTGTGAA GAACTTCCCT 6600
CCTCTTGCTG ATAGGTTTAT GAACACCGTG TTCTTCCTGC TGCCAAAATT TCATGGCGTG 6660
ATGAAGACTC TCTGTCTGGA GGTGGTACTG TGTCGTGCAG AGGAAATAAC AGATCTATAC 6720
TTACAGTTAA AGAGCAAGGA TTTCATTCAA GTCATGAGAC ATAGAGATGA TGAAAGACAA 6780
AAAGTGTGTT TGGACATAAT TTATAAGATG ATGGCAAGAT TGAAACCAGT AGAACTTCGA 6840
GAACTTCTGA ATCCTGTTGT AGAATTCATT TCTCATCCTT CTCCAGTGTG TAGGGAACAA 6900
ATGTATAACA TTCTCATGTG GATTCATGAC AATTATCGAG ATCCAGAAGG TCAGACAGAT 6960
GACGACTCCC AGGAAATATT TAAGTTGGCA AAAGATGTGT TGATTCAAGG ATTGATCGAT 7020
GAGAACCCTG GGCTTCAATT AATTATTCGA AATTTCTGGA GTCATGAAAC TAGGTTACCT 7080
TCAAATACCT TGGATCGATT GTTGGCACTA AATTCCCTAT ATTCTCCTAA GATAGAAGCA 7140
CACTTTTTAA GTTTAGCAAC AGATTTTCTG CTTGAAATGA CCAGCGTGAG CCCAGATTAT 7200
TCAAACCCTA TGTTTGATCA TCCTCTGTCA GAATGCAAAT TTCAGGAATA TACTATTGAT 7260
TCTGACTGGC GTTTCCGAAG TACTGTTCTC ACTCCAATGT TTATTGAGAC TCAGGCCTCC 7320
CAAAGTGCTC TGCAGACCCG GACCCAGGAA GGATCCCTCT CAGCTCGAGG GGTAATGACT 7380
GGGCAGATAC GGGCCACACA ACAGCAGTAT GATTTCACAC CTACGCAAAA TACAGATGGA 7440
AGAAGCTCTT TCAATTGGCT GACTGGGAAC AGCATTGACC CACTGGTGGA TTTTACGGTC 7500
TCCTCCTCAT CTGATTCTTT GTCTTCCTCC TTGCTGTTTG CTCACAAGAG GAGTGAAAAA 7560
TCACAGAGAG GACCCTTGAA GTCAGTAGGA CCTGATTTTG GGAAAAAAAG GCTGGGCCTT 7620
CCAGGGGATG AGGTGGATAA CAAAGCAAAA GGTACAGACA ATCGGGCGGA AATATTAAGA 7680
TTACGGAGAC GATTTTTAAA GGACCGAGAA AAGCTCAGTT TGATTTATGC CAGAAAAGGT 7740
GTTGCTGAAC AAAAACGAGA GAAGGAGATC AAGAGTGAGT TAAAAATGAA GCACGATGCC 7800
CAAGTCATTT TGTACAGAAG TTACCGTCAA GGAGACCTTC CTGACATTCA GATTAAATAC 7860
AGCAGCCTGA TCACTCCCTT GCAAGCTGTG GCCCAGAGAG ACCCAATAAT TGCAAAGCAG 7920
CTCTTTGGCA GCTTGTTTTC TGGAATTATA AAAGAGATGG ATAAATATAA GACCATGTCT 7980
GAAAAAAACA ACATTACTCA GAAGTTGCTC CAGGACTTCA ATAATTTTCT TAACACCACT 8040
GTCTCTTTCT TTCCACCTTT CATCTCCTGT ATCCAGGAAA TTAGTTGCCA ACACGCAGAC 8100
TTGCTGAGCC TCGACCCAGC TTCTGTCAGT GCCAGCTGCC TGGCCAGTCT GCAGCAGCCT 8160
GTAGGCGTCC GCCTTCTGGA GGAGGCCTTG CTCCACCTGC TGCCTGAAGA GCCACCTGCC 8220
AAGCGAGTTC GAGGGAGACC CTGTCTCTAC CCTGATTTTG TCAGATGGAT GGAACTTGCT 8280
AAACTGTATA GATCAATTGG AGAATATGAC ATCCTCCGTG GGATTTTTAA TAGTGAGATA 8340
GGAACAAAGC AAGTCACTCA GAATGCATTA TTAGCAGAAG CAAGAAATGA TTATTCTGAA 8400
GCCGTTAAGC AGTATAATGA GGCTCTCAAT AAACAAGACT GGGTAGATGG TGAGCCTATG 8460
GAAGCTGAGA AGGATTTTTG GGAACTTGCA TCCCTTGACT GTTATAACCA ACTTGCTGAG 8520
TGGAAATCAC TGGCATACTG TTCTACAGTC AGTGTTGACA GTGCGAACCC TCCAGATTTA 8580
AATAAAATGT GGAATGAACC ATTTTATCAG GAGACCTATC TACCTTACAT GATCCGCAGC 8640
AAGCTGAAGC TACTTCTGCA AGGTGAGGGA GACCAGTCCC TGCTGACATT TATTGATGAA 8700
GCTGTGAGCA AGGAGCTCCA GAAGGTCCTC GTAGAGCTTC ATTACAGTCA GGAATTGAGT 8760
CTCCTTTATA TCCTACAAGA TGACGTCGAC AGAGCCAAAT ATTATATTGA AAATTGCATT 8820
CGGATTTTCA TGCAGAGCTA TTCTAGTATT GATGTCCTTT TAGAGAGAAG TAGACTCACC 8880
AAATTGCAAT CTCTACAGGC TTTAATAGAA ATTCAGGAGT TCATCAGCTT TATAAGGAAA 8940
CAAGGTAATT TATCATCTCA AATTCCCCTT AAGAGACTTC TAAAAACCTG GACAAACAGA 9000
TATCCGGATG CTAAAATGGA CCCAATGAAC ATCTGGGATG ACATCATCAC AAATCGATGT 9060
TTCTTTCTCA GCAAAATAGA AGAAAAACTG ACTATTCCTC CAGATGATCA TAGTATGAAC 9120
ACAGATGGAG ATGAAGATTC CAGTGACAGA ATGAAAGTGC AGGAGCAGGA GGAAGATATT 9180
TATTCTCTGA TTAAGAGTGG TAAGTTTTCC ATGAAAATGA AGATGATAGA AAGTGCAAGG 9240
AAACAGAAAA ATTTCTCACT AGCCATGAAA CTATTAAAGG AGCTTCATAA AGAGTCAAAA 9300
ACAAGAGATG ACTGGCTGGT GAAATGGGTG CAGAGCTACT GTCGACTCAG TCACAGCCGG 9360
AGCCAGACCC AGAATCGTCC TGAGCAGATC CTTACTGTGT TGAAAACAGT CTCTTTGTTG 9420
GATGAGAACA CATCAAGCTA CTTAAGCAAA AATATTCCAG TTTCCCGTGA CCACAACATT 9480
CTCTTGGGTA CAACTTACAG GATCATAGCT AATGCTCTCA GCAGTGATCC AACTTGCCTT 9540
GCTGAAATCG GGGAAAGCAA GGCTAGAAGA ATCTTGGAGC TGTCTGGATC CAGTTTAGAG 9600
AATGCAGAAG AGGTGATCGC AGGTCTATAC CAGAGAGTGT TGCATCACCT TTCTGAGGCC 9660
GTGCGGATTG CAGAGGAGGA GGCCCAGCCT TTCACTAGAG GCCAGGAACC TGCAGTTGGG 9720
GTGATAGATG CTTACATGAC ACTGGTGGAT TTCTGTGACC AGCAGCTCCG CAAGGAGGAA 9780
GAGAGTTCAT CAGTTACTGA GTCTGTACAA CTGCAGATGT ATCCAGCCCT TGTGGTGGAC 9840
AAAATGTTAA AAGCTTTAAG ACTCGATTCC AATGAAGCCA GGCTGAAGTT TCCCAGACTA 9900
CTGCAGATTA TAGAACGGTA TCCAGAGGAG ACCCTGAGCC TAATGACCAA AGAGATTTCT 9960
TCCATTCCTT GCTGGCAGTT CATTGGCTGG ATCAGCCACA TGGTGGCCTT ACTGGACAAA 10020
GAGGAAGCTG TCGCTGTCCA TCGCACAGTG GAAGAGATTG CTGATAACTA TCCACAGGCG 10080
ATGGTCTACC CATTTATAAT AAGCAGTGAA AGCTATTCCT TCAAAGATAC TTCTACTGGT 10140
TATAAGAATA AGGAGTTTGT GGAAAGGATT AAAATTAAGT TGGATCAAGG AGGAGTGATT 10200
CAAGATTTTA TTAATGCCCT AGAACAGCTC TCTCATCCTG AAATGCTCTT TAAGGACTGG 10260
ACTGATGATA TCAAAGTTGA ACTTGAAAAA AACCCTGTAA ATAGAAAAAA CATTGAAAAG 10320
ATGTATGAAA AAATGTATGC AACCTTGGGA GACCCACAGG CTCCAGGTCT TGGGGCTTTT 10380
CGAAGAAGGT GTATTCAGGG TTTTGGAAAA GAATTTGATA AACACTTTGG GAGAGGAGGT 10440
TCTAAGCTAC CTGGAATGAA ATCCCGTGAA TTCAGTGATA TTACCAACTC ACTATTTTCA 10500
AAAATGTGCG AAGTCTCAAA GCCACCTGGG AATCTGAAAG AATGCTCGCC CTGGATGAGT 10560
GACTTCAAAG TAGAATTTTT GAGAAGTGAA CTGGAGATTC CTGGTCAGTA TGATGGCAAG 10620
GGAAAACCAG TGCCAGAATA CCATGCACGA ATTGCTGGGT TTGATGAGCG GATAAAAGTA 10680
ATGGCTTCTA TGAGAAAACC AAAGCGTATC ATCATCCGAG GCCATGATGA GAGAGAGTAC 10740
CCTTTCCTTG TGAAGGGAGG TGAAGATCTG AGGCAGGACC AACGCATCGA GCAGCTCTTC 10800
GAGGTCATGA ATGTCATCCT TTCCCAAGAT GCTACCTGTA GTCAGAGAAG CATGCAGCTA 10860
AAGACATACC AGGTCATACC CATGACCTCC AGATTAGGAC TAATTGAATG GATTGAAAAT 10920
ACTTTTACCT TGAAGGAACT TCTTTTGAGT AACATGTCAC AAGAGGAGAA AGCGGCTTGT 10980
ACAAGAGATC CCAAAGCACC ACCATTTGAA TATAGAGACT GGCTGACAAA GATGTCTGGG 11040
AAATGTGATG TTGGTGCTTA CATGCTAATG TATAAGGGAG CTAGTCGTAC TGAAACAGTC 11100
ACATCTTTTA GAAAAAGAGA AAGTAAGGTG CCAGCCGATC TCTTAAAGCG GGCCTTTGTG 11160
AAGATGAGTA CCAGCCCTGA GGCCTTCCTG ACACTCCGCT CACACTTTGC CGGCTCTCAC 11220
GCTTTGATAT GCATTAGTCA CTGGATTCCT GGGATTGGAG ATAGACATCT GAACAATTTC 11280
CTGGTAAGCA TGGAGACAGG TGGAGTGATT GGAATCGACT TTGGACATGC ATTTGGATCA 11340
GCTACTCAGT TTCTGCCGGT CCCTGAGTTG ATGCCTTTTC GTCTAACTCG CCAGTTTATC 11400
AATCTGATGT TACCAATGAA AGAAACAGGT GTTATGTACA GTATCATGGT GCATGCACTG 11460
AGAGCCTTCC GCTCGCAGTC CAACCTGCTT GCTAACACCA TGGACGTGTT TGTAAAGGAG 11520
CCTTCCTTCG ACTGGAAAAA TTTTGAACAG AAAATGCGGA AAAAAGGAGG ATCATGGATT 11580
CAAGAAATAA ATGTAACTGA AAAAAATTGG TATCCCCGGC AGAAAATACA TTATGCTAAG 11640
AGAAAGTTAG CTGGTGCCAA TCCAGCAGTT ATTACTTGTG ATGAGTTACT TCTGGGCCAT 11700
GAGAAGGCAG CTGCATTTGG AGATTATGTG GCTGTAGCAC GAGGAAGTGA AGATCACAAT 11760
ATCCGTGCCC AAGAACTGGA GAGTGACCTT TCAGAAGAAG CTCAGGTGAA GTGCTTGATT 11820
GACCAGGCAA CAGACCCCAA CATCCTTGGC AGAACCTTGG TAGGATGGGA GCCCTGGATG 11880
TGA 11883
(2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2987 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(v) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
Val Tyr Glu Leu Leu Gly Val Leu Gly Glu Val His Pro Ser Glu
5 10 15
Met Ile Ser Asn Ser Glu Gln Leu Phe Arg Ala Phe Leu Gly Glu
20 25 30
Leu Lys Ser Gln Met Thr Ser Thr Val Arg Glu Pro Lys Leu Pro
35 40 45
Val Leu Ala Gly Cys Leu Lys Gly Leu Ser Ser Leu Met Cys Asn
50 55 60
Phe Thr Lys Ser Met Glu Glu Asp Pro Gln Thr Ser Arg Glu Ile
65 70 75
Phe Asp Phe Ala Leu Lys Ala Ile Arg Pro Gln Ile Asp Leu Lys
80 85 90
Arg Tyr Ala Val Pro Leu Ala Gly Leu Cys Leu Phe Thr Leu His
95 100 105
Ala Ser Gln Phe Ser Thr Cys Leu Leu Glu Asn Tyr Val Ser Leu
110 115 120
Phe Glu Val Leu Ser Lys Trp Cys Gly His Thr Asn Ile Glu Leu
125 130 135
Lys Lys Ala Ala His Ser Ala Leu Glu Ser Phe Leu Lys Gln Val
140 145 150
Ser Phe Met Val Ala Lys Asp Ala Glu Arg His Lys Asn Lys Leu
155 160 165
Gln Tyr Phe Met Glu Gln Phe Tyr Gly Ile Ile Arg Asn Met Asp
170 175 180
Ser Asn Ser Lys Asp Leu Ser Ile Ala Ile Arg Gly Tyr Gly Leu
185 190 195
Phe Ala Gly Pro Cys Lys Val Ile Asn Ala Lys Asp Val Asp Phe
200 205 210
Met Tyr Val Glu Leu Ile Gln Arg Cys Lys Gln Leu Phe Leu Thr
215 220 225
Gln Thr Asp Thr Val Asp Asp His Ile Tyr Gln Met Pro Ser Phe
230 235 240
Leu Gln Ser Ile Val Ser Val Leu Leu Tyr Leu Asp Thr Ile Pro
245 250 255
Glu Val Tyr Thr Pro Val Leu Glu His Leu Met Val Val Gln Ile
260 265 270
Asp Ser Phe Pro Gln Tyr Ser Pro Lys Met Gln Pro Val Cys Cys
275 280 285
Arg Ala Ile Val Lys Leu Phe Leu Ala Leu Ala Glu Lys Gly Pro
290 295 300
Val Leu Trp Asn Cys Ile Ser Thr Val Val His Gln Gly Leu Ile
305 310 315
Arg Ile Cys Ser Lys Pro Val Val Phe Gln Lys Gly Ala Gly Ser
320 325 330
Glu Ser Glu Asp Tyr His Thr Ser Glu Glu Ala Arg Thr Gly Lys
335 340 345
Trp Lys Met Pro Thr Tyr Lys Asp Tyr Leu Asp Leu Phe Arg Tyr
350 355 360
Leu Leu Ser Cys Asp Gln Met Met Asp Ser Leu Leu Ala Asp Glu
365 370 375
Ala Phe Leu Phe Val Asn Ser Ser Leu His Ser Leu Asn Arg Leu
380 385 390
Leu Tyr Asp Glu Phe Val Lys Ser Val Leu Lys Ile Val Glu Lys
395 400 405
Leu Asp Leu Thr Leu Glu Lys Gln Asn Val Gly Glu Gln Glu Asp
410 415 420
Glu Thr Glu Ala Thr Gly Val Trp Val Ile Pro Thr Ser Asp Pro
425 430 435
Ala Ala Asn Leu His Pro Ala Lys Pro Lys Asp Phe Ser Ala Phe
440 445 450
Ile Asn Leu Val Glu Phe Cys Arg Glu Ile Leu Pro Glu Lys His
455 460 465
Val Glu Phe Phe Glu Pro Trp Val Tyr Ser Phe Ala Tyr Glu Leu
470 475 480
Ile Leu Gln Ser Thr Arg Leu Pro Leu Ile Ser Val Phe Tyr Lys
485 490 495
Leu Leu Ser Val Ala Val Arg Asn Ala Lys Lys Met Lys Tyr Phe
500 505 510
Glu Gly Val Gly Pro Lys Ser Gln Lys Gln Ser Pro Glu Asp Leu
515 520 525
Glu Lys Tyr Ser Cys Phe Ala Leu Phe Ala Lys Phe Ser Lys Glu
530 535 540
Val Ser Ile Lys Met Lys Gln Tyr Lys Asp Glu Leu Leu Ala Ser
545 550 555
Cys Leu Thr Phe Ile Leu Ser Leu Pro His Asp Ile Ile Glu Leu
560 565 570
Asp Val Arg Ala Tyr Val Pro Ala Leu Gln Met Ala Phe Lys Leu
575 580 585
Gly Leu Ser Tyr Thr Pro Leu Ala Glu Val Gly Leu Asn Ala Leu
590 595 600
Glu Glu Trp Ser Gly Tyr Ile Cys Lys His Val Ile Gln Pro Tyr
605 610 615
Tyr Lys Asp Ile Leu Pro Ser Leu Asp Gly Tyr Leu Lys Thr Ser
620 625 630
Val Leu Ser Asp Glu Thr Lys Asn Ser Trp Gln Val Ser Ala Leu
635 640 645
Ser Arg Ala Ala Gln Lys Gly Phe Asn Lys Val Val Leu Lys His
650 655 660
Leu Thr Lys Thr Lys Ser Ile Ser Ser Asn Glu Ala Leu Ser Leu
665 670 675
Glu Glu Val Arg Ile Arg Val Val Arg Ile Leu Gly Ser Leu Gly
680 685 690
Gly Gln Ile Asn Lys Asn Leu Val Thr Ala Ala Ser Ser Asp Glu
695 700 705
Met Met Lys Lys Cys Val Ala Trp Asp Arg Glu Lys Arg Leu Arg
710 715 720
Phe Ala Val Pro Phe Met Glu Met Lys Pro Val Ile Tyr Leu Asp
725 730 735
Leu Phe Leu Pro Arg Val Thr Glu Leu Ala Leu Ser Ala Ser Asp
740 745 750
Arg Gln Thr Thr Val Ala Ala Cys Glu Leu Leu His Ser Met Val
755 760 765
Met Phe Met Leu Gly Lys Ala Thr Gln Met Pro Glu Asp Gly Gln
770 775 780
Gly Ser Pro Pro Met Tyr Gln Leu Tyr Lys Arg Thr Phe Pro Val
785 790 795
Leu Leu Arg Leu Ala Cys Asp Val Asp Gln Val Thr Arg Gln Leu
800 805 810
Tyr Glu Pro Leu Val Met Gln Leu Ile His Trp Phe Thr Asn Asn
815 820 825
Lys Lys Phe Glu Ser Gln Asp Thr Val Ala Leu Leu Glu Thr Ile
830 835 840
Leu Asp Gly Ile Val Asp Pro Val Asp Ser Thr Leu Arg Asp Phe
845 850 855
Cys Gly Gln Cys Ile Gln Glu Phe Leu Lys Trp Ser Ile Lys Gln
860 865 870
Thr Thr Pro Gln Gln Gln Glu Lys Ser Pro Val Asn Thr Lys Ser
875 880 885
Leu Phe Lys Arg Leu Tyr Ser Phe Ala Leu His Pro Asn Ala Phe
890 895 900
Lys Arg Leu Gly Ala Ser Leu Ala Phe Asn Asn Ile Tyr Arg Glu
905 910 915
Phe Arg Glu Glu Glu Ser Leu Val Glu Gln Phe Val Phe Glu Ala
920 925 930
Leu Val Thr Tyr Met Glu Ser Leu Ala Leu Ala His Thr Asp Glu
935 940 945
Lys Ser Leu Gly Thr Ile Gln Gln Cys Cys Asp Ala Ile Asp His
950 955 960
Leu Ser Leu Ile Ile Glu Lys Lys His Val Ser Leu Asn Lys Ala
965 970 975
Lys Lys Arg Arg Leu Pro Arg Gly Phe Pro Pro Ala Thr Ser Leu
980 985 990
Cys Leu Leu Asp Val Val Gln Trp Leu Leu Ala Asn Cys Gly Arg
995 1000 1005
Pro Gln Thr Glu Cys Arg His Lys Ser Ile Glu Leu Phe Tyr Lys
1010 1015 1020
Phe Val Thr Leu Leu Pro Gly Asn Lys Ser Pro Phe Leu Trp Leu
1025 1030 1035
Lys Asp Ile Ile Lys Lys Glu Asp Ile Ser Phe Leu Ile Asn Thr
1040 1045 1050
Phe Glu Gly Gly Gly Ser Gly Arg Pro Ser Gly Ile Leu Ala Gln
1055 1060 1065
Pro Thr Leu Phe His Leu Gln Gly Pro Phe Ser Leu Arg Ala Ala
1070 1075 1080
Leu Gln Trp Met Asp Met Leu Leu Ala Ala Leu Glu Cys Tyr Asn
1085 1090 1095
Thr Phe Ile Glu Glu Lys Thr Leu Glu Ala Pro Lys Val Leu Gly
1100 1105 1110
Thr Glu Thr Gln Ser Ser Leu Trp Lys Ala Val Ala Phe Phe Leu
1115 1120 1125
Glu Ser Ile Ala Met His Asp Ile Met Ala Ala Glu Lys Tyr Phe
1130 1135 1140
Gly Thr Gly Ala Thr Gly Asn Arg Pro Ser Pro Gln Glu Gly Glu
1145 1150 1155
Arg Tyr Asn Tyr Ser Lys Cys Thr Ile Val Val Arg Ile Met Glu
1160 1165 1170
Phe Thr Thr Thr Leu Leu Ser Thr Ser Pro Glu Gly Trp Lys Leu
1175 1180 1185
Leu Glu Lys Asp Val Cys Asn Thr Asn Leu Met Lys Leu Leu Val
1190 1195 1200
Lys Thr Leu Cys Glu Pro Ser Ser Ile Gly Phe Asn Ile Gly Asp
1205 1210 1215
Val Ala Val Met Asn Tyr Leu Pro Ser Val Cys Thr Asn Leu Met
1220 1225 1230
Lys Ala Leu Lys Lys Ser Pro Tyr Lys Asp Ile Leu Glu Met His
1235 1240 1245
Leu Lys Glu Lys Ile Thr Ala Gln Ser Ile Glu Glu Leu Cys Ala
1250 1255 1260
Val Asp Leu Tyr Cys Pro Asp Ala Cys Val Asp Arg Ala Arg Leu
1265 1270 1275
Ala Ser Val Val Ser Ala Cys Lys Gln Leu His Arg Ala Gly Val
1280 1285 1290
Leu Cys Val Ile Ile Pro Ser Gln Ser Ala Asp Gln His His Ser
1295 1300 1305
Ile Gly Thr Lys Leu Leu Ser Leu Val Tyr Lys Ser Ile Ala Pro
1310 1315 1320
Gly Asp Glu Gln Gln Cys Leu Pro Ser Leu Asp Pro Asn Cys Lys
1325 1330 1335
Arg Leu Ala Ser Gly Leu Leu Glu Leu Ala Phe Ala Phe Gly Gly
1340 1345 1350
Leu Cys Glu His Leu Val Ser Leu Leu Leu Asp Thr Thr Val Leu
1355 1360 1365
Ser Met Pro Ser Arg Gly Gly Ser Gln Lys Asn Ile Val Ser Phe
1370 1375 1380
Ser His Gly Glu Tyr Phe Tyr Ser Leu Phe Ser Glu Thr Ile Asn
1385 1390 1395
Thr Glu Leu Leu Lys Asn Leu Asp Leu Ala Val Leu Glu Leu Met
1400 1405 1410
Lys Ser Ser Val Asp Asn Pro Lys Met Val Ser Asn Val Leu Asn
1415 1420 1425
Gly Met Leu Asp Gln Ser Phe Arg Asp Arg Thr Ser Glu Lys His
1430 1435 1440
Gln Gly Leu Lys Leu Ala Thr Ile Ile Leu Gln Asn Trp Lys Lys
1445 1450 1455
Cys Asp Ser Trp Trp Ala Lys Asp Ser Ala Pro Glu Ser Lys Met
1460 1465 1470
Ala Val Leu Thr Leu Leu Ala Lys Ile Phe Gln Ile Asp Ser Ser
1475 1480 1485
Val Cys Phe Asn Thr Asn His Cys Met Phe Pro Glu Val Phe Thr
1490 1495 1500
Thr Tyr Val Ser Leu Leu Ala Asp Ser Lys Leu Asp Leu His Leu
1505 1510 1515
Lys Gly Gln Ala Ile Ile Leu Leu Pro Phe Phe Thr Ser Leu Thr
1520 1525 1530
Gly Gly Ser Leu Glu Asp Leu Lys Val Val Leu Glu Asn Leu Ile
1535 1540 1545
Val Ser Asn Phe Pro Met Lys Ser Glu Glu Phe Pro Pro Gly Thr
1550 1555 1560
Leu Gln Tyr Asn Asn Tyr Val Asp Cys Met Lys Lys Phe Leu Asp
1565 1570 1575
Ala Leu Glu Leu Ser Lys Ser Pro Met Leu Leu Gln Leu Met Thr
1580 1585 1590
Glu Ile Leu Cys Arg Glu Gln Gln His Val Met Glu Glu Leu Phe
1595 1600 1605
Gln Ser Thr Phe Lys Lys Ile Ala Arg Lys Ser Ser Cys Ile Thr
1610 1615 1620
Gln Leu Gly Leu Leu Glu Ser Val Tyr Arg Met Phe Arg Arg Asp
1625 1630 1635
Asp Leu Leu Ser Asn Ile Thr Arg Gln Ala Phe Val Asp Arg Ser
1640 1645 1650
Leu Leu Thr Leu Leu Trp His Cys Ser Leu Asn Ala Leu Arg Glu
1655 1660 1665
Phe Phe Ser Lys Ile Val Val Glu Ala Ile Asn Val Leu Lys Ser
1670 1675 1680
Arg Phe Ile Lys Leu Asn Glu Ser Ala Phe Asp Thr Gln Ile Thr
1685 1690 1695
Lys Lys Met Gly Tyr Tyr Lys Met Leu Asp Val Met Tyr Ser Arg
1700 1705 1710
Leu Pro Lys Asp Asp Val His Ser Lys Glu Ser Lys Ile Asn Gln
1715 1720 1725
Val Phe His Gly Ser Cys Ile Thr Glu Gly Ser Glu Leu Thr Lys
1730 1735 1740
Thr Leu Ile Lys Leu Cys Tyr Asp Ala Phe Thr Glu Asn Met Ala
1745 1750 1755
Gly Glu Asn Gln Leu Leu Glu Arg Arg Arg Leu Tyr His Cys Ala
1760 1765 1770
Ala Tyr Asn Cys Ala Ile Ser Val Val Cys Cys Val Phe Asn Glu
1775 1780 1785
Leu Lys Phe Tyr Gln Gly Phe Leu Phe Thr Glu Lys Pro Glu Lys
1790 1795 1800
Asn Leu Leu Ile Phe Glu Asn Leu Ile Asp Leu Lys Arg Cys Tyr
1805 1810 1815
Thr Phe Pro Ile Glu Val Glu Val Pro Met Glu Arg Lys Lys Lys
1820 1825 1830
Tyr Leu Glu Ile Arg Lys Glu Ala Arg Glu Ala Ala Ala Ser Gly
1835 1840 1845
Asp Ser Asp Gly Pro Arg Tyr Ile Ser Ser Leu Ser Tyr Leu Ala
1850 1855 1860
Asp Ser Ser Leu Ser Glu Glu Met Ser Gln Phe Asp Phe Ser Thr
1865 1870 1875
Gly Val Gln Ser Tyr Ser Tyr Ser Ser Gln Asp Pro Lys Ser Thr
1880 1885 1890
Thr Ala His Phe Arg Arg Gln Lys His Lys Glu Ser Met Ile Gln
1895 1900 1905
Asp Asp Ile Leu Glu Leu Glu Met Asp Glu Leu Asn Gln His Glu
1910 1915 1920
Cys Met Ala Thr Met Thr Ala Leu Ile Lys His Met Gln Arg Asn
1925 1930 1935
Gln Ile Leu Pro Lys Glu Glu Glu Gly Ser Val Pro Arg Asn Leu
1940 1945 1950
Pro Pro Trp Met Lys Phe Leu His Asp Lys Leu Gly Asn Pro Ser
1955 1960 1965
Ile Ser Leu Asn Ile Arg Leu Phe Leu Ala Lys Leu Val Ile Asn
1970 1975 1980
Thr Glu Glu Val Phe Arg Pro Tyr Ala Arg Tyr Trp Leu Ser Pro
1985 1990 1995
Leu Leu Gln Leu Val Val Ser Gly Asn Asn Gly Gly Glu Gly Ile
2000 2005 2010
His Tyr Met Val Val Glu Ile Val Val Ile Ile Leu Ser Trp Thr
2015 2020 2025
Gly Leu Ala Thr Pro Ile Gly Val Pro Lys Asp Glu Val Leu Ala
2030 2035 2040
Asn Arg Leu Leu His Phe Leu Met His Val Phe His Gln Lys Arg
2045 2050 2055
Ala Val Phe Arg His Asn Leu Glu Ile Ile Lys Thr Leu Val Glu
2060 2065 2070
Cys Trp Lys Asp Cys Leu Ser Ile Pro Tyr Arg Leu Ile Phe Glu
2075 2080 2085
Lys Phe Ser Ser Thr Asp Pro Asn Ser Lys Asp Asn Ser Val Gly
2090 2095 2100
Ile Gln Leu Leu Gly Ile Val Met Ala Asn Asn Leu Pro Pro Tyr
2105 2110 2115
Asp Pro Lys Cys Gly Ile Glu Ser Ile Lys Tyr Phe Gln Ala Leu
2120 2125 2130
Val Asn Asn Met Ser Phe Val Arg Tyr Arg Glu Val Tyr Ala Ala
2135 2140 2145
Ala Ala Glu Val Leu Gly Leu Val Leu Arg Tyr Ile Thr Glu Arg
2150 2155 2160
Glu Asn Ile Leu Glu Glu Ser Val Cys Glu Leu Val Ile Lys Gln
2165 2170 2175
Leu Lys Gln His Gln Asn Thr Met Glu Asp Lys Phe Ile Val Cys
2180 2185 2190
Leu Asn Lys Ala Val Lys Asn Phe Pro Pro Leu Ala Asp Arg Phe
2195 2200 2205
Met Asn Thr Val Phe Phe Leu Leu Pro Lys Phe His Gly Val Met
2210 2215 2220
Lys Thr Leu Cys Leu Glu Val Val Leu Cys Arg Ala Glu Glu Ile
2225 2230 2235
Thr Asp Leu Tyr Leu Gln Leu Lys Ser Lys Asp Phe Ile Gln Val
2240 2245 2250
Met Arg His Arg Asp Asp Glu Arg Gln Lys Val Cys Leu Asp Ile
2255 2260 2265
Ile Tyr Lys Met Met Ala Arg Leu Lys Pro Val Glu Leu Arg Glu
2270 2275 2280
Leu Leu Asn Pro Val Val Glu Phe Ile Ser His Pro Ser Pro Val
2285 2290 2295
Cys Arg Glu Gln Met Tyr Asn Ile Leu Met Trp Ile His Asp Asn
2300 2305 2310
Tyr Arg Asp Pro Glu Gly Gln Thr Asp Asp Asp Ser Gln Glu Ile
2315 2320 2325
Phe Lys Leu Ala Lys Asp Val Leu Ile Gln Gly Leu Ile Asp Glu
2330 2335 2340
Asn Pro Gly Leu Gln Leu Ile Ile Arg Asn Phe Trp Ser His Glu
2345 2350 2355
Thr Arg Leu Pro Ser Asn Thr Leu Asp Arg Leu Leu Ala Leu Asn
2360 2365 2370
Ser Leu Tyr Ser Pro Lys Ile Glu Ala His Phe Leu Ser Leu Ala
2375 2380 2385
Thr Asp Phe Leu Leu Glu Met Thr Ser Val Ser Pro Asp Tyr Ser
2390 2395 2400
Asn Pro Met Phe Asp His Pro Leu Ser Glu Cys Lys Phe Gln Glu
2405 2410 2415
Tyr Thr Ile Asp Ser Asp Trp Arg Phe Arg Ser Thr Val Leu Thr
2420 2425 2430
Pro Met Phe Ile Glu Thr Gln Ala Ser Gln Ser Ala Leu Gln Thr
2435 2440 2445
Arg Thr Gln Glu Gly Ser Leu Ser Ala Arg Gly Val Met Thr Gly
2450 2455 2460
Gln Ile Arg Ala Thr Gln Gln Gln Tyr Asp Phe Thr Pro Thr Gln
2465 2470 2475
Asn Thr Asp Gly Arg Ser Ser Phe Asn Trp Leu Thr Gly Asn Ser
2480 2485 2490
Ile Asp Pro Leu Val Asp Phe Thr Val Ser Ser Ser Ser Asp Ser
2495 2500 2505
Leu Ser Ser Ser Leu Leu Phe Ala His Lys Arg Ser Glu Lys Ser
2510 2515 2520
Gln Arg Gly Pro Leu Lys Ser Val Gly Pro Asp Phe Gly Lys Lys
2525 2530 2535
Arg Leu Gly Leu Pro Gly Asp Glu Val Asp Asn Lys Ala Lys Gly
2540 2545 2550
Thr Asp Asn Arg Ala Glu Ile Leu Arg Leu Arg Arg Arg Phe Leu
2555 2560 2565
Lys Asp Arg Glu Lys Leu Ser Leu Ile Tyr Ala Arg Lys Gly Val
2570 2575 2580
Ala Glu Gln Lys Arg Glu Lys Glu Ile Lys Ser Glu Leu Lys Met
2585 2590 2595
Lys His Asp Ala Gln Val Ile Leu Tyr Arg Ser Tyr Arg Gln Gly
2600 2605 2610
Asp Leu Pro Asp Ile Gln Ile Lys Tyr Ser Ser Leu Ile Thr Pro
2615 2620 2625
Leu Gln Ala Val Ala Gln Arg Asp Pro Ile Ile Ala Lys Gln Leu
2630 2635 2640
Phe Gly Ser Leu Phe Ser Gly Ile Ile Lys Glu Met Asp Lys Tyr
2645 2650 2655
Lys Thr Met Ser Glu Lys Asn Asn Ile Thr Gln Lys Leu Leu Gln
2660 2665 2670
Asp Phe Asn Asn Phe Leu Asn Thr Thr Val Ser Phe Phe Pro Pro
2675 2680 2685
Phe Ile Ser Cys Ile Gln Glu Ile Ser Cys Gln His Ala Asp Leu
2690 2695 2700
Leu Ser Leu Asp Pro Ala Ser Val Ser Ala Ser Cys Leu Ala Ser
2705 2710 2715
Leu Gln Gln Pro Val Gly Val Arg Leu Leu Glu Glu Ala Leu Leu
2720 2725 2730
His Leu Leu Pro Glu Glu Pro Pro Ala Lys Arg Val Arg Gly Arg
2735 2740 2745
Pro Cys Leu Tyr Pro Asp Phe Val Arg Trp Met Glu Leu Ala Lys
2750 2755 2760
Leu Tyr Arg Ser Ile Gly Glu Tyr Asp Ile Leu Arg Gly Ile Phe
2765 2770 2775
Asn Ser Glu Ile Gly Thr Lys Gln Val Thr Gln Asn Ala Leu Leu
2780 2785 2790
Ala Glu Ala Arg Asn Asp Tyr Ser Glu Ala Val Lys Gln Tyr Asn
2795 2800 2805
Glu Ala Leu Asn Lys Gln Asp Trp Val Asp Gly Glu Pro Met Glu
2810 2815 2820
Ala Glu Lys Asp Phe Trp Glu Leu Ala Ser Leu Asp Cys Tyr Asn
2825 2830 2835
Gln Leu Ala Glu Trp Lys Ser Leu Ala Tyr Cys Ser Thr Val Ser
2840 2845 2850
Val Asp Ser Ala Asn Pro Pro Asp Leu Asn Lys Met Trp Asn Glu
2855 2860 2865
Pro Phe Tyr Gln Glu Thr Tyr Leu Pro Tyr Met Ile Arg Ser Lys
2870 2875 2880
Leu Lys Leu Leu Leu Gln Gly Glu Gly Asp Gln Ser Leu Leu Thr
2885 2890 2895
Phe Ile Asp Glu Ala Val Ser Lys Glu Leu Gln Lys Val Leu Val
2900 2905 2910
Glu Leu His Tyr Ser Gln Glu Leu Ser Leu Leu Tyr Ile Leu Gln
2915 2920 2925
Asp Asp Val Asp Arg Ala Lys Tyr Tyr Ile Glu Asn Cys Ile Arg
2930 2935 2940
Ile Phe Met Gln Ser Tyr Ser Ser Ile Asp Val Leu Leu Glu Arg
2945 2950 2955
Ser Arg Leu Thr Lys Leu Gln Ser Leu Gln Ala Leu Ile Glu Ile
2960 2965 2970
Gln Glu Phe Ile Ser Phe Ile Arg Lys Gln Gly Asn Leu Ser Xaa
2975 2980 2985
Ser Pro
(2) INFORMATION FOR SEQ ID NO: 30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 3959 amino acid
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(v) SEQUENCE DESCRIPTION: SEQ ID NO: 30:
Val Tyr Glu Leu Leu Gly Val Leu Gly Glu Val His Pro Ser Glu
5 10 15
Met Ile Ser Asn Ser Glu Gln Leu Phe Arg Ala Phe Leu Gly Glu
20 25 30
Leu Lys Ser Gln Met Thr Ser Thr Val Arg Glu Pro Lys Leu Pro
35 40 45
Val Leu Ala Gly Cys Leu Lys Gly Leu Ser Ser Leu Met Cys Asn
50 55 60
Phe Thr Lys Ser Met Glu Glu Asp Pro Gln Thr Ser Arg Glu Ile
65 70 75
Phe Asp Phe Ala Leu Lys Ala Ile Arg Pro Gln Ile Asp Leu Lys
80 85 90
Arg Tyr Ala Val Pro Leu Ala Gly Leu Cys Leu Phe Thr Leu His
95 100 105
Ala Ser Gln Phe Ser Thr Cys Leu Leu Glu Asn Tyr Val Ser Leu
110 115 120
Phe Glu Val Leu Ser Lys Trp Cys Gly His Thr Asn Ile Glu Leu
125 130 135
Lys Lys Ala Ala His Ser Ala Leu Glu Ser Phe Leu Lys Gln Val
140 145 150
Ser Phe Met Val Ala Lys Asp Ala Glu Arg His Lys Asn Lys Leu
155 160 165
Gln Tyr Phe Met Glu Gln Phe Tyr Gly Ile Ile Arg Asn Met Asp
170 175 180
Ser Asn Ser Lys Asp Leu Ser Ile Ala Ile Arg Gly Tyr Gly Leu
185 190 195
Phe Ala Gly Pro Cys Lys Val Ile Asn Ala Lys Asp Val Asp Phe
200 205 210
Met Tyr Val Glu Leu Ile Gln Arg Cys Lys Gln Leu Phe Leu Thr
215 220 225
Gln Thr Asp Thr Val Asp Asp His Ile Tyr Gln Met Pro Ser Phe
230 235 240
Leu Gln Ser Ile Val Ser Val Leu Leu Tyr Leu Asp Thr Ile Pro
245 250 255
Glu Val Tyr Thr Pro Val Leu Glu His Leu Met Val Val Gln Ile
260 265 270
Asp Ser Phe Pro Gln Tyr Ser Pro Lys Met Gln Pro Val Cys Cys
275 280 285
Arg Ala Ile Val Lys Leu Phe Leu Ala Leu Ala Glu Lys Gly Pro
290 295 300
Val Leu Trp Asn Cys Ile Ser Thr Val Val His Gln Gly Leu Ile
305 310 315
Arg Ile Cys Ser Lys Pro Val Val Phe Gln Lys Gly Ala Gly Ser
320 325 330
Glu Ser Glu Asp Tyr His Thr Ser Glu Glu Ala Arg Thr Gly Lys
335 340 345
Trp Lys Met Pro Thr Tyr Lys Asp Tyr Leu Asp Leu Phe Arg Tyr
350 355 360
Leu Leu Ser Cys Asp Gln Met Met Asp Ser Leu Leu Ala Asp Glu
365 370 375
Ala Phe Leu Phe Val Asn Ser Ser Leu His Ser Leu Asn Arg Leu
380 385 390
Leu Tyr Asp Glu Phe Val Lys Ser Val Leu Lys Ile Val Glu Lys
395 400 405
Leu Asp Leu Thr Leu Glu Lys Gln Asn Val Gly Glu Gln Glu Asp
410 415 420
Glu Thr Glu Ala Thr Gly Val Trp Val Ile Pro Thr Ser Asp Pro
425 430 435
Ala Ala Asn Leu His Pro Ala Lys Pro Lys Asp Phe Ser Ala Phe
440 445 450
Ile Asn Leu Val Glu Phe Cys Arg Glu Ile Leu Pro Glu Lys His
455 460 465
Val Glu Phe Phe Glu Pro Trp Val Tyr Ser Phe Ala Tyr Glu Leu
470 475 480
Ile Leu Gln Ser Thr Arg Leu Pro Leu Ile Ser Val Phe Tyr Lys
485 490 495
Leu Leu Ser Val Ala Val Arg Asn Ala Lys Lys Met Lys Tyr Phe
500 505 510
Glu Gly Val Gly Pro Lys Ser Gln Lys Gln Ser Pro Glu Asp Leu
515 520 525
Glu Lys Tyr Ser Cys Phe Ala Leu Phe Ala Lys Phe Ser Lys Glu
530 535 540
Val Ser Ile Lys Met Lys Gln Tyr Lys Asp Glu Leu Leu Ala Ser
545 550 555
Cys Leu Thr Phe Ile Leu Ser Leu Pro His Asp Ile Ile Glu Leu
560 565 570
Asp Val Arg Ala Tyr Val Pro Ala Leu Gln Met Ala Phe Lys Leu
575 580 585
Gly Leu Ser Tyr Thr Pro Leu Ala Glu Val Gly Leu Asn Ala Leu
590 595 600
Glu Glu Trp Ser Gly Tyr Ile Cys Lys His Val Ile Gln Pro Tyr
605 610 615
Tyr Lys Asp Ile Leu Pro Ser Leu Asp Gly Tyr Leu Lys Thr Ser
620 625 630
Val Leu Ser Asp Glu Thr Lys Asn Ser Trp Gln Val Ser Ala Leu
635 640 645
Ser Arg Ala Ala Gln Lys Gly Phe Asn Lys Val Val Leu Lys His
650 655 660
Leu Thr Lys Thr Lys Ser Ile Ser Ser Asn Glu Ala Leu Ser Leu
665 670 675
Glu Glu Val Arg Ile Arg Val Val Arg Ile Leu Gly Ser Leu Gly
680 685 690
Gly Gln Ile Asn Lys Asn Leu Val Thr Ala Ala Ser Ser Asp Glu
695 700 705
Met Met Lys Lys Cys Val Ala Trp Asp Arg Glu Lys Arg Leu Arg
710 715 720
Phe Ala Val Pro Phe Met Glu Met Lys Pro Val Ile Tyr Leu Asp
725 730 735
Leu Phe Leu Pro Arg Val Thr Glu Leu Ala Leu Ser Ala Ser Asp
740 745 750
Arg Gln Thr Thr Val Ala Ala Cys Glu Leu Leu His Ser Met Val
755 760 765
Met Phe Met Leu Gly Lys Ala Thr Gln Met Pro Glu Asp Gly Gln
770 775 780
Gly Ser Pro Pro Met Tyr Gln Leu Tyr Lys Arg Thr Phe Pro Val
785 790 795
Leu Leu Arg Leu Ala Cys Asp Val Asp Gln Val Thr Arg Gln Leu
800 805 810
Tyr Glu Pro Leu Val Met Gln Leu Ile His Trp Phe Thr Asn Asn
815 820 825
Lys Lys Phe Glu Ser Gln Asp Thr Val Ala Leu Leu Glu Thr Ile
830 835 840
Leu Asp Gly Ile Val Asp Pro Val Asp Ser Thr Leu Arg Asp Phe
845 850 855
Cys Gly Gln Cys Ile Gln Glu Phe Leu Lys Trp Ser Ile Lys Gln
860 865 870
Thr Thr Pro Gln Gln Gln Glu Lys Ser Pro Val Asn Thr Lys Ser
875 880 885
Leu Phe Lys Arg Leu Tyr Ser Phe Ala Leu His Pro Asn Ala Phe
890 895 900
Lys Arg Leu Gly Ala Ser Leu Ala Phe Asn Asn Ile Tyr Arg Glu
905 910 915
Phe Arg Glu Glu Glu Ser Leu Val Glu Gln Phe Val Phe Glu Ala
920 925 930
Leu Val Thr Tyr Met Glu Ser Leu Ala Leu Ala His Thr Asp Glu
935 940 945
Lys Ser Leu Gly Thr Ile Gln Gln Cys Cys Asp Ala Ile Asp His
950 955 960
Leu Ser Leu Ile Ile Glu Lys Lys His Val Ser Leu Asn Lys Ala
965 970 975
Lys Lys Arg Arg Leu Pro Arg Gly Phe Pro Pro Ala Thr Ser Leu
980 985 990
Cys Leu Leu Asp Val Val Gln Trp Leu Leu Ala Asn Cys Gly Arg
995 1000 1005
Pro Gln Thr Glu Cys Arg His Lys Ser Ile Glu Leu Phe Tyr Lys
1010 1015 1020
Phe Val Thr Leu Leu Pro Gly Asn Lys Ser Pro Phe Leu Trp Leu
1025 1030 1035
Lys Asp Ile Ile Lys Lys Glu Asp Ile Ser Phe Leu Ile Asn Thr
1040 1045 1050
Phe Glu Gly Gly Gly Ser Gly Arg Pro Ser Gly Ile Leu Ala Gln
1055 1060 1065
Pro Thr Leu Phe His Leu Gln Gly Pro Phe Ser Leu Arg Ala Ala
1070 1075 1080
Leu Gln Trp Met Asp Met Leu Leu Ala Ala Leu Glu Cys Tyr Asn
1085 1090 1095
Thr Phe Ile Glu Glu Lys Thr Leu Glu Ala Pro Lys Val Leu Gly
1100 1105 1110
Thr Glu Thr Gln Ser Ser Leu Trp Lys Ala Val Ala Phe Phe Leu
1115 1120 1125
Glu Ser Ile Ala Met His Asp Ile Met Ala Ala Glu Lys Tyr Phe
1130 1135 1140
Gly Thr Gly Ala Thr Gly Asn Arg Pro Ser Pro Gln Glu Gly Glu
1145 1150 1155
Arg Tyr Asn Tyr Ser Lys Cys Thr Ile Val Val Arg Ile Met Glu
1160 1165 1170
Phe Thr Thr Thr Leu Leu Ser Thr Ser Pro Glu Gly Trp Lys Leu
1175 1180 1185
Leu Glu Lys Asp Val Cys Asn Thr Asn Leu Met Lys Leu Leu Val
1190 1195 1200
Lys Thr Leu Cys Glu Pro Ser Ser Ile Gly Phe Asn Ile Gly Asp
1205 1210 1215
Val Ala Val Met Asn Tyr Leu Pro Ser Val Cys Thr Asn Leu Met
1220 1225 1230
Lys Ala Leu Lys Lys Ser Pro Tyr Lys Asp Ile Leu Glu Met His
1235 1240 1245
Leu Lys Glu Lys Ile Thr Ala Gln Ser Ile Glu Glu Leu Cys Ala
1250 1255 1260
Val Asp Leu Tyr Cys Pro Asp Ala Cys Val Asp Arg Ala Arg Leu
1265 1270 1275
Ala Ser Val Val Ser Ala Cys Lys Gln Leu His Arg Ala Gly Val
1280 1285 1290
Leu Cys Val Ile Ile Pro Ser Gln Ser Ala Asp Gln His His Ser
1295 1300 1305
Ile Gly Thr Lys Leu Leu Ser Leu Val Tyr Lys Ser Ile Ala Pro
1310 1315 1320
Gly Asp Glu Gln Gln Cys Leu Pro Ser Leu Asp Pro Asn Cys Lys
1325 1330 1335
Arg Leu Ala Ser Gly Leu Leu Glu Leu Ala Phe Ala Phe Gly Gly
1340 1345 1350
Leu Cys Glu His Leu Val Ser Leu Leu Leu Asp Thr Thr Val Leu
1355 1360 1365
Ser Met Pro Ser Arg Gly Gly Ser Gln Lys Asn Ile Val Ser Phe
1370 1375 1380
Ser His Gly Glu Tyr Phe Tyr Ser Leu Phe Ser Glu Thr Ile Asn
1385 1390 1395
Thr Glu Leu Leu Lys Asn Leu Asp Leu Ala Val Leu Glu Leu Met
1400 1405 1410
Lys Ser Ser Val Asp Asn Pro Lys Met Val Ser Asn Val Leu Asn
1415 1420 1425
Gly Met Leu Asp Gln Ser Phe Arg Asp Arg Thr Ser Glu Lys His
1430 1435 1440
Gln Gly Leu Lys Leu Ala Thr Ile Ile Leu Gln Asn Trp Lys Lys
1445 1450 1455
Cys Asp Ser Trp Trp Ala Lys Asp Ser Ala Pro Glu Ser Lys Met
1460 1465 1470
Ala Val Leu Thr Leu Leu Ala Lys Ile Phe Gln Ile Asp Ser Ser
1475 1480 1485
Val Cys Phe Asn Thr Asn His Cys Met Phe Pro Glu Val Phe Thr
1490 1495 1500
Thr Tyr Val Ser Leu Leu Ala Asp Ser Lys Leu Asp Leu His Leu
1505 1510 1515
Lys Gly Gln Ala Ile Ile Leu Leu Pro Phe Phe Thr Ser Leu Thr
1520 1525 1530
Gly Gly Ser Leu Glu Asp Leu Lys Val Val Leu Glu Asn Leu Ile
1535 1540 1545
Val Ser Asn Phe Pro Met Lys Ser Glu Glu Phe Pro Pro Gly Thr
1550 1555 1560
Leu Gln Tyr Asn Asn Tyr Val Asp Cys Met Lys Lys Phe Leu Asp
1565 1570 1575
Ala Leu Glu Leu Ser Lys Ser Pro Met Leu Leu Gln Leu Met Thr
1580 1585 1590
Glu Ile Leu Cys Arg Glu Gln Gln His Val Met Glu Glu Leu Phe
1595 1600 1605
Gln Ser Thr Phe Lys Lys Ile Ala Arg Lys Ser Ser Cys Ile Thr
1610 1615 1620
Gln Leu Gly Leu Leu Glu Ser Val Tyr Arg Met Phe Arg Arg Asp
1625 1630 1635
Asp Leu Leu Ser Asn Ile Thr Arg Gln Ala Phe Val Asp Arg Ser
1640 1645 1650
Leu Leu Thr Leu Leu Trp His Cys Ser Leu Asn Ala Leu Arg Glu
1655 1660 1665
Phe Phe Ser Lys Ile Val Val Glu Ala Ile Asn Val Leu Lys Ser
1670 1675 1680
Arg Phe Ile Lys Leu Asn Glu Ser Ala Phe Asp Thr Gln Ile Thr
1685 1690 1695
Lys Lys Met Gly Tyr Tyr Lys Met Leu Asp Val Met Tyr Ser Arg
1700 1705 1710
Leu Pro Lys Asp Asp Val His Ser Lys Glu Ser Lys Ile Asn Gln
1715 1720 1725
Val Phe His Gly Ser Cys Ile Thr Glu Gly Ser Glu Leu Thr Lys
1730 1735 1740
Thr Leu Ile Lys Leu Cys Tyr Asp Ala Phe Thr Glu Asn Met Ala
1745 1750 1755
Gly Glu Asn Gln Leu Leu Glu Arg Arg Arg Leu Tyr His Cys Ala
1760 1765 1770
Ala Tyr Asn Cys Ala Ile Ser Val Val Cys Cys Val Phe Asn Glu
1775 1780 1785
Leu Lys Phe Tyr Gln Gly Phe Leu Phe Thr Glu Lys Pro Glu Lys
1790 1795 1800
Asn Leu Leu Ile Phe Glu Asn Leu Ile Asp Leu Lys Arg Cys Tyr
1805 1810 1815
Thr Phe Pro Ile Glu Val Glu Val Pro Met Glu Arg Lys Lys Lys
1820 1825 1830
Tyr Leu Glu Ile Arg Lys Glu Ala Arg Glu Ala Ala Ala Ser Gly
1835 1840 1845
Asp Ser Asp Gly Pro Arg Tyr Ile Ser Ser Leu Ser Tyr Leu Ala
1850 1855 1860
Asp Ser Ser Leu Ser Glu Glu Met Ser Gln Phe Asp Phe Ser Thr
1865 1870 1875
Gly Val Gln Ser Tyr Ser Tyr Ser Ser Gln Asp Pro Lys Ser Thr
1880 1885 1890
Thr Ala His Phe Arg Arg Gln Lys His Lys Glu Ser Met Ile Gln
1895 1900 1905
Asp Asp Ile Leu Glu Leu Glu Met Asp Glu Leu Asn Gln His Glu
1910 1915 1920
Cys Met Ala Thr Met Thr Ala Leu Ile Lys His Met Gln Arg Asn
1925 1930 1935
Gln Ile Leu Pro Lys Glu Glu Glu Gly Ser Val Pro Arg Asn Leu
1940 1945 1950
Pro Pro Trp Met Lys Phe Leu His Asp Lys Leu Gly Asn Pro Ser
1955 1960 1965
Ile Ser Leu Asn Ile Arg Leu Phe Leu Ala Lys Leu Val Ile Asn
1970 1975 1980
Thr Glu Glu Val Phe Arg Pro Tyr Ala Arg Tyr Trp Leu Ser Pro
1985 1990 1995
Leu Leu Gln Leu Val Val Ser Gly Asn Asn Gly Gly Glu Gly Ile
2000 2005 2010
His Tyr Met Val Val Glu Ile Val Val Ile Ile Leu Ser Trp Thr
2015 2020 2025
Gly Leu Ala Thr Pro Ile Gly Val Pro Lys Asp Glu Val Leu Ala
2030 2035 2040
Asn Arg Leu Leu His Phe Leu Met His Val Phe His Gln Lys Arg
2045 2050 2055
Ala Val Phe Arg His Asn Leu Glu Ile Ile Lys Thr Leu Val Glu
2060 2065 2070
Cys Trp Lys Asp Cys Leu Ser Ile Pro Tyr Arg Leu Ile Phe Glu
2075 2080 2085
Lys Phe Ser Ser Thr Asp Pro Asn Ser Lys Asp Asn Ser Val Gly
2090 2095 2100
Ile Gln Leu Leu Gly Ile Val Met Ala Asn Asn Leu Pro Pro Tyr
2105 2110 2115
Asp Pro Lys Cys Gly Ile Glu Ser Ile Lys Tyr Phe Gln Ala Leu
2120 2125 2130
Val Asn Asn Met Ser Phe Val Arg Tyr Arg Glu Val Tyr Ala Ala
2135 2140 2145
Ala Ala Glu Val Leu Gly Leu Val Leu Arg Tyr Ile Thr Glu Arg
2150 2155 2160
Glu Asn Ile Leu Glu Glu Ser Val Cys Glu Leu Val Ile Lys Gln
2165 2170 2175
Leu Lys Gln His Gln Asn Thr Met Glu Asp Lys Phe Ile Val Cys
2180 2185 2190
Leu Asn Lys Ala Val Lys Asn Phe Pro Pro Leu Ala Asp Arg Phe
2195 2200 2205
Met Asn Thr Val Phe Phe Leu Leu Pro Lys Phe His Gly Val Met
2210 2215 2220
Lys Thr Leu Cys Leu Glu Val Val Leu Cys Arg Ala Glu Glu Ile
2225 2230 2235
Thr Asp Leu Tyr Leu Gln Leu Lys Ser Lys Asp Phe Ile Gln Val
2240 2245 2250
Met Arg His Arg Asp Asp Glu Arg Gln Lys Val Cys Leu Asp Ile
2255 2260 2265
Ile Tyr Lys Met Met Ala Arg Leu Lys Pro Val Glu Leu Arg Glu
2270 2275 2280
Leu Leu Asn Pro Val Val Glu Phe Ile Ser His Pro Ser Pro Val
2285 2290 2295
Cys Arg Glu Gln Met Tyr Asn Ile Leu Met Trp Ile His Asp Asn
2300 2305 2310
Tyr Arg Asp Pro Glu Gly Gln Thr Asp Asp Asp Ser Gln Glu Ile
2315 2320 2325
Phe Lys Leu Ala Lys Asp Val Leu Ile Gln Gly Leu Ile Asp Glu
2330 2335 2340
Asn Pro Gly Leu Gln Leu Ile Ile Arg Asn Phe Trp Ser His Glu
2345 2350 2355
Thr Arg Leu Pro Ser Asn Thr Leu Asp Arg Leu Leu Ala Leu Asn
2360 2365 2370
Ser Leu Tyr Ser Pro Lys Ile Glu Ala His Phe Leu Ser Leu Ala
2375 2380 2385
Thr Asp Phe Leu Leu Glu Met Thr Ser Val Ser Pro Asp Tyr Ser
2390 2395 2400
Asn Pro Met Phe Asp His Pro Leu Ser Glu Cys Lys Phe Gln Glu
2405 2410 2415
Tyr Thr Ile Asp Ser Asp Trp Arg Phe Arg Ser Thr Val Leu Thr
2420 2425 2430
Pro Met Phe Ile Glu Thr Gln Ala Ser Gln Ser Ala Leu Gln Thr
2435 2440 2445
Arg Thr Gln Glu Gly Ser Leu Ser Ala Arg Gly Val Met Thr Gly
2450 2455 2460
Gln Ile Arg Ala Thr Gln Gln Gln Tyr Asp Phe Thr Pro Thr Gln
2465 2470 2475
Asn Thr Asp Gly Arg Ser Ser Phe Asn Trp Leu Thr Gly Asn Ser
2480 2485 2490
Ile Asp Pro Leu Val Asp Phe Thr Val Ser Ser Ser Ser Asp Ser
2495 2500 2505
Leu Ser Ser Ser Leu Leu Phe Ala His Lys Arg Ser Glu Lys Ser
2510 2515 2520
Gln Arg Gly Pro Leu Lys Ser Val Gly Pro Asp Phe Gly Lys Lys
2525 2530 2535
Arg Leu Gly Leu Pro Gly Asp Glu Val Asp Asn Lys Ala Lys Gly
2540 2545 2550
Thr Asp Asn Arg Ala Glu Ile Leu Arg Leu Arg Arg Arg Phe Leu
2555 2560 2565
Lys Asp Arg Glu Lys Leu Ser Leu Ile Tyr Ala Arg Lys Gly Val
2570 2575 2580
Ala Glu Gln Lys Arg Glu Lys Glu Ile Lys Ser Glu Leu Lys Met
2585 2590 2595
Lys His Asp Ala Gln Val Ile Leu Tyr Arg Ser Tyr Arg Gln Gly
2600 2605 2610
Asp Leu Pro Asp Ile Gln Ile Lys Tyr Ser Ser Leu Ile Thr Pro
2615 2620 2625
Leu Gln Ala Val Ala Gln Arg Asp Pro Ile Ile Ala Lys Gln Leu
2630 2635 2640
Phe Gly Ser Leu Phe Ser Gly Ile Ile Lys Glu Met Asp Lys Tyr
2645 2650 2655
Lys Thr Met Ser Glu Lys Asn Asn Ile Thr Gln Lys Leu Leu Gln
2660 2665 2670
Asp Phe Asn Asn Phe Leu Asn Thr Thr Val Ser Phe Phe Pro Pro
2675 2680 2685
Phe Ile Ser Cys Ile Gln Glu Ile Ser Cys Gln His Ala Asp Leu
2690 2695 2700
Leu Ser Leu Asp Pro Ala Ser Val Ser Ala Ser Cys Leu Ala Ser
2705 2710 2715
Leu Gln Gln Pro Val Gly Val Arg Leu Leu Glu Glu Ala Leu Leu
2720 2725 2730
His Leu Leu Pro Glu Glu Pro Pro Ala Lys Arg Val Arg Gly Arg
2735 2740 2745
Pro Cys Leu Tyr Pro Asp Phe Val Arg Trp Met Glu Leu Ala Lys
2750 2755 2760
Leu Tyr Arg Ser Ile Gly Glu Tyr Asp Ile Leu Arg Gly Ile Phe
2765 2770 2775
Asn Ser Glu Ile Gly Thr Lys Gln Val Thr Gln Asn Ala Leu Leu
2780 2785 2790
Ala Glu Ala Arg Asn Asp Tyr Ser Glu Ala Val Lys Gln Tyr Asn
2795 2800 2805
Glu Ala Leu Asn Lys Gln Asp Trp Val Asp Gly Glu Pro Met Glu
2810 2815 2820
Ala Glu Lys Asp Phe Trp Glu Leu Ala Ser Leu Asp Cys Tyr Asn
2825 2830 2835
Gln Leu Ala Glu Trp Lys Ser Leu Ala Tyr Cys Ser Thr Val Ser
2840 2845 2850
Val Asp Ser Ala Asn Pro Pro Asp Leu Asn Lys Met Trp Asn Glu
2855 2860 2865
Pro Phe Tyr Gln Glu Thr Tyr Leu Pro Tyr Met Ile Arg Ser Lys
2870 2875 2880
Leu Lys Leu Leu Leu Gln Gly Glu Gly Asp Gln Ser Leu Leu Thr
2885 2890 2895
Phe Ile Asp Glu Ala Val Ser Lys Glu Leu Gln Lys Val Leu Val
2900 2905 2910
Glu Leu His Tyr Ser Gln Glu Leu Ser Leu Leu Tyr Ile Leu Gln
2915 2920 2925
Asp Asp Val Asp Arg Ala Lys Tyr Tyr Ile Glu Asn Cys Ile Arg
2930 2935 2940
Ile Phe Met Gln Ser Tyr Ser Ser Ile Asp Val Leu Leu Glu Arg
2945 2950 2955
Ser Arg Leu Thr Lys Leu Gln Ser Leu Gln Ala Leu Ile Glu Ile
2960 2965 2970
Gln Glu Phe Ile Ser Phe Ile Arg Lys Gln Gly Asn Leu Ser Ser
2975 2980 2985
Gln Ile Pro Leu Lys Arg Leu Leu Lys Thr Trp Thr Asn Arg Tyr
2990 2995 3000
Pro Asp Ala Lys Met Asp Pro Met Asn Ile Trp Asp Asp Ile Ile
3005 3010 3015
Thr Asn Arg Cys Phe Phe Leu Ser Lys Ile Glu Glu Lys Leu Thr
3020 3025 3030
Ile Pro Pro Asp Asp His Ser Met Asn Thr Asp Gly Asp Glu Asp
3035 3040 3045
Ser Ser Asp Arg Met Lys Val Gln Glu Gln Glu Glu Asp Ile Tyr
3050 3055 3060
Ser Leu Ile Lys Ser Gly Lys Phe Ser Met Lys Met Lys Met Ile
3065 3070 3075
Glu Ser Ala Arg Lys Gln Lys Asn Phe Ser Leu Ala Met Lys Leu
3080 3085 3090
Leu Lys Glu Leu His Lys Glu Ser Lys Thr Arg Asp Asp Trp Leu
3095 3100 3105
Val Lys Trp Val Gln Ser Tyr Cys Arg Leu Ser His Ser Arg Ser
3110 3115 3120
Gln Thr Gln Asn Arg Pro Glu Gln Ile Leu Thr Val Leu Lys Thr
3125 3130 3135
Val Ser Leu Leu Asp Glu Asn Thr Ser Ser Tyr Leu Ser Lys Asn
3140 3145 3150
Ile Pro Val Ser Arg Asp His Asn Ile Leu Leu Gly Thr Thr Tyr
3155 3160 3165
Arg Ile Ile Ala Asn Ala Leu Ser Ser Asp Pro Thr Cys Leu Ala
3170 3175 3180
Glu Ile Gly Glu Ser Lys Ala Arg Arg Ile Leu Glu Leu Ser Gly
3185 3190 3195
Ser Ser Leu Glu Asn Ala Glu Glu Val Ile Ala Gly Leu Tyr Gln
3200 3205 3210
Arg Val Leu His His Leu Ser Glu Ala Val Arg Ile Ala Glu Glu
3215 3220 3225
Glu Ala Gln Pro Phe Thr Arg Gly Gln Glu Pro Ala Val Gly Val
3230 3235 3240
Ile Asp Ala Tyr Met Thr Leu Val Asp Phe Cys Asp Gln Gln Leu
3245 3250 3255
Arg Lys Glu Glu Glu Ser Ser Ser Val Thr Glu Ser Val Gln Leu
3260 3265 3270
Gln Met Tyr Pro Ala Leu Val Val Asp Lys Met Leu Lys Ala Leu
3275 3280 3285
Arg Leu Asp Ser Asn Glu Ala Arg Leu Lys Phe Pro Arg Leu Leu
3290 3295 3300
Gln Ile Ile Glu Arg Tyr Pro Glu Glu Thr Leu Ser Leu Met Thr
3305 3310 3315
Lys Glu Ile Ser Ser Ile Pro Cys Trp Gln Phe Ile Gly Trp Ile
3320 3325 3330
Ser His Met Val Ala Leu Leu Asp Lys Glu Glu Ala Val Ala Val
3335 3340 3345
His Arg Thr Val Glu Glu Ile Ala Asp Asn Tyr Pro Gln Ala Met
3350 3355 3360
Val Tyr Pro Phe Ile Ile Ser Ser Glu Ser Tyr Ser Phe Lys Asp
3365 3370 3375
Thr Ser Thr Gly Tyr Lys Asn Lys Glu Phe Val Glu Arg Ile Lys
3380 3385 3390
Ile Lys Leu Asp Gln Gly Gly Val Ile Gln Asp Phe Ile Asn Ala
3395 3400 3405
Leu Glu Gln Leu Ser His Pro Glu Met Leu Phe Lys Asp Trp Thr
3410 3415 3420
Asp Asp Ile Lys Val Glu Leu Glu Lys Asn Pro Val Asn Arg Lys
3425 3430 3435
Asn Ile Glu Lys Met Tyr Glu Lys Met Tyr Ala Thr Leu Gly Asp
3440 3445 3450
Pro Gln Ala Pro Gly Leu Gly Ala Phe Arg Arg Arg Cys Ile Gln
3455 3460 3465
Gly Phe Gly Lys Glu Phe Asp Lys His Phe Gly Arg Gly Gly Ser
3470 3475 3480
Lys Leu Pro Gly Met Lys Ser Arg Glu Phe Ser Asp Ile Thr Asn
3485 3490 3495
Ser Leu Phe Ser Lys Met Cys Glu Val Ser Lys Pro Pro Gly Asn
3500 3505 3510
Leu Lys Glu Cys Ser Pro Trp Met Ser Asp Phe Lys Val Glu Phe
3515 3520 3525
Leu Arg Ser Glu Leu Glu Ile Pro Gly Gln Tyr Asp Gly Lys Gly
3530 3535 3540
Lys Pro Val Pro Glu Tyr His Ala Arg Ile Ala Gly Phe Asp Glu
3545 3550 3555
Arg Ile Lys Val Met Ala Ser Met Arg Lys Pro Lys Arg Ile Ile
3560 3565 3570
Ile Arg Gly His Asp Glu Arg Glu Tyr Pro Phe Leu Val Lys Gly
3575 3580 3585
Gly Glu Asp Leu Arg Gln Asp Gln Arg Ile Glu Gln Leu Phe Glu
3590 3595 3600
Val Met Asn Val Ile Leu Ser Gln Asp Ala Thr Cys Ser Gln Arg
3605 3610 3615
Ser Met Gln Leu Lys Thr Tyr Gln Val Ile Pro Met Thr Ser Arg
3620 3625 3630
Leu Gly Leu Ile Glu Trp Ile Glu Asn Thr Phe Thr Leu Lys Glu
3635 3640 3645
Leu Leu Leu Ser Asn Met Ser Gln Glu Glu Lys Ala Ala Cys Thr
3650 3655 3660
Arg Asp Pro Lys Ala Pro Pro Phe Glu Tyr Arg Asp Trp Leu Thr
3665 3670 3675
Lys Met Ser Gly Lys Cys Asp Val Gly Ala Tyr Met Leu Met Tyr
3680 3685 3690
Lys Gly Ala Ser Arg Thr Glu Thr Val Thr Ser Phe Arg Lys Arg
3695 3700 3705
Glu Ser Lys Val Pro Ala Asp Leu Leu Lys Arg Ala Phe Val Lys
3710 3715 3720
Met Ser Thr Ser Pro Glu Ala Phe Leu Thr Leu Arg Ser His Phe
3725 3730 3735
Ala Gly Ser His Ala Leu Ile Cys Ile Ser His Trp Ile Pro Gly
3740 3745 3750
Ile Gly Asp Arg His Leu Asn Asn Phe Leu Val Ser Met Glu Thr
3755 3760 3765
Gly Gly Val Ile Gly Ile Asp Phe Gly His Ala Phe Gly Ser Ala
3770 3775 3780
Thr Gln Phe Leu Pro Val Pro Glu Leu Met Pro Phe Arg Leu Thr
3785 3790 3795
Arg Gln Phe Ile Asn Leu Met Leu Pro Met Lys Glu Thr Gly Val
3800 3805 3810
Met Tyr Ser Ile Met Val His Ala Leu Arg Ala Phe Arg Ser Gln
3815 3820 3825
Ser Asn Leu Leu Ala Asn Thr Met Asp Val Phe Val Lys Glu Pro
3830 3835 3840
Ser Phe Asp Trp Lys Asn Phe Glu Gln Lys Met Arg Lys Lys Gly
3845 3850 3855
Gly Ser Trp Ile Gln Glu Ile Asn Val Thr Glu Lys Asn Trp Tyr
3860 3865 3870
Pro Arg Gln Lys Ile His Tyr Ala Lys Arg Lys Leu Ala Gly Ala
3875 3880 3885
Asn Pro Ala Val Ile Thr Cys Asp Glu Leu Leu Leu Gly His Glu
3890 3895 3900
Lys Ala Ala Ala Phe Gly Asp Tyr Val Ala Val Ala Arg Gly Ser
3905 3910 3915
Glu Asp His Asn Ile Arg Ala Gln Glu Leu Glu Ser Asp Leu Ser
3920 3925 3930
Glu Glu Ala Gln Val Lys Cys Leu Ile Asp Gln Ala Thr Asp Pro
3935 3940 3945
Asn Ile Leu Gly Arg Thr Leu Val Gly Trp Glu Pro Trp Met
3950 3955
(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11878 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:
GTATATGAGC TCCTAGGAGT ATTAGGTGAA GTTCATCCTA GTGAGATGAT AAGTAATTCA 60
GAACAACTGT TCCGGGCTTT TCTGGGTGAA CTTAAGTCCC AGATGACATC AACAGTAAGA 120
GAGCCCAAAC TACCTGTTCT GGCAGGGTGT CTGAAGGGAT TGTCATCACT TATGTGTAAC 180
TTCACTAAGT CCATGGAAGA AGATCCCCAG ACTTCAAGGG AGATTTTTGA TTTTGCGTTA 240
AAGGCAATTC GTCCTCAGAT TGATCTGAAG AGATATGCAG TGCCCTTAGC TGGTTTATGC 300
TTATTTACCC TGCATGCATC TCAATTTAGC ACCTGCCTTT TGGAGAACTA CGTTTCTTTG 360
TTTGAAGTGC TGTCAAAATG GTGTGGCCAT ACAAACATAG AATTGAAAAA AGCCGCACAT 420
TCAGCTCTGG AGTCTTTTCT GAAACAGGTT TCTTTTATGG TGGCAAAAGA TGCAGAAAGG 480
CATAAGAATA AGCTGCAGTA CTTTATGGAG CAATTCTATG GAATCATCAG GAACATGGAT 540
TCAAATAGCA AGGATTTATC AATTGCAATT CGTGGATATG GACTTTTTGC AGGCCCTTGC 600
AAGGTTATAA ACGCAAAAGA TGTTGACTTC ATGTACGTAG AGCTCATTCA GCGCTGCAAG 660
CAGCTGTTCC TCACCCAGAC AGATACTGTT GATGACCATA TTTACCAGAT GCCCAGTTTC 720
CTCCAATCTA TTGTAAGTGT CTTGCTTTAC CTTGATACAA TTCCTGAGGT GTATACTCCG 780
GTTCTGGAAC ATCTCATGGT GGTACAGATA GACAGCTTCC CACAGTATAG TCCAAAAATG 840
CAGCCGGTGT GTTGTAGAGC CATAGTGAAA CTTTTCCTAG CCTTAGCAGA AAAGGGACCA 900
GTTCTCTGGA ATTGCATTAG TACTGTGGTG CATCAAGGTT TAATTAGAAT ATGTTCTAAA 960
CCAGTCGTCT TTCAAAAGGG TGCTGGGTCT GAATCCGAAG ACTATCATAC ATCAGAGGAA 1020
GCTAGAACTG GCAAATGGAA AATGCCCACA TACAAAGACT ATTTGGATCT TTTTAGATAT 1080
CTCCTGAGCT GTGACCAGAT GATGGATTCT CTTTTAGCAG ATGAAGCATT TCTCTTTGTG 1140
AATTCCTCCC TTCATAGTCT GAATCGTTTG CTGTATGATG AATTTGTAAA ATCAGTTTTG 1200
AAGATTGTTG AGAAATTGGA TCTTACACTA GAAAAACAGA ATGTTGGGGA GCAAGAGGAT 1260
GAAACTGAAG CTACTGGTGT TTGGGTGATC CCGACTTCAG ATCCAGCGGC TAACTTGCAC 1320
CCTGCTAAAC CTAAAGATTT TTCAGCTTTC ATTAACCTGG TGGAATTTTG CAGAGAGATT 1380
CTTCCTGAGA AACATGTAGA ATTTTTTGAG CCATGGGTTT ACTCATTTGC GTATGAATTA 1440
ATTTTGCAGT CTACACGGTT ACCACTCATC AGTGTTTTTT ACAAATTGCT TTCTGTTGCT 1500
GTGAGAAATG CCAAGAAAAT GAAGTATTTT GAAGGAGTTG GTCCAAAGAG TCAGAAACAG 1560
TCTCCTGAGG ACCTAGAAAA GTATTCTTGC TTTGCTTTGT TTGCAAAATT TAGTAAAGAG 1620
GTATCAATTA AAATGAAGCA ATACAAAGAT GAACTTTTGG CCTCCTGTTT GACCTTTATT 1680
CTGTCCCTGC CACATGACAT CATTGAACTT GATGTTAGAG CCTACGTTCC TGCATTGCAG 1740
ATGGCTTTTA AACTGGGCCT GAGCTATACT CCATTGGCGG AAGTAGGCCT GAATGCTCTA 1800
GAAGAATGGT CAGGTTACAT CTGCAAACAT GTAATTCAGC CCTATTATAA GGACATTCTA 1860
CCCAGCCTTG ATGGATATCT GAAAACTTCA GTCTTATCAG ATGAGACCAA GAATAGCTGG 1920
CAAGTGTCAG CACTTTCTCG GGCTGCCCAG AAAGGATTTA ATAAAGTTGT GCTAAAGCAT 1980
CTGACAAAGA CAAAGAGCAT TTCATCAAAT GAAGCACTGT CCTTAGAAGA AGTGAGGATT 2040
AGAGTAGTCG GATACTTGGC TCTCTAGGAG GACAAATAAA CAAGAATCTC GTAACAGCTG 2100
CATCATCAGA TGAAATGATG AAGAAGTGTG TGGCATGGGA CAGAGAAAAA AGACTCCGTT 2160
TTGCAGTACC ATTTATGGAG ATGAAGCCTG TCATTTATCT GGATCTATTC CTGCCTCGGG 2220
TCACCGAGTT AGCTCTTTCA GCTAGTGACA GGCAGACTAC AGTTGCAGCC TGTGAACTTT 2280
TACATAGCAT GGTTATGTTT ATGTTGGGAA AAGCCACTCA GATGCCTGAA GATGGTCAGG 2340
GTTCCCCACC CATGTACCAG CTCTATAAGC GAACTTTTCC TGTTTTACTT CGACTTGCAT 2400
GTGATGTAGA TCAGGTGACA AGGCAACTGT ATGAGCCACT AGTTATGCAA CTGATTCACT 2460
GGTTCACTAA CAACAAGAAA TTTGAAAGTC AGGACACTGT CGCCTTACTA GAAACGATAT 2520
TGGATGGAAT TGTGGACCCT GTTGACAGTA CTTTGAGAGA TTTTTGTGGT CAGTGTATTC 2580
AAGAATTCCT TAAATGGTCC ATTAAGCAGA CGACACCACA GCAGCAGGAA AAAAGTCCAG 2640
TAAATACCAA ATCGCTTTTC AAGCGACTGT ATAGCTTTGC ACTTCATCCG AATGCCTTCA 2700
AGAGGCTGGG AGCATCACTT GCTTTTAATA ATATCTACAG GGAATTCAGG GAAGAAGAGT 2760
CTCTGGTAGA ACAGTTTGTG TTTGAAGCCT TGGTAACGTA TATGGAAAGT CTGGCCTTAG 2820
CACATACAGA TGAGAAATCC TTAGGTACAA TTCAACAATG TTGTGATGCC ATTGATCATC 2880
TCAGTCTTAT CATTGAGAAG AAGCACGTTT CTTTAAACAA AGCAAAAAAA CGACGTTTGC 2940
CACGAGGCTT TCCACCTGCG ACATCACTGT GTTTATTGGA TGTGGTCCAG TGGCTTTTAG 3000
CAAATTGTGG GAGACCCCAG ACAGAATGTC GACACAAATC CATAGAACTC TTTTATAAAT 3060
TTGTTACTTT ATTGCCAGGC AACAAATCCC CTTTTTTATG GCTGAAAGAT ATTATCAAGA 3120
AAGAAGATAT TTCCTTTCTC ATAAACACAT TTGAGGGCGG GGGAAGTGGT CGGCCGTCAG 3180
GCATCCTTGC TCAGCCAACC CTCTTCCATT TGCAAGGGCC GTTCAGTCTC AGAGCTGCCC 3240
TGCAGTGGAT GGACATGCTT CTGGCAGCAC TGGAGTGCTA CAACACATTC ATTGAAGAGA 3300
AAACTCTGGA AGCACCCAAG GTCCTAGGTA CTGAAACCCA GTCTTCACTT TGGAAAGCGG 3360
TGGCTTTCTT TTTAGAAAGC ATTGCTATGC ATGATATTAT GGCAGCAGAA AAGTACTTTG 3420
GCACTGGGGC AACAGGTAAC AGACCCAGCC CACAAGAAGG AGAAAGATAT AATTATAGCA 3480
AATGTACAAT TGTGGTCCGC ATTATGGAAT TTACCACAAC GCTCCTCAGC ACCTCCCCAG 3540
AAGGCTGGAA GCTGCTTGAG AAGGATGTGT GTAACACAAA CCTTATGAAA CTCTTAGTGA 3600
AAACCCTGTG TGAGCCCTCA AGCATAGGTT TCAACATCGG AGATGTCGCA GTTATGAACT 3660
ATCTTCCCAG TGTTTGTACC AACCTGATGA AAGCACTGAA GAAGTCCCCA TACAAAGACA 3720
TCCTGGAGAT GCACCTCAAG GAAAAGATAA CAGCACAGAG CATTGAAGAG CTCTGTGCAG 3780
TTGACTTGTA TTGCCCTGAT GCTTGCGTGG ACAGGGCCAG GCTGGCTTCT GTCGTGTCAG 3840
CTTGTAAACA ACTTCATAGA GCGGGGGTTT TGTGTGTTAT AATACCATCT CAGTCTGCAG 3900
ATCAGCATCA TTCTATTGGC ACAAAACTTC TTTCCTTGGT TTATAAAAGC ATTGCACCTG 3960
GAGATGAACA ACAGTGCCTT CCTTCACTAG ATCCCAATTG TAAGCGATTG GCCAGTGGAC 4020
TTCTGGAGTT GGCCTTTGCT TTTGGAGGAC TGTGTGAGCA CCTTGTGAGT CTTCTCCTGG 4080
ACACGACAGT GTTGTCATGC CATCCAGAGG AGGGTCCCAG AAAAACATCG TCAGCTTCTC 4140
TCATGGAGAG TATTTTTATA GCTTGTTCTC AGAAACGATC AACACTGAAT TGTTGAAAAA 4200
TCTAGATCTT GCTGTATTGG AGCTCATGAA ATCATCTGTG GATAATCCCA AAATGGTGAG 4260
CAATGTTTTG AATGGTATGT TAGATCAGAG CTTCAGGGAT CGAACCAGTG AGAAACACCA 4320
AGGACTGAAA CTTGCAACTA TAATTCTGCA AAACTGGAAG AAGTGTGATT CATGGTGGGC 4380
CAAAGATTCT GCTCCTGAAA GTAAAATGGC AGTGCTTACC TTGTTGGCAA AAATTTTCCA 4440
GATTGATTCA TCTGTTTGTT TTAATACAAA TCACTGCATG TTCCCTGAAG TCTTTACAAC 4500
ATATGTTAGT CTACTTGCTG ATTCAAAGTT GGACCTGCAT TTAAAGGGCC AAGCTATAAT 4560
TCTTCTTCCA TTCTTCACCA GTCTTACTGG AGGCAGCCTT GAGGACCTTA AGGTTGTTCT 4620
TGAAAACCTC ATCGTTTCTA ATTTTCCTAT GAAATCTGAA GAATTTCCCC CAGGAACTCT 4680
GCAGTACAAT AATTATGTGG ACTGCATGAA GAAGTTTCTA GATGCATTGG AATTATCTAA 4740
AAGCCCTATG TTGTTGCAGT TGATGACAGA AATTCTTTGT CGTGAACAGC AACATGTTAT 4800
GGAAGAATTA TTTCAGTCTA CTTTCAAAAA GATTGCCAGA AAGAGTTCAT GTATCACACA 4860
ATTAGGCCTT CTGGAAAGTG TATATAGAAT GTTCAGGAGG GATGACCTGC TTTCAAATAT 4920
CACTCGCCAA GCATTTGTAG ACCGTTCTCT GCTCACTCTG TTGTGGCACT GTAGCTTGAA 4980
TGCTTTGAGG GAATTTTTTA GCAAAATTGT GGTGGAAGCC ATTAATGTGT TGAAGTCCAG 5040
ATTTATAAAG CTGAATGAAT CTGCCTTTGA TACTCAAATC ACCAAGAAGA TGGGCTACTA 5100
TAAGATGTTA GATGTGATGT ATTCTCGTCT TCCAAAAGAT GATGTTCACT CTAAGGAATC 5160
TAAAATTAAT CAAGTTTTCC ATGGCTCATG TATTACAGAA GGAAGTGAAC TTACAAAGAC 5220
ACTTATTAAA TTGTGCTATG ATGCCTTTAC AGAGAACATG GCAGGCGAGA ACCAGTTGCT 5280
GGAGAGGAGA AGACTTTACC ATTGTGCTGC ATACAACTGT GCCATTTCTG TTGTCTGCTG 5340
TGTCTTCAAT GAATTAAAAT TTTACCAAGG TTTTCTGTTT ACTGAAAAAC CAGAAAAGAA 5400
CTTGCTTATT TTTGAAAATC TGATAGACTT GAAGCGCTGC TACACGTTTC CTATAGAAGT 5460
TGAGGTTCCT ATGGAGAGAA AGAAAAAGTA CCTTGAAATT AGAAAAGAAG CCAGGGAAGC 5520
AGCAGCAAGT GGGGATTCAG ATGGTCCTCG TTATATATCT TCCTTGTCAT ATTTGGCAGA 5580
CAGTAGCCTG AGTGAGGAAA TGAGTCAATT TGATTTCTCG ACTGGAGTGC AGAGCTATTC 5640
ATATAGTTCC CAAGACCCTA AATCTACCAC TGCTCATTTT CGGAGACAGA AACATAAAGA 5700
GTCCATGATC CAAGATGATA TCCTGGAGTT AGAGATGGAT GAACTCAATC AACACGAATG 5760
TATGGCAACT ATGACTGCTC TGATTAAGCA CATGCAGAGA AATCAGATCC TCCCTAAGGA 5820
AGAAGAGGGT TCAGTGCCAA GAAATCTTCC TCCTTGGATG AAATTTCTTC ATGACAAACT 5880
AGGAAATCCA TCAATATCAT TAAATATCCG TCTCTTCTTA GCCAAGCTTG TTATTAATAC 5940
AGAAGAAGTC TTTCGTCCTT ACGCGAGATA CTGGCTCAGC CCTTTGCTGC AGCTGGTTGT 6000
TTCTGGAAAC AACGGAGGAG AAGGAATTCA CTATATGGTG GTTGAGATAG TGGTTATTAT 6060
TCTTTCATGG ACAGGATTAG CTACTCCTAT AGGTGTCCCT AAAGATGAAG TGTTAGCAAA 6120
TCGATTGCTT CATTTCCTAA TGAACATGTT TTTCATCAAA AAAGAGCTGT GTTTAGACAC 6180
AACCTCGAAA TTATAAAAAC CCTTGTTGAA TGCTGGAAGG ATTGTTTATC CATCCCTTAC 6240
AGGTTAATAT TTGAAAAGTT TTCCAGTACA GATCCTAATT CTAAAGACAA TTCAGTAGGA 6300
ATTCAATTAC TAGGCATTGT AATGGCCAAT AACTTGCCTC CTTATGACCC AAAATGTGGC 6360
ATAGAGAGCA TAAAATACTT TCAAGCTTTG GTCAATAATA TGTCCTTTGT AAGATATAGA 6420
GAGGTATATG CAGCAGCGGC AGAAGTTCTA GGACTTGTTC TTCGATATAT TACTGAGAGA 6480
GAAAATATAC TGGAGGAGTC TGTGTGTGAA CTGGTCATAA AACAGTTGAA GCAACATCAG 6540
AATACGATGG AGGACAAATT TATTGTGTGC TTGAACAAAG CTGTGAAGAA CTTCCCTCCT 6600
CTTGCTGATA GGTTTATGAA CACCGTGTTC TTCCTGCTGC CAAAATTTCA TGGCGTGATG 6660
AAGACTCTCT GTCTGGAGGT GGTACTGTGT CGTGCAGAGG AAATAACAGA TCTATACTTA 6720
CAGTTAAAGA GCAAGGATTT CATTCAAGTC ATGAGACATA GAGATGATGA AAGACAAAAA 6780
GTGTGTTTGG ACATAATTTA TAAGATGATG GCAAGATTGA AACCAGTAGA ACTTCGAGAA 6840
CTTCTGAATC CTGTTGTAGA ATTCATTTCT CATCCTTCTC CAGTGTGTAG GGAACAAATG 6900
TATAACATTC TCATGTGGAT TCATGACAAT TATCGAGATC CAGAAGGTCA GACAGATGAC 6960
GACTCCCAGG AAATATTTAA GTTGGCAAAA GATGTGTTGA TTCAAGGATT GATCGATGAG 7020
AACCCTGGGC TTCAATTAAT TATTCGAAAT TTCTGGAGTC ATGAAACTAG GTTACCTTCA 7080
AATACCTTGG ATCGATTGTT GGCACTAAAT TCCCTATATT CTCCTAAGAT AGAAGCACAC 7140
TTTTTAAGTT TAGCAACAGA TTTTCTGCTT GAAATGACCA GCGTGAGCCC AGATTATTCA 7200
AACCCTATGT TTGATCATCC TCTGTCAGAA TGCAAATTTC AGGAATATAC TATTGATTCT 7260
GACTGGCGTT TCCGAAGTAC TGTTCTCACT CCAATGTTTA TTGAGACTCA GGCCTCCCAA 7320
AGTGCTCTGC AGACCCGGAC CCAGGAAGGA TCCCTCTCAG CTCGAGGGGT AATGACTGGG 7380
CAGATACGGG CCACACAACA GCAGTATGAT TTCACACCTA CGCAAAATAC AGATGGAAGA 7440
AGCTCTTTCA ATTGGCTGAC TGGGAACAGC ATTGACCCAC TGGTGGATTT TACGGTCTCC 7500
TCCTCATCTG ATTCTTTGTC TTCCTCCTTG CTGTTTGCTC ACAAGAGGAG TGAAAAATCA 7560
CAGAGAGGAC CCTTGAAGTC AGTAGGACCT GATTTTGGGA AAAAAAGGCT GGGCCTTCCA 7620
GGGGATGAGG TGGATAACAA AGCAAAAGGT ACAGACAATC GGGCGGAAAT ATTAAGATTA 7680
CGGAGACGAT TTTTAAAGGA CCGAGAAAAG CTCAGTTTGA TTTATGCCAG AAAAGGTGTT 7740
GCTGAACAAA AACGAGAGAA GGAGATCAAG AGTGAGTTAA AAATGAAGCA CGATGCCCAA 7800
GTCATTTTGT ACAGAAGTTA CCGTCAAGGA GACCTTCCTG ACATTCAGAT TAAATACAGC 7860
AGCCTGATCA CTCCCTTGCA AGCTGTGGCC CAGAGAGACC CAATAATTGC AAAGCAGCTC 7920
TTTGGCAGCT TGTTTTCTGG AATTATAAAA GAGATGGATA AATATAAGAC CATGTCTGAA 7980
AAAAACAACA TTACTCAGAA GTTGCTCCAG GACTTCAATA ATTTTCTTAA CACCACTGTC 8040
TCTTTCTTTC CACCTTTCAT CTCCTGTATC CAGGAAATTA GTTGCCAACA CGCAGACTTG 8100
CTGAGCCTCG ACCCAGCTTC TGTCAGTGCC AGCTGCCTGG CCAGTCTGCA GCAGCCTGTA 8160
GGCGTCCGCC TTCTGGAGGA GGCCTTGCTC CACTGCTGCC TGAAGAGCCA CCTGCCAAGC 8220
GAGTTCGAGG GAGACCCTGT CTCTACCCTG ATTTTGTCAG ATGGATGGAA CTTGCTAAAC 8280
TGTATAGATC AATTGGAGAA TATGACATCC TCCGTGGGAT TTTTAATAGT GAGATAGGAA 8340
CAAAGCAAGT CACTCAGAAT GCATTATTAG CAGAAGCAAG AAATGATTAT TCTGAAGCCG 8400
TTAAGCAGTA TAATGAGGCT CTCAATAAAC AAGACTGGGT AGATGGTGAG CCTATGGAAG 8460
CTGAGAAGGA TTTTTGGGAA CTTGCATCCC TTGACTGTTA TAACCAACTT GCTGAGTGGA 8520
AATCACTGGC ATACTGTTCT ACAGTCAGTG TTGACAGTGC GAACCCTCCA GATTTAAATA 8580
AAATGTGGAA TGAACCATTT TATCAGGAGA CCTATCTACC TTACATGATC CGCAGCAAGC 8640
TGAAGCTACT TCTGCAAGGT GAGGGAGACC AGTCCCTGCT GACATTTATT GATGAAGCTG 8700
TGAGCAAGGA GCTCCAGAAG GTCCTCGTAG AGCTTCATTA CAGTCAGGAA TTGAGTCTCC 8760
TTTATATCCT ACAAGATGAC GTCGACAGAG CCAAATATTA TATTGAAAAT TGCATTCGGA 8820
TTTTCATGCA GAGCTATTCT AGTATTGATG TCCTTTTAGA GAGAAGTAGA CTCACCAAAT 8880
TGCAATCTCT ACAGGCTTTA ATAGAAATTC AGGAGTTCAT CAGCTTTATA AGGAAACAAG 8940
GTAATTTATC ATCTCAAATT CCCCTTAAGA GACTTCTAAA AACCTGGACA AACAGATATC 9000
CGGATGCTAA AATGGACCCA ATGAACATCT GGGATGACAT CATCACAAAT CGATGTTTCT 9060
TTCTCAGCAA AATAGAAGAA AAACTGACTA TTCCTCCAGA TGATCATAGT ATGAACACAG 9120
ATGGAGATGA AGATTCCAGT GACAGAATGA AAGTGCAGGA GCAGGAGGAA GATATTTATT 9180
CTCTGATTAA GAGTGGTAAG TTTTCCATGA AAATGAAGAT GATAGAAAGT GCAAGGAAAC 9240
AGAAAAATTT CTCACTAGCC ATGAAACTAT TAAAGGAGCT TCATAAAGAG TCAAAAACAA 9300
GAGATGACTG GCTGGTGAAA TGGGTGCAGA GCTACTGTCG ACTCAGTCAC AGCCGGAGCC 9360
AGACCCAGAA TCGTCCTGAG CAGATCCTTA CTGTGTTGAA AACAGTCTCT TTGTTGGATG 9420
AGAACACATC AAGCTACTTA AGCAAAAATA TTCCAGTTTC CCGTGACCAC AACATTCTCT 9480
TGGGTACAAC TTACAGGATC ATAGCTAATG CTCTCAGCAG TGATCCAACT TGCCTTGCTG 9540
AAATCGGGGA AAGCAAGGCT AGAAGAATCT TGGAGCTGTC TGGATCCAGT TTAGAGAATG 9600
CAGAAGAGGT GATCGCAGGT CTATACCAGA GAGTGTTGCA TCACCTTTCT GAGGCCGTGC 9660
GGATTGCAGA GGAGGAGGCC CAGCCTTTCA CTAGAGGCCA GGAACCTGCA GTTGGGGTGA 9720
TAGATGCTTA CATGACACTG GTGGATTTCT GTGACCAGCA GCTCCGCAAG GAGGAAGAGA 9780
GTTCATCAGT TACTGAGTCT GTACAACTGC AGATGTATCC AGCCCTTGTG GTGGACAAAA 9840
TGTTAAAAGC TTTAAGACTC GATTCCAATG AAGCCAGGCT GAAGTTTCCC AGACTACTGC 9900
AGATTATAGA ACGGTATCCA GAGGAGACCC TGAGCCTAAT GACCAAAGAG ATTTCTTCCA 9960
TTCCTTGCTG GCAGTTCATT GGCTGGATCA GCCACATGGT GGCCTTACTG GACAAAGAGG 10020
AAGCTGTCGC TGTCCATCGC ACAGTGGAAG AGATTGCTGA TAACTATCCA CAGGCGATGG 10080
TCTACCCATT TATAATAAGC AGTGAAAGCT ATTCCTTCAA AGATACTTCT ACTGGTTATA 10140
AGAATAAGGA GTTTGTGGAA AGGATTAAAA TTAAGTTGGA TCAAGGAGGA GTGATTCAAG 10200
ATTTTATTAA TGCCCTAGAA CAGCTCTCTC ATCCTGAAAT CTCTTTAAGG ACTGGACTGA 10260
TGATATCAAA GTTGAACTTG AAAAAAACCC TGTAAATAGA AAAAACATTG AAAAGATGTA 10320
TGAAAAAATG TATGCAACCT TGGGAGACCC ACAGGCTCCA GGTCTTGGGG CTTTTCGAAG 10380
AAGGTGTATT CAGGGTTTTG GAAAAGAATT TGATAAACAC TTTGGGAGAG GAGGTTCTAA 10440
GCTACCTGGA ATGAAATCCC GTGAATTCAG TGATATTACC AACTCACTAT TTTCAAAAAT 10500
GTGCGAAGTC TCAAAGCCAC CTGGGAATCT GAAAGAATGC TCGCCCTGGA TGAGTGACTT 10560
CAAAGTAGAA TTTTTGAGAA GTGAACTGGA GATTCCTGGT CAGTATGATG GCAAGGGAAA 10620
ACCAGTGCCA GAATACCATG CACGAATTGC TGGGTTTGAT GAGCGGATAA AAGTAATGGC 10680
TTCTATGAGA AAACCAAAGC GTATCATCAT CCGAGGCCAT GATGAGAGAG AGTACCCTTT 10740
CCTTGTGAAG GGAGGTGAAG ATCTGAGGCA GGACCAACGC ATCGAGCAGC TCTTCGAGGT 10800
CATGAATGTC ATCCTTTCCC AAGATGCTAC CTGTAGTCAG AGAAGCATGC AGCTAAAGAC 10860
ATACCAGGTC ATACCCATGA CCTCCAGATT AGGACTAATT GAATGGATTG AAAATACTTT 10920
TACCTTGAAG GAACTTCTTT TGAGTAACAT GTCACAAGAG GAGAAAGCGG CTTGTACAAG 10980
AGATCCCAAA GCACCACCAT TTGAATATAG AGACTGGCTG ACAAAGATGT CTGGGAAATG 11040
TGATGTTGGT GCTTACATGC TAATGTATAA GGGAGCTAGT CGTACTGAAA CAGTCACATC 11100
TTTTAGAAAA AGAGAAAGTA AGGTGCCAGC CGATCTCTTA AAGCGGGCCT TTGTGAAGAT 11160
GAGTACCAGC CCTGAGGCCT TCCTGACACT CCGCTCACAC TTTGCCGGCT CTCACGCTTT 11220
GATATGCATT AGTCACTGGA TTCCTGGGAT TGGAGATAGA CATCTGAACA ATTTCCTGGT 11280
AAGCATGGAG ACAGGTGGAG TGATTGGAAT CGACTTTGGA CATGCATTTG GATCAGCTAC 11340
TCAGTTTCTG CCGGTCCCTG AGTTGATGCC TTTTCGTCTA ACTCGCCAGT TTATCAATCT 11400
GATGTTACCA ATGAAAGAAA CAGGTGTTAT GTACAGTATC ATGGTGCATG CACTGAGAGC 11460
CTTCCGCTCG CAGTCCAACC TGCTTGCTAA CACCATGGAC GTGTTTGTAA AGGAGCCTTC 11520
CTTCGACTGG AAAAATTTTG AACAGAAAAT GCGGAAAAAA GGAGGATCAT GGATTCAAGA 11580
AATAAATGTA ACTGAAAAAA ATTGGTATCC CCGGCAGAAA ATACATTATG CTAAGAGAAA 11640
GTTAGCTGGT GCCAATCCAG CAGTTATTAC TTGTGATGAG TTACTTCTGG GCCATGAGAA 11700
GGCAGCTGCA TTTGGAGATT ATGTGGCTGT AGCACGAGGA AGTGAAGATC ACAATATCCG 11760
TGCCCAAGAA CTGGAGAGTG ACCTTTCAGA AGAAGCTCAG GTGAAGTGCT TGATTGACCA 11820
GGCAACAGAC CCCAACATCC TTGGCAGAAC CTTGGTAGGA TGGGAGCCCT GGATGTGA 11878
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11873 bp
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double stranded
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE:
(A) DESCRIPTION: other nucleic acid
(iii) HYPOTHETICAL: no
(iv) ANTI-SENSE: no
(vi) ORIGINAL SOURCE:
(ix) FEATURE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:
GTATATGAGC TCCTAGGAGT ATTAGGTGAA GTTCATCCTA GTGAGATGAT AAGTAATTCA 60
GAACAACTGT TCCGGGCTTT TCTGGGTGAA CTTAAGTCCC AGATGACATC AACAGTAAGA 120
GAGCCCAAAC TACCTGTTCT GGCAGGGTGT CTGAAGGGAT TGTCATCACT TATGTGTAAC 180
TTCACTAAGT CCATGGAAGA AGATCCCCAG ACTTCAAGGG AGATTTTTGA TTTTGCGTTA 240
AAGGCAATTC GTCCTCAGAT TGATCTGAAG AGATATGCAG TGCCCTTAGC TGGTTTATGC 300
TTATTTACCC TGCATGCATC TCAATTTAGC ACCTGCCTTT TGGAGAACTA CGTTTCTTTG 360
TTTGAAGTGC TGTCAAAATG GTGTGGCCAT ACAAACATAG AATTGAAAAA AGCCGCACAT 420
TCAGCTCTGG AGTCTTTTCT GAAACAGGTT TCTTTTATGG TGGCAAAAGA TGCAGAAAGG 480
CATAAGAATA AGCTGCAGTA CTTTATGGAG CAATTCTATG GAATCATCAG GAACATGGAT 540
TCAAATAGCA AGGATTTATC AATTGCAATT CGTGGATATG GACTTTTTGC AGGCCCTTGC 600
AAGGTTATAA ACGCAAAAGA TGTTGACTTC ATGTACGTAG AGCTCATTCA GCGCTGCAAG 660
CAGCTGTTCC TCACCCAGAC AGATACTGTT GATGACCATA TTTACCAGAT GCCCAGTTTC 720
CTCCAATCTA TTGTAAGTGT CTTGCTTTAC CTTGATACAA TTCCTGAGGT GTATACTCCG 780
GTTCTGGAAC ATCTCATGGT GGTACAGATA GACAGCTTCC CACAGTATAG TCCAAAAATG 840
CAGCCGGTGT GTTGTAGAGC CATAGTGAAA CTTTTCCTAG CCTTAGCAGA AAAGGGACCA 900
GTTCTCTGGA ATTGCATTAG TACTGTGGTG CATCAAGGTT TAATTAGAAT ATGTTCTAAA 960
CCAGTCGTCT TTCAAAAGGG TGCTGGGTCT GAATCCGAAG ACTATCATAC ATCAGAGGAA 1020
GCTAGAACTG GCAAATGGAA AATGCCCACA TACAAAGACT ATTTGGATCT TTTTAGATAT 1080
CTCCTGAGCT GTGACCAGAT GATGGATTCT CTTTTAGCAG ATGAAGCATT TCTCTTTGTG 1140
AATTCCTCCC TTCATAGTCT GAATCGTTTG CTGTATGATG AATTTGTAAA ATCAGTTTTG 1200
AAGATTGTTG AGAAATTGGA TCTTACACTA GAAAAACAGA ATGTTGGGGA GCAAGAGGAT 1260
GAAACTGAAG CTACTGGTGT TTGGGTGATC CCGACTTCAG ATCCAGCGGC TAACTTGCAC 1320
CCTGCTAAAC CTAAAGATTT TTCAGCTTTC ATTAACCTGG TGGAATTTTG CAGAGAGATT 1380
CTTCCTGAGA AACATGTAGA ATTTTTTGAG CCATGGGTTT ACTCATTTGC GTATGAATTA 1440
ATTTTGCAGT CTACACGGTT ACCACTCATC AGTGTTTTTT ACAAATTGCT TTCTGTTGCT 1500
GTGAGAAATG CCAAGAAAAT GAAGTATTTT GAAGGAGTTG GTCCAAAGAG TCAGAAACAG 1560
TCTCCTGAGG ACCTAGAAAA GTATTCTTGC TTTGCTTTGT TTGCAAAATT TAGTAAAGAG 1620
GTATCAATTA AAATGAAGCA ATACAAAGAT GAACTTTTGG CCTCCTGTTT GACCTTTATT 1680
CTGTCCCTGC CACATGACAT CATTGAACTT GATGTTAGAG CCTACGTTCC TGCATTGCAG 1740
ATGGCTTTTA AACTGGGCCT GAGCTATACT CCATTGGCGG AAGTAGGCCT GAATGCTCTA 1800
GAAGAATGGT CAGGTTACAT CTGCAAACAT GTAATTCAGC CCTATTATAA GGACATTCTA 1860
CCCAGCCTTG ATGGATATCT GAAAACTTCA GTCTTATCAG ATGAGACCAA GAATAGCTGG 1920
CAAGTGTCAG CACTTTCTCG GGCTGCCCAG AAAGGATTTA ATAAAGTTGT GCTAAAGCAT 1980
CTGACAAAGA CAAAGAGCAT TTCATCAAAT GAAGCACTGT CCTTAGAAGA AGTGAGGATT 2040
AGAGTAGTCG GATACTTGGC TCTCTAGGAG GACAAATAAA CAAGAATCTC GTAACAGCTG 2100
CATCATCAGA TGAAATGATG AAGAAGTGTG TGGCATGGGA CAGAGAAAAA AGACTCCGTT 2160
TTGCAGTACC ATTTATGGAG ATGAAGCCTG TCATTTATCT GGATCTATTC CTGCCTCGGG 2220
TCACCGAGTT AGCTCTTTCA GCTAGTGACA GGCAGACTAC AGTTGCAGCC TGTGAACTTT 2280
TACATAGCAT GGTTATGTTT ATGTTGGGAA AAGCCACTCA GATGCCTGAA GATGGTCAGG 2340
GTTCCCCACC CATGTACCAG CTCTATAAGC GAACTTTTCC TGTTTTACTT CGACTTGCAT 2400
GTGATGTAGA TCAGGTGACA AGGCAACTGT ATGAGCCACT AGTTATGCAA CTGATTCACT 2460
GGTTCACTAA CAACAAGAAA TTTGAAAGTC AGGACACTGT CGCCTTACTA GAAACGATAT 2520
TGGATGGAAT TGTGGACCCT GTTGACAGTA CTTTGAGAGA TTTTTGTGGT CAGTGTATTC 2580
AAGAATTCCT TAAATGGTCC ATTAAGCAGA CGACACCACA GCAGCAGGAA AAAAGTCCAG 2640
TAAATACCAA ATCGCTTTTC AAGCGACTGT ATAGCTTTGC ACTTCATCCG AATGCCTTCA 2700
AGAGGTTGGG AGCATCACTT GCTTTTAATA ATATCTACAG GGAATTCAGG GAAGAAGAGT 2760
CTCTGGTAGA ACAGTTTGTG TTTGAAGCCT TGGTAACGTA TATGGAAAGT CTGGCCTTAG 2820
CACATACAGA TGAGAAATCC TTAGGTACAA TTCAACAATG TTGTGATGCC ATTGATCATC 2880
TCAGTCTTAT CATTGAGAAG AAGCACGTTT CTTTAAACAA AGCAAAAAAA CGACGTTTGC 2940
CACGAGGCTT TCCACCTGCG ACATCACTGT GTTTATTGGA TGTGGTCCAG TGGCTTTTAG 3000
CAAATTGTGG GAGACCCCAG ACAGAATGTC GACACAAATC CATAGAACTC TTTTATAAAT 3060
TTGTTACTTT ATTGCCAGGC AACAAATCCC CTTTTTTATG GCTGAAAGAT ATTATCAAGA 3120
AAGAAGATAT TTCCTTTCTC ATAAACACAT TTGAGGGCGG GGGAAGTGGT CGGCCGTCAG 3180
GCATCCTTGC TCAGCCAACC CTCTTCCATT TGCAAGGGCC GTTCAGTCTC AGAGCTGCCC 3240
TGCAGTGGAT GGACATGCTT CTGGCAGCAC TGGAGTGCTA CAACACATTC ATTGAAGAGA 3300
AAACTCTGGA AGCACCCAAG GTCCTAGGTA CTGAAACCCA GTCTTCACTT TGGAAAGCGG 3360
TGGCTTTCTT TTTAGAAAGC ATTGCTATGC ATGATATTAT GGCAGCAGAA AAGTACTTTG 3420
GCACTGGGGC AACAGGTAAC AGACCCAGCC CACAAGAAGG AGAAAGATAT AATTATAGCA 3480
AATGTACAAT TGTGGTCCGC ATTATGGAAT TTACCACAAC GCTCCTCAGC ACCTCCCCAG 3540
AAGGCTGGAA GCTGCTTGAG AAGGATGTGT GTAACACAAA CCTTATGAAA CTCTTAGTGA 3600
AAACCCTGTG TGAGCCCTCA AGCATAGGTT TCAACATCGG AGATGTCGCA GTTATGAACT 3660
ATCTTCCCAG TGTTTGTACC AACCTGATGA AAGCACTGAA GAAGTCCCCA TACAAAGACA 3720
TCCTGGAGAT GCACCTCAAG GAAAAGATAA CAGCACAGAG CATTGAAGAG CTCTGTGCAG 3780
TTGACTTGTA TTGCCCTGAT GCTTGCGTGG ACAGGGCCAG GCTGGCTTCT GTCGTGTCAG 3840
CTTGTAAACA ACTTCATAGA GCGGGGGTTT TGTGTGTTAT AATACCATCT CAGTCTGCAG 3900
ATCAGCATCA TTCTATTGGC ACAAAACTTC TTTCCTTGGT TTATAAAAGC ATTGCACCTG 3960
GAGATGAACA ACAGTGCCTT CCTTCACTAG ATCCCAATTG TAAGCGATTG GCCAGTGGAC 4020
TTCTGGAGTT GGCCTTTGCT TTTGGAGGAC TGTGTGAGCA CCTTGTGAGT CTTCTCCTGG 4080
ACACGACAGT GTTGTCATGC CATCCAGAGG AGGGTCCCAG AAAAACATCG TCAGCTTCTC 4140
TCATGGAGAG TATTTTTATA GCTTGTTCTC AGAAACGATC AACACTGAAT TGTTGAAAAA 4200
TCTAGATCTT GCTGTATTGG AGCTCATGAA ATCATCTGTG GATAATCCCA AAATGGTGAG 4260
CAATGTTTTG AATGGTATGT TAGATCAGAG CTTCAGGGAT CGAACCAGTG AGAAACACCA 4320
AGGACTGAAA CTTGCAACTA TAATTCTGCA AAACTGGAAG AAGTGTGATT CATGGTGGGC 4380
CAAAGATTCT GCTCCTGAAA GTAAAATGGC AGTGCTTACC TTGTTGGCAA AAATTTTCCA 4440
GATTGATTCA TCTGTTTGTT TTAATACAAA TCACTGCATG TTCCCTGAAG TCTTTACAAC 4500
ATATGTTAGT CTACTTGCTG ATTCAAAGTT GGACCTGCAT TTAAAGGGCC AAGCTATAAT 4560
TCTTCTTCCA TTCTTCACCA GTCTTACTGG AGGCAGCCTT GAGGACCTTA AGGTTGTTCT 4620
TGAAAACCTC ATCGTTTCTA ATTTTCCTAT GAAATCTGAA GAATTTCCCC CAGGAACTCT 4680
GCAGTACAAT AATTATGTGG ACTGCATGAA GAAGTTTCTA GATGCATTGG AATTATCTAA 4740
AAGCCCTATG TTGTTGCAGT TGATGACAGA AATTCTTTGT CGTGAACAGC AACATGTTAT 4800
GGAAGAATTA TTTCAGTCTA CTTTCAAAAA GATTGCCAGA AAGAGTTCAT GTATCACACA 4860
ATTAGGCCTT CTGGAAAGTG TATATAGAAT GTTCAGGAGG GATGACCTGC TTTCAAATAT 4920
CACTCGCCAA GCATTTGTAG ACCGTTCTCT GCTCACTCTG TTGTGGCACT GTAGCTTGAA 4980
TGCTTTGAGG GAATTTTTTA GCAAAATTGT GGTGGAAGCC ATTAATGTGT TGAAGTCCAG 5040
ATTTATAAAG CTGAATGAAT CTGCCTTTGA TACTCAAATC ACCAAGAAGA TGGGCTACTA 5100
TAAGATGTTA GATGTGATGT ATTCTCGTCT TCCAAAAGAT GATGTTCACT CTAAGGAATC 5160
TAAAATTAAT CAAGTTTTCC ATGGCTCATG TATTACAGAA GGAAGTGAAC TTACAAAGAC 5220
ACTTATTAAA TTGTGCTATG ATGCCTTTAC AGAGAACATG GCAGGCGAGA ACCAGTTGCT 5280
GGAGAGGAGA AGACTTTACC ATTGTGCTGC ATACAACTGT GCCATTTCTG TTGTCTGCTG 5340
TGTCTTCAAT GAATTAAAAT TTTACCAAGG TTTTCTGTTT ACTGAAAAAC CAGAAAAGAA 5400
CTTGCTTATT TTTGAAAATC TGATAGACTT GAAGCGCTGC TACACGTTTC CTATAGAAGT 5460
TGAGGTTCCT ATGGAGAGAA AGAAAAAGTA CCTTGAAATT AGAAAAGAAG CCAGGGAAGC 5520
AGCAGCAAGT GGGGATTCAG ATGGTCCTCG TTATATATCT TCCTTGTCAT ATTTGGCAGA 5580
CAGTAGCCTG AGTGAGGAAA TGAGTCAATT TGATTTCTCG ACTGGAGTGC AGAGCTATTC 5640
ATATAGTTCC CAAGACCCTA AATCTACCAC TGCTCATTTT CGGAGACAGA AACATAAAGA 5700
GTCCATGATC CAAGATGATA TCCTGGAGTT AGAGATGGAT GAACTCAATC AACACGAATG 5760
TATGGCAACT ATGACTGCTC TGATTAAGCA CATGCAGAGA AATCAGATCC TCCCTAAGGA 5820
AGAAGAGGGT TCAGTGCCAA GAAATCTTCC TCCTTGGATG AAATTTCTTC ATGACAAACT 5880
AGGAAATCCA TCAATATCAT TAAATATCCG TCTCTTCTTA GCCAAGCTTG TTATTAATAC 5940
AGAAGAAGTC TTTCGTCCTT ACGCGAGATA CTGGCTCAGC CCTTTGCTGC AGCTGGTTGT 6000
TTCTGGAAAC AACGGAGGAG AAGGAATTCA CTATATGGTG GTTGAGATAG TGGTTATTAT 6060
TCTTTCATGG ACAGGATTAG CTACTCCTAT AGGTGTCCCT AAAGATGAAG TGTTAGCAAA 6120
TCGATTGCTT CATTTCCTAA TGAACATGTT TTTCATCAAA AAAGAGCTGT GTTTAGACAC 6180
AACCTCGAAA TTATAAAAAC CCTTGTTGAA TGCTGGAAGG ATTGTTTATC CATCCCTTAC 6240
AGGTTAATAT TTGAAAAGTT TTCCAGTACA GATCCTAATT CTAAAGACAA TTCAGTAGGA 6300
ATTCAATTAC TAGGCATTGT AATGGCCAAT AACTTGCCTC CTTATGACCC AAAATGTGGC 6360
ATAGAGAGCA TAAAATACTT TCAAGCTTTG GTCAATAATA TGTCCTTTGT AAGATATAGA 6420
GAGGTATATG CAGCAGCGGC AGAAGTTCTA GGACTTGTTC TTCGATATAT TACTGAGAGA 6480
GAAAATATAC TGGAGGAGTC TGTGTGTGAA CTGGTCATAA AACAGTTGAA GCAACATCAG 6540
AATACGATGG AGGACAAATT TATTGTGTGC TTGAACAAAG CTGTGAAGAA CTTCCCTCCT 6600
CTTGCTGATA GGTTTATGAA CACCGTGTTC TTCCTGCTGC CAAAATTTCA TGGCGTGATG 6660
AAGACTCTCT GTCTGGAGGT GGTACTGTGT CGTGCAGAGG AAATAACAGA TCTATACTTA 6720
CAGTTAAAGA GCAAGGATTT CATTCAAGTC ATGAGACATA GAGATGATGA AAGACAAAAA 6780
GTGTGTTTGG ACATAATTTA TAAGATGATG GCAAGATTGA AACCAGTAGA ACTTCGAGAA 6840
CTTCTGAATC CTGTTGTAGA ATTCATTTCT CATCCTTCTC CAGTGTGTAG GGAACAAATG 6900
TATAACATTC TCATGTGGAT TCATGACAAT TATCGAGATC CAGAAGGTCA GACAGATGAC 6960
GACTCCCAGG AAATATTTAA GTTGGCAAAA GATGTGTTGA TTCAAGGATT GATCGATGAG 7020
AACCCTGGGC TTCAATTAAT TATTCGAAAT TTCTGGAGTC ATGAAACTAG GTTACCTTCA 7080
AATACCTTGG ATCGATTGTT GGCACTAAAT TCCCTATATT CTCCTAAGAT AGAAGCACAC 7140
TTTTTAAGTT TAGCAACAGA TTTTCTGCTT GAAATGACCA GCGTGAGCCC AGATTATTCA 7200
AACCCTATGT TTGATCATCC TCTGTCAGAA TGCAAATTTC AGGAATATAC TATTGATTCT 7260
GACTGGCGTT TCCGAAGTAC TGTTCTCACT CCAATGTTTA TTGAGACTCA GGCCTCCCAA 7320
AGTGCTCTGC AGACCCGGAC CCAGGAAGGA TCCCTCTCAG CTCGAGGGGT AATGACTGGG 7380
CAGATACGGG CCACACAACA GCAGTATGAT TTCACACCTA CGCAAAATAC AGATGGAAGA 7440
AGCTCTTTCA ATTGGCTGAC TGGGAACAGC ATTGACCCAC TGGTGGATTT TACGGTCTCC 7500
TCCTCATCTG ATTCTTTGTC TTCCTCCTTG CTGTTTGCTC ACAAGAGGAG TGAAAAATCA 7560
CAGAGAGGAC CCTTGAAGTC AGTAGGACCT GATTTTGGGA AAAAAAGGCT GGGCCTTCCA 7620
GGGGATGAGG TGGATAACAA AGCAAAAGGT ACAGACAATC GGGCGGAAAT ATTAAGATTA 7680
CGGAGACGAT TTTTAAAGGA CCGAGAAAAG CTCAGTTTGA TTTATGCCAG AAAAGGTGTT 7740
GCTGAACAAA AACGAGAGAA GGAGATCAAG AGTGAGTTAA AAATGAAGCA CGATGCCCAA 7800
GTCATTTTGT ACAGAAGTTA CCGTCAAGGA GACCTTCCTG ACATTCAGAT TAAATACAGC 7860
AGCCTGATCA CTCCCTTGCA AGCTGTGGCC CAGAGAGACC CAATAATTGC AAAGCAGCTC 7920
TTTGGCAGCT TGTTTTCTGG AATTATAAAA GAGATGGATA AATATAAGAC CATGTCTGAA 7980
AAAAACAACA TTACTCAGAA GTTGCTCCAG GACTTCAATA ATTTTCTTAA CACCACTGTC 8040
TCTTTCTTTC CACCTTTCAT CTCCTGTATC CAGGAAATTA GTTGCCAACA CGCAGACTTG 8100
CTGAGCCTCG ACCCAGCTTC TGTCAGTGCC AGCTGCCTGG CCAGTCTGCA GCAGCCTGTA 8160
GGCGTCCGCC TTCTGGAGGA GGCCTTGCTC CACTGCTGCC TGAAGAGCCA CCTGCCAAGC 8220
GAGTTCGAGG GAGACCCTGT CTCTACCCTG ATTTTGTCAG ATGGATGGAA CTTGCTAAAC 8280
TGTATAGATC AATTGGAGAA TATGACATCC TCCGTGGGAT TTTTAATAGT GAGATAGGAA 8340
CAAAGCAAGT CACTCAGAAT GCATTATTAG CAGAAGCAAG AAATGATTAT TCTGAAGCCG 8400
TTAAGCAGTA TAATGAGGCT CTCAATAAAC AAGACTGGGT AGATGGTGAG CCTATGGAAG 8460
CTGAGAAGGA TTTTTGGGAA CTTGCATCCC TTGACTGTTA TAACCAACTT GCTGAGTGGA 8520
AATCACTGGC ATACTGTTCT ACAGTCAGTG TTGACAGTGC GAACCCTCCA GATTTAAATA 8580
AAATGTGGAA TGAACCATTT TATCAGGAGA CCTATCTACC TTACATGATC CGCAGCAAGC 8640
TGAAGCTACT TCTGCAAGGT GAGGGAGACC AGTCCCTGCT GACATTTATT GATGAAGCTG 8700
TGAGCAAGGA GCTCCAGAAG GTCCTCGTAG AGCTTCATTA CAGTCAGGAA TTGAGTCTCC 8760
TTTATATCCT ACAAGATGAC GTCGACAGAG CCAAATATTA TATTGAAAAT TGCATTCGGA 8820
TTTTCATGCA GAGCTATTCT AGTATTGATG TCCTTTTAGA GAGAAGTAGA CTCACCAAAT 8880
TGCAATCTCT ACAGGCTTTA ATAGAAATTC AGGAGTTCAT CAGCTTTATA AGGAAACAAG 8940
GTAATTTATC AAATTCCCCT TAAGAGACTT CTAAAAACCT GGACAAACAG ATATCCGGAT 9000
GCTAAAATGG ACCCAATGAA CATCTGGGAT GACATCATCA CAAATCGATG TTTCTTTCTC 9060
AGCAAAATAG AAGAAAAACT GACTATTCCT CCAGATGATC ATAGTATGAA CACAGATGGA 9120
GATGAAGATT CCAGTGACAG AATGAAAGTG CAGGAGCAGG AGGAAGATAT TTATTCTCTG 9180
ATTAAGAGTG GTAAGTTTTC CATGAAAATG AAGATGATAG AAAGTGCAAG GAAACAGAAA 9240
AATTTCTCAC TAGCCATGAA ACTATTAAAG GAGCTTCATA AAGAGTCAAA AACAAGAGAT 9300
GACTGGCTGG TGAAATGGGT GCAGAGCTAC TGTCGACTCA GTCACAGCCG GAGCCAGACC 9360
CAGAATCGTC CTGAGCAGAT CCTTACTGTG TTGAAAACAG TCTCTTTGTT GGATGAGAAC 9420
ACATCAAGCT ACTTAAGCAA AAATATTCCA GTTTCCCGTG ACCACAACAT TCTCTTGGGT 9480
ACAACTTACA GGATCATAGC TAATGCTCTC AGCAGTGATC CAACTTGCCT TGCTGAAATC 9540
GGGGAAAGCA AGGCTAGAAG AATCTTGGAG CTGTCTGGAT CCAGTTTAGA GAATGCAGAA 9600
GAGGTGATCG CAGGTCTATA CCAGAGAGTG TTGCATCACC TTTCTGAGGC CGTGCGGATT 9660
GCAGAGGAGG AGGCCCAGCC TTTCACTAGA GGCCAGGAAC CTGCAGTTGG GGTGATAGAT 9720
GCTTACATGA CACTGGTGGA TTTCTGTGAC CAGCAGCTCC GCAAGGAGGA AGAGAGTTCA 9780
TCAGTTACTG AGTCTGTACA ACTGCAGATG TATCCAGCCC TTGTGGTGGA CAAAATGTTA 9840
AAAGCTTTAA GACTCGATTC CAATGAAGCC AGGCTGAAGT TTCCCAGACT ACTGCAGATT 9900
ATAGAACGGT ATCCAGAGGA GACCCTGAGC CTAATGACCA AAGAGATTTC TTCCATTCCT 9960
TGCTGGCAGT TCATTGGCTG GATCAGCCAC ATGGTGGCCT TACTGGACAA AGAGGAAGCT 10020
GTCGCTGTCC ATCGCACAGT GGAAGAGATT GCTGATAACT ATCCACAGGC GATGGTCTAC 10080
CCATTTATAA TAAGCAGTGA AAGCTATTCC TTCAAAGATA CTTCTACTGG TTATAAGAAT 10140
AAGGAGTTTG TGGAAAGGAT TAAAATTAAG TTGGATCAAG GAGGAGTGAT TCAAGATTTT 10200
ATTAATGCCC TAGAACAGCT CTCTCATCCT GAAATGCTCT TAAGGACTGG ACTGATGATA 10260
TCAAAGTTGA ACTTGAAAAA AACCCTGTAA ATAGAAAAAA CATTGAAAAG ATGTATGAAA 10320
AAATGTATGC AACCTTGGGA GACCCACAGG CTCCAGGTCT TGGGGCTTTT CGAAGAAGGT 10380
GTATTCAGGG TTTTGGAAAA GAATTTGATA AACACTTTGG GAGAGGAGGT TCTAAGCTAC 10440
CTGGAATGAA ATCCCGTGAA TTCAGTGATA TTACCAACTC ACTATTTTCA AAAATGTGCG 10500
AAGTCTCAAA GCCACCTGGG AATCTGAAAG AATGCTCGCC CTGGATGAGT GACTTCAAAG 10560
TAGAATTTTT GAGAAGTGAA CTGGAGATTC CTGGTCAGTA TGATGGCAAG GGAAAACCAG 10620
TGCCAGAATA CCATGCACGA ATTGCTGGGT TTGATGAGCG GATAAAAGTA ATGGCTTCTA 10680
TGAGAAAACC AAAGCGTATC ATCATCCGAG GCCATGATGA GAGAGAGTAC CCTTTCCTTG 10740
TGAAGGGAGG TGAAGATCTG AGGCAGGACC AACGCATCGA GCAGCTCTTC GAGGTCATGA 10800
ATGTCATCCT TTCCCAAGAT GCTACCTGTA GTCAGAGAAG CATGCAGCTA AAGACATACC 10860
AGGTCATACC CATGACCTCC AGATTAGGAC TAATTGAATG GATTGAAAAT ACTTTTACCT 10920
TGAAGGAACT TCTTTTGAGT AACATGTCAC AAGAGGAGAA AGCGGCTTGT ACAAGAGATC 10980
CCAAAGCACC ACCATTTGAA TATAGAGACT GGCTGACAAA GATGTCTGGG AAATGTGATG 11040
TTGGTGCTTA CATGCTAATG TATAAGGGAG CTAGTCGTAC TGAAACAGTC ACATCTTTTA 11100
GAAAAAGAGA AAGTAAGGTG CCAGCCGATC TCTTAAAGCG GGCCTTTGTG AAGATGAGTA 11160
CCAGCCCTGA GGCCTTCCTG ACACTCCGCT CACACTTTGC CGGCTCTCAC GCTTTGATAT 11220
GCATTAGTCA CTGGATTCCT GGGATTGGAG ATAGACATCT GAACAATTTC CTGGTAAGCA 11280
TGGAGACAGG TGGAGTGATT GGAATCGACT TTGGACATGC ATTTGGATCA GCTACTCAGT 11340
TTCTGCCGGT CCCTGAGTTG ATGCCTTTTC GTCTAACTCG CCAGTTTATC AATCTGATGT 11400
TACCAATGAA AGAAACAGGT GTTATGTACA GTATCATGGT GCATGCACTG AGAGCCTTCC 11460
GCTCGCAGTC CAACCTGCTT GCTAACACCA TGGACGTGTT TGTAAAGGAG CCTTCCTTCG 11520
ACTGGAAAAA TTTTGAACAG AAAATGCGGA AAAAAGGAGG ATCATGGATT CAAGAAATAA 11580
ATGTAACTGA AAAAAATTGG TATCCCCGGC AGAAAATACA TTATGCTAAG AGAAAGTTAG 11640
CTGGTGCCAA TCCAGCAGTT ATTACTTGTG ATGAGTTACT TCTGGGCCAT GAGAAGGCAG 11700
CTGCATTTGG AGATTATGTG GCTGTAGCAC GAGGAAGTGA AGATCACAAT ATCCGTGCCC 11760
AAGAACTGGA GAGTGACCTT TCAGAAGAAG CTCAGGTGAA GTGCTTGATT GACCAGGCAA 11820
CAGACCCCAA CATCCTTGGC AGAACCTTGG TAGGATGGGA GCCCTGGATG TGA 11873

Claims (14)

What is claimed is:
1. An oligonucleotide of 15 to 25 bases that hybridizes to the severe combined immunodeficiency (SCID) determinant region of nucleic acid encoding the DNA-dependent protein kinasecatalytic subunit in Arabian horses (SEQ ID No:28).
2. The oligonucleotide of claim 1, wherein said oligonucleotide comprises a label.
3. The oligonucleotide of claim 2, wherein said label is a radioactive element, a fluorescent material or an enzyme.
4. A primer pair that amplifies the severe combined immunodeficiency (SCID) determinant region of nucleic acid encoding the DNA-dependent protein kinasecatalytic subunit in Arabian horses (SEQ ID No:28).
5. A method of identifying an Arabian horse that is a cater for equine severe combined immunodeficiency comprising determining the presence or absence of a gene encoding a functional DNA-dependent protein kinasecatalytic subunit in Arabian horses (SEQ ID No:28).
6. The method of claim 5, wherein said determining comprises differential hybridization.
7. The method of claim 5, wherein said determining comprises DNA amplification.
8. A method of identifying an Arabian horse that is a carrier of equine severe combined immunodeficiency comprising the step of determining whether said horse has a mutation in the severe combined immunodeficiency (SCID) determinant region of nucleic acid encoding the DNA-dependent protein kinasecatalytic subunit in Arabian horses (SEQ ID No:28).
9. The method of claim 8, wherein said determining comprises differential hybridization.
10. The method of claim 8, wherein said determining comprises DNA amplification.
11. A method of identifying an Arabian horse that is a cattier of equine severe combined immunodeficiency comprising the step of determining whether said horse carries the severe combined immunodeficiency (SCID) allele of the DNA-dependent protein kinasecatalytic subunit in Arabian horses, said allele comprising SEQ ID No:25.
12. The method of claim 11, wherein said determining comprises differential hybridization.
13. The method of claim 11, wherein said determining comprises DNA amplification.
14. An isolated DNA molecule encoding a DNA-dependent protein kinasecatalytic subunit of SEQ ID No:29.
US09/407,562 1996-11-15 1999-09-28 Genetic test for equine severe combined immunodeficiency disease Expired - Lifetime US6294334B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/407,562 US6294334B1 (en) 1996-11-15 1999-09-28 Genetic test for equine severe combined immunodeficiency disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3126196P 1996-11-15 1996-11-15
US08/970,269 US5976803A (en) 1996-11-15 1997-11-14 Genetic test for equine severe combined immunodeficiency disease
US09/407,562 US6294334B1 (en) 1996-11-15 1999-09-28 Genetic test for equine severe combined immunodeficiency disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/970,269 Continuation US5976803A (en) 1996-11-15 1997-11-14 Genetic test for equine severe combined immunodeficiency disease

Publications (1)

Publication Number Publication Date
US6294334B1 true US6294334B1 (en) 2001-09-25

Family

ID=21858479

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/970,269 Expired - Lifetime US5976803A (en) 1996-11-15 1997-11-14 Genetic test for equine severe combined immunodeficiency disease
US09/407,562 Expired - Lifetime US6294334B1 (en) 1996-11-15 1999-09-28 Genetic test for equine severe combined immunodeficiency disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US08/970,269 Expired - Lifetime US5976803A (en) 1996-11-15 1997-11-14 Genetic test for equine severe combined immunodeficiency disease

Country Status (5)

Country Link
US (2) US5976803A (en)
AU (1) AU745234B2 (en)
CA (1) CA2272850C (en)
GB (1) GB2335984B (en)
WO (1) WO1998021367A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1315535A (en) * 2000-03-27 2001-10-03 上海博德基因开发有限公司 Polypeptide-human DNA-dependent protein kinase 9 and polynucleotide for coding it
US6436453B1 (en) * 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US20050013902A1 (en) * 2002-02-11 2005-01-20 Edizone, Lc Fiber nutritional drink
WO2008018305A1 (en) * 2006-08-08 2008-02-14 Arkray, Inc. Method of detecting variation and kit to be used therein
CN108728487B (en) * 2017-04-21 2020-07-14 北京百奥赛图基因生物技术有限公司 Plasmid composition, construction method of DNAPK gene knockout rat model and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US5476996A (en) * 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3654090B1 (en) 1968-09-24 1982-07-20
US3850752A (en) 1970-11-10 1974-11-26 Akzona Inc Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US5476996A (en) * 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
Bailey et al., "Linkage of the gene for equine combined immunodeficiency diseaseto microsattelite markers HTG8 and HTG4; synteny and FISH mapping to EAC9," Animal Genetics, 28:268-273, 1997.
Blunt T. et al. "Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse" ABSTRACT, Proc. Natl. Acad. Sci. USA, 93(19):10285-90, 1996.
Bosma et al., "A severe combined immunodeficiency mutation in the mouse" ABSTRACT, Nature, 301(5900):527-30, 1983.
Danska J. S. et al. "Biochemical and genetic defects in the DNA-dependent protein kinase in murine scid lymphocytes" ABSTRACT, Mol. Cell Biol., 16(10):5507-17, 1996.
Errami et al. "Ku86 defines the genetic defect and restores X-ray resistance and V(D)J recombination to complementation group 5 hamster cell mutants," ABSTRACT, Mol Cell Biol., 16(4):1519-26, 1996.
Hartley, K. O. et al. "DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product." ABSTRACT, Cell, 82(5):849-56, 1995.
McGuire and Poppie, "Hypogammaglobulinemia and thymic hypoplasia in horses: a primary combined immunodeficiency disorder," Infect. Immun., 8(2):272-7, 1973.
Poltoratsky et al., "Human DNA-activated protein kinase (DNA-PK) is homologous to phosphatidylinositol kinases," J Immunol., 155(10):4529-33, 1995.
Shin et al., "A kinase-negative mutation of DNA-PKcs in equine SCID results in defective coding and signal joint formation," J. Immun., 158:3565-3569, 1997.
Shin et al., J. Am. Vet. Med. Assoc. 211(10), 1268-1270 (1997).*
Wiler et al., Proc. Natl. Acad. Sci. U.S.A. 92, 11485-11489 (1995).*
Wiler et al., Vet. Immunol. Immunopath. 54, 19 (1996).*

Also Published As

Publication number Publication date
GB9911334D0 (en) 1999-07-14
AU745234B2 (en) 2002-03-14
GB2335984A (en) 1999-10-06
GB2335984B (en) 2000-11-29
CA2272850A1 (en) 1998-05-22
WO1998021367A1 (en) 1998-05-22
AU5444698A (en) 1998-06-03
CA2272850C (en) 2009-02-24
GB2335984A8 (en) 1999-11-15
US5976803A (en) 1999-11-02

Similar Documents

Publication Publication Date Title
Almind et al. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus
US20040132021A1 (en) Osteolevin gene polymorphisms
US20170183736A1 (en) Mutations of the parkin gene, compositions, methods and uses
Cazzaniga et al. Chromosomal mapping, isolation, and characterization of the mouse xanthine dehydrogenase gene
US6670460B2 (en) Method of detection of alterations in MSH5
CA2172963C (en) Aspartoacylase gene, protein, and methods of screening for mutations associated with canavan disease
US6294334B1 (en) Genetic test for equine severe combined immunodeficiency disease
EP1448587B1 (en) Noonan syndrome gene
US5955277A (en) Mutant cDNA encoding the p85α subunit of phosphatidylinositol 3-kinase
US20070277251A1 (en) Diagnosis and Prediction of Parkinson&#39;s Disease
Abidi et al. Novel mutations in Rsk-2, the gene for Coffin-Lowry syndrome (CLS)
US6599728B2 (en) Second mammalian tankyrase
WO2000022166A2 (en) Genes for assessing cardiovascular status and compositions for use thereof
WO1999055915A2 (en) IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF Xq13
JP2005528089A (en) Peripheral artery occlusion disease genes
WO2004042358A2 (en) HUMAN TYPE II DIABETES GENE-SLIT-3 LOCATED ON CHROMOSOME 5q35
US6218524B1 (en) Genetic polymorphisms in the microsomal triglyceride transfer protein promoter and uses thereof
US7001720B1 (en) Cloning of a gene mutation for parkinson&#39;s disease
US20040106138A1 (en) Methods for identifying subjects susceptible to ataxic neurological disease
JP2000316577A (en) Diagnosis of citrullinemia type ii onset in adult
WO1994029345A1 (en) Mutant dna encoding insulin receptor substrate 1
US20040126787A1 (en) Sodium channel alpha subunit variants
US6913885B2 (en) Association of dopamine beta-hydroxylase polymorphisms with bipolar disorder
US20040161747A1 (en) Method for screening for autoimmune disease by identifying polymorphisms in il-12 p40
US20030223986A1 (en) Methods

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:THE UNIVERSITY OF TEXAS SYSTEM;REEL/FRAME:023574/0477

Effective date: 20091124

FPAY Fee payment

Year of fee payment: 12